Duquesne University

Duquesne Scholarship Collection
Electronic Theses and Dissertations

Fall 2009

Performance-Based Quality Specifications: The
Link between Product Development and Clinical
Outcomes
Steven Short

Follow this and additional works at: https://dsc.duq.edu/etd
Recommended Citation
Short, S. (2009). Performance-Based Quality Specifications: The Link between Product Development and Clinical Outcomes
(Doctoral dissertation, Duquesne University). Retrieved from https://dsc.duq.edu/etd/1190

This Immediate Access is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic
Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. For more information, please contact
phillipsg@duq.edu.

PERFORMANCE-BASED QUALITY SPECIFICATIONS: THE LINK BETWEEN
PRODUCT DEVELOPMENT AND CLINICAL OUTCOMES

A Dissertation
Submitted to the Graduate School of Pharmaceutical Sciences

Duquesne University

In partial fulfillment of the requirements for
the degree of Doctor of Philosophy
(Pharmaceutics)

By
Steven M. Short

December 2009

Copyright by
Steven M. Short

2009

PERFORMANCE-BASED QUALITY SPECIFICATIONS: THE LINK BETWEEN
PRODUCT DEVELOPMENT AND CLINICAL OUTCOMES

By
Steven M. Short
Approved October 23, 2009

________________________________
Carl. A. Anderson, Ph.D.
Associate Professor of Pharmaceutics
Graduate School of Pharmaceutical
Sciences
(Committee Chair)

________________________________
James K. Drennen, III, Ph.D.
Associate Professor of Pharmaceutics
Associate Dean for Graduate Programs
and Research
Mylan School of Pharmacy
(Committee Member)

________________________________
Robert P. Cogdill, Ph.D.
Director of Research Development
College of Engineering
University of Nebraska, Lincoln
Lincoln, NE
(Committee Member)

________________________________
Ira S. Buckner, Ph.D.
Assistant Professor of Pharmaceutics
Graduate School of Pharmaceutical
Sciences
(Committee Member)

________________________________
Frank D’Amico, Ph.D.
Professor of Statistics
McAnulty Graduate School of Liberal
Arts
(Committee Member)

________________________________
J. Douglas Bricker, Ph.D.
Dean, Mylan School of Pharmacy and the
Graduate School of Pharmaceutical
Sciences

iii

ABSTRACT

PERFORMANCE-BASED QUALITY SPECIFICATIONS: THE LINK BETWEEN
PRODUCT DEVELOPMENT AND CLINICAL OUTCOMES

By
Steven M. Short
December 2009

Dissertation supervised by Carl A. Anderson, Ph.D.
The design of drug delivery systems and their corresponding dosing guidelines
are critical product development functions supported by clinical pharmacokinetic (PK)
and pharmacodynamic (PD) data. Largely, the importance of variance and covariance in
product and patient attributes is poorly understood. The existence of PK/PD diversity
among myriad patient sub-populations further complicates efforts to gauge the
importance of product quality variation. Nevertheless, a platform capable of evaluating
the effects of product and patient variability on clinical performance was constructed.
This dissertation was predicated on requests to re-define pharmaceutical quality in terms
of risk by relating clinical attributes to production characteristics.
To avoid in vivo studies, simulated experimental trials were conducted using the
model drug, theophylline, for which data and models could be acquired from the
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literature. Where comprehensive data were unavailable (e.g., production variability
statistics), initial estimates were acquired via laboratory-scale experiments. Model
asthmatic patients were generated using Monte Carlo simulation and published
population distributions of various anothropometric measurements, disease rates, and
lifestyle factors.
Mathematical constructs for in vitro-in vivo correlations provide a linkage
between Quality by Design (QbD) product and process models, PK/PD models, and
patient population statistics. The combined models formed the foundation for Monte
Carlo risk assessments, which characterized the risk of inefficacy and toxicity for dosing
of extended-release theophylline tablets. Sensitivity analyses revealed that patient
compliance and content uniformity significantly influenced the probability of observing
an adverse event.
The Monte Carlo risk assessment platform defined the link between the critical
quality attributes (CQAs) and clinical performance (i.e., performance-based quality
specifications (PBQS)). The PBQS were subsequently utilized to generate process
independent design spaces conditioned on inefficacy and toxicity risk. These design
spaces, which directly account for the conditional relationships between product quality
and patient variability, can be transferred to a specific process via models that relate
process critical control parameters to the CQAs. Process Analytical Technology,
therefore, can be integrated into the QbD production environment to control the safety
and efficacy of the final product. This work demonstrated that process and product
knowledge can be used to estimate the risk that final product quality imparts to clinical
performance.
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Chapter 1: Introduction

1.1 Statement of the Problem
“Personal” computers that were once so massive they occupied more space than a
small house have now been reduced to roughly the dimensions of a sheet of letter paper,
yet they are orders of magnitude more powerful, not to mention less expensive, than their
predecessors. Automobiles, which were once so costly they were a luxury to the most
affluent of individuals, have since been mass-produced at reasonable prices with
increased reliability and operational efficiency, revolutionizing the means by which
practically all people commute. These are simple and obvious examples of the myriad
unfathomable achievements that rest in the chronicles of history.
Numerous industrial sectors boast of extraordinary long-term progress regarding
their innovative products and technological developments. The pharmaceutical industry,
however, might not be able to do so. Granted, pioneering products such as osmotic
tablets, drug eluting stents, and targeted gene delivery devices have all been developed
near the turn of the century. Novel goods, however, are not the exclusive gauge of
advancement. By and large, the pharmaceutical industry lags well behind other
manufacturing sectors in terms of “quality.” A study published in 2007 based on
available benchmarks reported that pharmaceutical manufacturers operate on a level of
approximately 35,000 defective units per 1,000,000 produced,1 which is intolerable
considering that other sectors have already achieved Six Sigma production (i.e., 3.4
defects for every 1,000,000 units); this is likely a function of the specifications more so
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than the product. Moreover, disastrous clinical outcomes, perhaps best epitomized by the
tragic Vioxx incident, further dilute the universal standard of quality associated with the
pharmaceutical industry.
The Food and Drug Administration (FDA) has candidly acknowledged the lack of
innovation that has impeded the growth of the pharmaceutical industry. Accepting partial
responsibility for the current state, the FDA released a number of reports, initiatives, and
guidances in the past decade to transform regulatory oversight and outwardly encourage
reform, innovation, and low-risk, affordable medical products. The modified regulatory
architecture is risk-based; the degree of regulatory scrutiny is commensurate to the risk a
particular product imparts to the public. Companies that are able to adequately
demonstrate the safety and efficacy of their products using risk- and science-based
approaches will, therefore, be granted more regulatory flexibility.
In certain industries, faulty merchandise can result in mere inconvenience and
frustration for the consumer. Defective (i.e., substandard quality) pharmaceutical
products, however, may be ineffective or toxic, either of which can have grave
consequences. The quality of medical products is typically assessed by a series of tests
that characterize the products as acceptable or unacceptable. Acceptability is gauged via
lower and/or upper specification limits, thresholds set with respect to a target value,
which are to be derived based on product safety and efficacy. Product that is within the
range defined by the specification(s) is deemed acceptable. Despite all of the collective
efforts to ensure low-risk medical products, quality in the pharmaceutical industry is
currently evaluated in such a way that the relationship between product specifications and
clinical performance is implicit at best.
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Numerous controllable and uncontrollable factors affect the safety and efficacy of
pharmaceutical products. Pharmaceutical production involves the integration of several
unit operations, each of which functions via a number of confounding
parameters/variables that, if not controlled, have the potential to negatively influence
product quality. Manufacturing requires a thorough understanding of these
parameters/variables, and an appreciation for their interaction. Human variability also
complicates safety and efficacy. Not all humans respond identically to the same drug
administered at an equivalent dose; numerous physiologic and pathophysiologic variables
affect clinical performance. Thus, these patient-specific factors also must be indentified
and accounted for.
Recognizing the potential severity of defective pharmaceutical products, a lack of
understanding is typically addressed by increasing the strictness of the specification; in
other words, the range that defines product acceptability is reduced in an attempt to
mitigate the likelihood of an adverse event. This, however, is often counterproductive.
First, if the specifications are not explicitly derived in relation to the product’s safety and
efficacy, they may be too strict. Excessive thresholds carry the risk of not approving a
product based on the misunderstanding the process and/or product. Contrary, overly
stringent specifications may result in wasted resources allocated to improve the precision
of the manufacturing process, which unnecessarily inflates the price of the final product.
Worse yet, the adjustments may be too lenient, especially for certain high-risk
subpopulations that were not identified or adequately evaluated during clinical testing.
This may be caught by the company during post-marketing surveillance, or may be
revealed through a high-profile incident, such as a death attributed to the drug. The
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former would most likely mean costly re-evaluations of the dosing guidelines, the
manufacturing process, and/or the product itself, which may even need to be temporarily
pulled from the market. The latter, however, would almost inevitably result in immediate
cessation of production and sale imposed by a regulatory consent decree, and potentially
severe legal ramifications.
It is evident that inaccurate or unsubstantiated specifications contradict efforts to
provide high-quality (i.e., low-risk), affordable medical products. The FDA, the
pharmaceutical industry, and the general public unanimously desire safe and efficacious
medical products. Given that quality has not been explicitly assessed in terms of clinical
performance, the current perception of pharmaceutical quality may very well be
inaccurate, in part, due to the way in which quality is defined and the lack of
understanding regarding material and process variability. Inconsistent definitions and
uninformative appraisals of pharmaceutical quality have initiated requests to standardize
its definition in terms of risk to safety and efficacy. This work demonstrates how
pharmaceutical process and product understanding can be used to supervise
manufacturing based on the quantifiable risk that final product quality attributes impart to
clinical performance.
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1.2 Hypothesis and Objectives
This dissertation is based on the central hypothesis that pharmaceutical process
and product understanding can be simultaneously utilized to model the risk that final
product quality imparts to clinical performance.
Given the central hypothesis, the objectives of this dissertation were to:
1. Combine patient-specific factors with a pharmacokinetic model and an in vitro-in
vivo correlation model to simulate drug plasma concentration profiles, which will
be used in combination with a pharmacodynamic model to estimate patient risk in
terms of inefficacy and toxicity.
2. Utilize Monte Carlo simulation and probabilistic risk assessment modeling to
estimate the impact that changes in pharmaceutical manufacturing variability
impart to patients.
3. Demonstrate how the risk simulation platform can be used to determine the
conditional risk of product variation on clinical performance for a model solid
oral dosage system.
4. Generate design spaces that are conditioned on quantitative estimations of
inefficacy and toxicity risk.
Further, the methodologies developed in this work were used as the basis to propose a
hypothetical scenario that couples Process Analytical Technology with Quality by Design
such that production can be maintained in a low-risk state.
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1.3 Literature Survey
1.3.1 The Pharmaceutical Quality Revolution
W. Edwards Deming, one of the forefathers of the quality revolution, once said
that quality “… means a predictable degree of uniformity (variation) and dependability at
low cost suited to the market.”2 Quality is unquestionably a cornerstone tenet that
influences commerce, but what exactly is “quality” and more specifically, what does it
mean to the pharmaceutical industry? The International Conference on Harmonisation
(ICH), an organization that seeks to unify the regulatory bodies of Europe, Japan, and the
United States and their respective pharmaceutical experts in an effort to register
pharmaceuticals for human use, has posited several definitions during the past decade.
The ICH Harmonised Tripartite Guideline Q6A defines quality as “the suitability of
either a drug substance or drug product for its intended use. This term includes such
attributes as the identity, strength, and purity.”3 The ICH Harmonised Tripartite
Guideline Q9 offers an alternative definition: “the degree to which a set of inherent
properties of a product, system, or process fulfills requirements.”4
Although a standardized definition of “pharmaceutical quality” has yet to be
acknowledged, its significance (or the lack thereof) has. The general public is ultimately
the customer of pharmaceutical goods (and, therefore, the ones who dictate the level of
acceptable quality). It is often assumed, however, that they are unable to adequately
appraise these products. Therefore, regulatory authorities have absorbed this function so
that patients need not be concerned about the medications they consume. The FDA has
acknowledged that maintaining a scientific framework that ensures quality (low-risk),
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innovative, pharmaceutical products is a primary public health objective. The Agency’s
ultimate mission (as it relates to the pharmaceutical industry) is to guarantee that the
products available in the United States are consistently high in quality.5
It is well understood that “quality cannot be tested into products; it should be
built-in or should be by design.”6 As a result, numerous regulatory initiatives, reports,
and guidances have been introduced in the past several decades to recommend (both
binding and non-binding) procedures and precautions to help ensure quality. In 1978, the
FDA published 21 Code of Federal Regulations (CFR), Parts 210 and 211, which outline
the minimum current good manufacturing practice (CGMP) methods as well as the
facilities and controls to be implemented for the manufacturing, processing, packaging,
and/or holding of pharmaceutical products.7 Segments of Parts 210 and 211 have since
been revised. Although the CGMP regulations predate ICH Q6A, the underlying
objective is to guarantee that the final products adhere to the standards of quality set forth
by the ICH document. The regulations do not, however, define quality, nor do they
adequately detail how to achieve quality during development and production.7
The CGMPs for the 21st Century initiative was launched by the FDA in August of
2002 to “modernize” the Agency’s role in overseeing pharmaceutical manufacturing and
product quality. In addition to underscoring its regulatory responsibility, the initiative
implicitly stresses the obligatory role of all vested parties to supply quality medical
products. To accomplish this, the existing CGMP programs were scrutinized to help
assemble the regulatory architecture for overseeing manufacturing quality, which
includes the concepts of risk management and quality systems. This clearly marked the
beginnings of a risk-based inspection and enforcement program where regulatory
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resources were employed in a manner commensurate with the threat to public safety.
Eventually, the final report entitled Pharmaceutical CGMPs for the 21st Century – A
Risk-Based Approach was released in 2004 to connect the CFR regulations and the
Agency’s existing views regarding quality systems.5
A formal guidance for quality systems, The Quality Systems Approach to
Pharmaceutical CGMP Regulations, was released in 2006.8 This document introduces
the quality system as it relates to the pharmaceutical industry, which is a strategic
business plan that formalizes corporate functions to attain product/service (quality)
requirements, customer approval, and continuous improvement to ultimately achieve “ …
the public and private sectors’ mutual goal of providing high-quality drug product to
patients and prescribers.” Designed appropriately, a quality system mitigates the risk of
inferior (i.e., recalled, returned, salvaged, defective) products reaching the general public.
Consequently, it has the potential to alleviate regulatory oversight considering that the
robustness of the system is used as a criterion for determining the necessary extent of
supervision.5 The quality system is also advantageous in that it establishes the foundation
for implementation of key developmental activities such as Quality by Design (QbD),
continual improvement, and risk management.8
Backtracking in time, the FDA introduced several influential reports/guidances
during the 2004 calendar year. The first of these was the Critical Path Initiative (via
Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical
Products), which intends to expedite the development (i.e., time-to-market) of novel,
safe, and effective medical products.9 This is to be accomplished, in part, by taking a
different approach to product development, which includes the use of innovative
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techniques (e.g., computer models) to investigate the manufacturability, safety, and
efficacy of candidate molecules and/or drug products.
The advent of comparability protocols is also integral to the objectives of the
Critical Path Initiative. Comparability protocols were established via the Comparability
Protocols Protein Drug Products and Biological Products – Chemistry, Manufacturing,
and Controls Information draft guidance in September of 2003.10 A comparability
protocol “is a comprehensive, detailed, written plan that describes the specific tests and
studies, analytical procedures, and acceptance criteria to be achieved to demonstrate the
lack of adverse effect for a specified type of CMC [chemistry, manufacturing, and
controls] change that may relate to the safety or effectiveness of a drug product.”5
Hence, a manufacturer can meet the criteria for a more lenient reporting category
provided that they sufficiently demonstrate how the amendment will alter product quality
(and, therefore, the risk to public health). This is accomplished by exhibiting a thorough
understanding of the drug, its manufacturing methods and controls, and the effects that
the projected change(s) will have on clinical performance. In certain scenarios, the
change may actually be implemented prior to receiving regulatory approval, potentially
decreasing the time-to-market.10
September of 2004 brought the release of two documents that are central to the
pharmaceutical quality revolution, the Pharmaceutical CGMPs for the 21st Century – A
Risk-Based Approach5 and the Process Analytical Technology (PAT) guidance.6 The
CGMPs for the 21st century was previously addressed as it relates to the CFR regulations.
This report is also significant in that it helped launch the QbD Initiative to encourage
sound development of (quality) pharmaceutical products.5 The QbD architecture
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encompasses “designing and developing a product and associated manufacturing process
that will be used during product development to ensure that the product consistently
attains a predefined quality at the end of the manufacturing process.”8 Subsequently, the
FDA advocated that “under the QbD paradigm, quality is built into the final product by
understanding and controlling formulation and manufacturing variables: testing is used to
confirm the quality of the product.”11 The ICH has also weighed in on QbD, describing it
as “a systematic approach to development that begins with predefined objectives and
emphasizes product and process understanding and process control, based on sound
science and quality risk management.”12 Comprised of several factors including
identification of critical quality attributes (CQAs), risk assessment, and continuous
improvement,13 the most renowned component of QbD is perhaps design space.12
The second 2004 document was the PAT guidance.6 Process Analytical
Technology is “… a system for designing, analyzing, and controlling manufacturing
through timely measurements (i.e., during processing) of critical quality and performance
attributes of raw and in-process materials and processes, with the goal of ensuring final
product quality.” The PAT guidance details a scientific, risk-based regulatory framework
that encourages innovative pharmaceutical development, manufacturing, and quality
assurance through enhanced process understanding. The intent is to instill confidence in
those implementing novel approaches that innovation, when conducted properly, does not
beget additional regulatory scrutiny. In fact, manufacturing processes can be controlled
and validated using the concepts discussed within the guidance.
Although not a definitive indicator, validating pharmaceutical production
processes helps to assure quality. Given its importance, the FDA recently released a draft
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guidance titled Process Validation: General Principles and Practices.14 Process
validation “… is defined as the collection and evaluation of data, from the process design
stage throughout production, which establishes scientific evidence that a process is
capable of consistently delivering quality products.” This assumes that (1) quality has
been integrated into the process (recall that it cannot be tested into a product via inprocess and final-product assessments) and (2) each unit operation is under control such
that the products adhere to all design characteristics and quality attributes, which include
the established specifications derived from predetermined (tolerable) process average and
dispersion estimates.7 All processes, even those founded upon risk- and science-based
design approaches, should incorporate in-process controls to assure product quality.
When controlled appropriately, batch-to-batch, lot-to-lot, and unit-to-unit variability is
such that the units sampled meet or exceed the validation criteria, giving the
manufacturer, the regulatory authorities, (and in essence, the patient) confidence that the
distributed products accurately reflect the label claims. Effective validation requires (1)
an appreciation of the sources of variability, (2) detectability and sensitivity to variation,
and (3) the capacity to “control the variation in a manner commensurate with the risk it
represents to the process and product.”14 With liberty, the final statement also implies
that a certain degree of variability is tolerable; acceptability should be proportionate to
the risk it presents to patients. Validation also intends to confirm that the process is
robust to factors that have the potential to stifle yield (e.g., raw material, manufacturing,
environmental, and/or analytical method variability). Reductions in market supply
clearly hurt the manufacturer, but more importantly, they impact the public well-being.
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Continuous improvement is an underlying theme in each of the aforementioned
documents and is critical to enhancing quality. Although the theory of continuous
improvement is tacit within regulatory guidances, its premise is obvious. Continuous
improvement involves the ongoing effort to enhance the efficiency and effectiveness of
services or manufactured goods, and, therefore, broadly encompasses efforts that
facilitate understanding, innovation, and the availability of affordable, quality drug
therapies. Philosophies and initiatives such as Total Quality Management, Lean
(Manufacturing), and Six Sigma are integral components of continuous improvement and
should not be overlooked within the context of pharmaceutical quality (www.asq.org).
The ultimate goal of continuous improvement is zero-defect production, where all units
(drug products) conform to the utmost level of quality.
1.3.1.1 A Specification-Based World
ICH Q9 states that the “manufacturing and use of a drug product, including its
components, necessarily entail some degree of risk.”4 It is understood that a certain level
of variability is inherent to production. Moreover, the potential sources of variability are
extensive, which increases the complexity of manufacturing. Variability, in turn, imparts
risk to those who manufacture, regulate, prescribe, or consume medical products. It is
therefore necessary to account for its influence. Variability (in essence, quality) is
commonly evaluated via in-process and end-product tests (e.g., blend uniformity and
content uniformity analyses, dissolution testing), which are centered on predetermined
specifications. A specification is “a list of tests, references to analytical procedures, and
appropriate acceptance criteria, which are numerical limits, ranges, or other criteria for
the tests described.”3
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Despite the importance of specifications, there is little guidance available
detailing how they are to be determined. Specifications: Test Procedures and Acceptance
Criteria for New Drug Substances and New Drug Products: Chemical Substances Q6A3
and Specifications: Test Procedures and Acceptance Criteria for
Biotechnological/Biological Products Q6B15 are arguably the foremost documents on
establishing specifications for the endorsement of non-registered new chemical and
biological drug products, respectively; specifications for delivery systems that utilize
well-documented active pharmaceutical ingredients (APIs) are often outlined in
pharmacopoeias, such as the United States Pharmacopeia-National Formulary (USP-NF)
monographs. Within ICH Q6A and Q6B guidelines, specifications are cast as an integral
component in the overall control strategy of ensuring the consistency and quality of drug
products; the control strategy includes (but is not limited to) validated manufacturing
processes and test procedures, good manufacturing practices (GMPs), and raw-material,
in-process, and stability testing. ICH Q6A states that the thorough understanding
acquired during product characterization should be used to establish specifications.
Guidances only imply that specifications should be derived with careful consideration of
process critical control parameters (PCCPs) and product CQAs. Critical quality
attributes are the physical, chemical, biological, or microbiological properties or
characteristics that are known to affect product quality whereas process critical control
parameters are the process variables that affect product CQAs. As such, PCCPs and
CQAs should be identified during product development and, subsequently, should be
controlled within tolerable operational and performance limits using data obtained during
clinical and toxicological studies.
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Acceptance criteria for new drug products are typically proposed, with
accompanying rationalization, by the manufacturer and are approved by the regulatory
agencies. They are implemented not to fully characterize a product, but to substantiate its
quality. It is important to underscore, however, that testing via well-designed
specifications is not the entirety of quality assurance. As stated in ICH Q6A, “the quality
of drug substances and drug products is determined by their design, development, inprocess controls, GMP controls, and process validation, and by specifications applied to
them throughout development and manufacture.”3
Needless to say, specifications serve as surrogates for quality within the current
paradigm. All marketed drug products, via representative sampling, have, therefore,
conformed to the established specifications, providing assurance to the patients that they
are receiving safe and efficacious products. That is not to say, however, that the
practitioners and patients themselves cannot impart additional risk by, for example,
deviating from established dosing guidelines; dynamics such as this are likely to
exacerbate risks imparted by manufacturing. Quality assessments that utilize numerical
acceptance ranges dichotomize quality as either acceptable or unacceptable; only samples
that fall within the upper and lower specification limits are deemed fit-for-use. At best,
all marketed units of a given product are then, by default, categorized as low-risk or
quality outputs. This message is rather misleading given that risk can be readily
communicated as a continuous rather than a nominal metric. Moreover, even when all
other factors are equitable, risk is often disparate within patient populations, which,
although designed not to, can provide a false sense of security to patients.
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Although not always the case, the formulae for performance measurements and
acceptance tests often assume that the response is symmetric with respect to the target or
average value. This suggests that both positive and negative deviations from the target
carry the same intrinsic risk, which, in reality, may be incorrect. Take, for example,
capability, which compares process performance to established specifications. A
common metric for estimating capability is the process capability index (Cpk)

⎡USL − μ μ − LSL ⎤
Cpk = min ⎢
,
3σ ⎥⎦
⎣ 3σ

(1.1)

where μ and σ are the mean and standard deviation of the process, which is assumed to be
normally distributed, and USL and LSL are the upper and lower specification limits,
respectively. Cpk can take on values of (-∞, ∞) and is negative only when the process
mean is beyond the specifications. While certain capability metrics are meaningful only
when the process is centered (e.g., Cp or process capability), Cpk reflects that processes
are not always on target.
The process capability index, which assesses the specification range in relation to
the breadth of the process, is taken as the minimum of the two estimates; the estimates
are equal when the process is centered. Cpk can be enhanced by (1) reducing short-term
variability, (2) altering the mean, or (3) relaxing the USL and LSL. Cpk and/or process
sigma (via the Six Sigma program) estimates are often used to convey the level of
repeatability or quality for a production process. Cpk and process sigma differ only by a
factor of 3.0; hence, a Cpk of 2.0 is equivalent to a process sigma of 6.0.16 Both metrics
have statistical interpretation in that they communicate the likelihood of observing a unit
outside of the specification limits (sometimes referred to as the defect rate), which is
typically expressed as defects per million observations (DPMO) or defects per billion
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observations (DPBO). For example, a Cpk of 2.0 (i.e., process sigma of 6.0) corresponds
to 2.0 DPBO. It is important to note that a process sigma of 6.0 corresponds to 3.4
DPMO when the 1.5 σ shift is applied to account for drifts in the process mean.1 The
corresponding DPMO or DPBO for any Cpk can be determined from a z table for the
standard normal distribution.
Capability, therefore, addresses the issue of how well the process is controlled
with respect to the specifications by quantifying the measurements that are within the
limits. Assuming that the specifications are established to mitigate risk (and that the
more in control a process is, the less risk it poses), Cpk and risk are inversely related.
Quality and Cpk, however, are positively correlated. Recognizing that the USL and LSL
are typically set equidistant from the target value, Cpk does not take into consideration
whether the deviation is positive or negative with respect to the mean, despite the fact
that it can analyze non-centered processes. Given that risk is likely asymmetric with
respect to the process mean (e.g., positive and negative deviations from the nominal API
level may pose different risks), Cpk can be misleading if quality is interpreted, for
instance, in terms of clinical performance. While this is irrelevant in certain industries,
this is critical in regards to pharmaceutical products.
1.3.1.2 21st Century Pharmaceutical Production
ICH recently released the Harmonised Tripartite Guideline Q8(R1) to address the
development of pharmaceutical products and their associated manufacturing methods.12
One of the key objectives of Q8(R1) is to offer direction for effectively reporting process
and product knowledge obtained through risk- and science-based design and development
efforts to regulatory officials. Additionally, issues that often provide evidence to
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inspectors and reviewers that the applicants have achieved an enhanced understanding are
highlighted. Enhanced product and process knowledge combined with effective
reporting methods mitigate risk to public safety, which can lead to reduced regulatory
oversight.
ICH Q8(R1) also supports the QbD initiative. Not only does process and product
design help to establish specifications and manufacturing controls, they aid in the
construction of the design space(s). A design space is “the multidimensional
combination and interaction of input variables (e.g., material attributes) and process
parameters that have been demonstrated to provide assurance of quality.”12 The design
space(s) is included in the application package and is therefore reviewable. Since it is
subject to approval, only intentional deviations outside of the design space constitute a
post-approval change; inadvertent departures are potential bases for product failure.
Appendix 1 of ICH Q8(R1) contrasts two very different approaches to
pharmaceutical development; the minimal (sometimes referred to as the traditional)17 and
the QbD approach. The two methodologies are compared side by side in Table 1.1 based
on six different categories: overall pharmaceutical development, manufacturing process,
process controls, product specifications, control strategy, and lifecycle management.12 At
the one extreme, the traditional methodology underscores a rather archaic approach to
pharmaceutical production. This approach embraces many of the practices that helped
spur the pharmaceutical quality revolution. On the other hand, the QbD methodology
employs the guiding principles of the quality revolution and serves as a step towards the
desired state (i.e., risk- and science-based design, control strategies centered on quality,
real-time release, risk-based regulatory architecture). While neither methodology

17

accurately summarizes the whole of pharmaceutical production, it is a safe assumption
that the current state is more aptly outlined by the minimal approach.
Table 1.1 Comparison of the minimal and QbD methodologies for pharmaceutical development. Amended
from ICH Q8(R1).

Aspect
Overall
Pharmaceutical
Development

Minimal … The Current
State?
• Empirically driven
• Inefficient experimental
design

Manufacturing
Process

• Fixed
• Concerned with
reproducibility

Process
Controls

• In-process testing only
when necessary
• Off-line analyses

Product
Specifications

• Principle method of control
• Derived according to batch
data

Control
Strategy

• In-process and final
product testing

Lifecycle
Management

• Reactive; action taken
typically only when
problems arise
• Post-approval change

QbD…A Trend Towards the
Desired State
• Mechanistically and
scientifically driven
• Multivariate experimental
design
• Incorporation of PAT and
design space
• Flexible (within design
space)
• Concerned with robustness
and a quality control
strategy
• PAT system
• Feed forward and feedback
via process and control
models
• Integrated component of
quality control strategy
• Derived according to
desired product
performance
• Risk- and science-based
quality control strategy
• Real-time release
• Continuous improvement

As pharmaceutical production progresses towards the desired state, it is apparent
that both PAT and QbD will have, at least for the foreseeable future, a central role in
assuring product quality. Figure 1.1 illustrates the role of design space with regard to
risk- and science-based pharmaceutical manufacturing. PAT is integral to designing,
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analyzing, and controlling processes.6 As a thorough understanding of the product and
process is acquired through the PAT system, PCCPs and CQAs are identified. Research
and development efforts are essential in gaining product and process knowledge.
Additional experimentation, however, increases the manufacture’s investment, which is
why the direction and extent of research needs to be carefully balanced with the potential
benefits in order to provide affordable, safe, and innovative medical products to the
public. Experimental design, which is a key aspect of PAT, should be utilized to obtain
the maximum amount of information in as few trials as possible. Experimental design
undoubtedly extends operational ranges well past that which is implemented during
controlled production, which enhances sensitivity to the critical parameters/attributes.
These data are then used to construct the n-dimensional design space, which is comprised
of inter-related PCCPs (e.g., compaction pressure) and material attributes that are known
to affect product quality. The perimeter of the hyperspace is established according to a
thorough understanding of the inputs and their relationship to a given performance
metric(s). Efficient design and modeling not only reduce the ambiguity surrounding the
boundaries, they increase the robustness of the design space, which minimizes the
potential for upset (i.e., product of unacceptable quality) due to unanticipated variation.
The critical-to-quality variables are then monitored (via sensors) and controlled (via
process and control models) to be within the limits of the design space. This ultimately
ensures the desired level of product quality. Ideally, the design space would be defined
according to clinical risk.
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Figure 1.1. The inter-relationship between PAT, design space, and pharmaceutical manufacturing. Adapted
from R.C. Lyon, Process monitoring of pilot-scale pharmaceutical blends by near-infrared chemical
imaging and spectrosocopy, Eastern Analytical Symposium (EAS), Somerset, NJ, 2006.

Given the overall complexity of pharmaceutical manufacturing, the number of
material, process, and product attributes/parameters that potentially influence quality is
sizeable. Experimental design and risk assessment can be utilized to not only help
identify those factors that affect product CQAs, but to rank the importance of the
individual factors based on their significance and elucidate potential confounding
attributes/parameters. As development efforts progress and more data become available,
they can be incorporated to gain additional understanding. These data also help establish
the processing conditions under which quality product is reliably produced. The
corresponding operational ranges of the PCCPs (as they relate to CQAs) can then be used
to construct the design space.
As ICH Q8(R1) outlines, considerable regulatory flexibility is promised to sound
submissions that provide justification for the inputs and process parameters that were
included in (and excluded from) the design space.12 A number of sequential design
spaces can be generated for each unit operation within a manufacturing process. Figure
1.2 was reproduced from ICH Q8(R1), Appendix 2, Example 3.12 It illustrates a design
space for drying where the target moisture content is 1-2 %. Assuming that there were
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additional unit operations downstream from drying, intermediate material outside the
design space limits would not be suitable for further processing due to excessive impurity
formation or excessive particle attrition. Alternatively, a single design space that bridges
all unit operations is also acceptable. Figure 1.3, which was reproduced from ICH
Q8(R1), Appendix 2, Example 2,12 is an example of one such overarching design space
that was constructed from two single attribute design spaces for friability and dissolution
testing. The limits are simply defined as the overlapping ranges of tolerable outputs,
which were both dependent on the two PCCPs. Given that both friability and dissolution
are dependent on a number of inter-related factors, for example, the type and proportion
of excipients, the homogeneity of the blend, the radial tensile strength of the tablets
(which itself is dependent on a number of confounding manufacturing parameters, such
as compaction pressure, turret speed, blending speed, blending time, charge order,
blender volume, etc.), it is easy to conceptualize how this one design space accounts for
numerous processing parameters and product attributes. Regardless of whether several
consecutive hyperspaces or one overarching hyperspace is utilized, manufacturers can
specify if they will operate within the entire design space or within some restricted area.
Despite the flexibility, one thing should always be consistent from design space to design
space: operation within the limits yields quality product.12
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Figure 1.2. Example design space illustrating the moisture content as a function of time during drying. The
target moisture content is 1 - 2 %. Intermediate material outside the limits would not be suitable for further
processing. This figure was reproduced from ICH Harmonised Tripartite Guideline Pharmaceutical
Development Q8(R1), November, 2008.

Figure 1.3. Overarching design space determined from two inter-related design spaces. Friability and
dissolution were identified as the CQAs while two parameters (labeled 1 and 2) of a wet granulation unit
operation were identified as the PCCPs (e.g., excipient particle size distribution, water content, granule
size). The overlapping regions of the two inter-related hyperspaces are identified here as "Design Space."
This figure was reproduced from the ICH Harmonised Tripartite Guideline Pharmaceutical Development
Q8(R1), November, 2008.
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Whether or not QbD concepts are integrated, the minimum compulsory
components to be included in pharmaceutical development are:12
1. A quality target product profile
2. Potential product CQAs
3. CQAs of the API, excipients, and other integral components. This includes
selection of the appropriate inactive ingredients and their proportions in the final
delivery system.
4. A suitable manufacturing route
5. A control strategy.
These items are necessary to control the manufacturing process such that component and
product CQAs are suitable to yield the desired quality target product profile (QTPP). A
quality target product profile is “a prospective summary of the quality characteristics of a
drug product that ideally will be achieved to ensure the desired quality, taking into
account safety and efficacy of the drug product.”12 As such, product design and
development efforts are structured around the QTPP. Overall, quality can not be assured
when one or more of these elements are, in whole or part, absent.
While the above strategy can be followed to assure quality, the QbD initiative
incorporates several supplementary strategies, which help lay the foundation for
continuous improvement over the lifetime of the product. The QbD approach
comprises:12
1. Systematically assessing and improving the product and process design, which
includes
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a. Use of a priori knowledge, experimental design, and risk assessment to
identify material characteristics and process parameters that are potentially
critical-to-quality
b. Determining, either empirically or via first principles, the mechanistic
relationships between material characteristics and process parameters to
product CQAs
2. Developing a control strategy founded upon process and product knowledge and
quality risk management techniques. The control strategy may contain design
space(s) and/or measures for real-time release testing.
Unlike final product testing, which as the name implies, involves assessing the product as
or after it leaves the production line, real-time release testing is the assessment of inprocess and/or final product quality via process data, which would consist of various
PCCPs and CQAs. As quality is incorporated within the design, the product and its
intermediates are assessed in real-time (i.e., during processing) to substantiate its quality.
Real-time release therefore becomes a surrogate for the various analytical procedures
necessary for final product release.6
The QTPP is clearly a crucial element in pharmaceutical development whether or
not QbD tactics are incorporated. As consumers are more or less incapable of assessing
quality, the manufacturer (by defining the QTPP) and the regulatory agency (by
approving the product and its QTPP) ultimately dictate the level of quality that is
acceptable for patients. The QTPP should be established according to numerous product
and performance features, which include:
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1. “Intended use in clinical setting, route of administration, dosage form,
delivery systems;
2. Dosage strength(s);
3. Container closure system;
4. Therapeutic moiety release or delivery and attributes affecting
pharmacokinetic characteristics (e.g., dissolution, aerodynamic performance)
appropriate to the drug product dosage form being developed;
5. Drug product quality criteria (e.g., sterility, purity, stability and drug release)
appropriate for the intended marketed product.”12
Since the QTPP specifies the desired quality and design space has a critical role in
assuring product quality, it stands to reason that when pharmaceutical development
involves QbD, the limits of the design space(s) can be defined by aspects of the QTPP.
Moreover, the most important facet of the QTPP is the safety and efficacy of the drug
product. Therefore, efforts should be made to construct the design space according to the
attributes and parameters that directly affect safety and efficacy. After all, safety and
efficacy are truly the principal benchmarks of pharmaceutical quality.
1.3.1.3 A New Definition of “Pharmaceutical Quality”
Quality is equally vital to the manufacturers, regulators, and consumers of
pharmaceutical products. Regulatory officials, researchers, and academicians alike
appreciate the disharmony surrounding pharmaceutical quality. In an effort to more
effectively communicate allowable consumer risk, in part, determined through content
uniformity testing, Williams et al.18 suggested an alternative method where (risk)
tolerance limits (for content uniformity) would be “based on a better understanding of
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population and individual dose/response curves for efficacy and toxicity.” Janet
Woodcock, Director of the Center for Drug Evaluation and Research (CDER) at the
FDA, pushed the envelope when she summarized several of the industry’s (quality)
shortcomings (e.g., quality assessment via end-product testing) and thus, the underlying
frustrations of many individuals amid the “current state.”19 At the conclusion of her
article, Dr. Woodcock purposed re-defining pharmaceutical quality in terms of risk by
relating clinical attributes to production characteristics. The ideas put forth by Williams
et al. and Woodcock are, at minimum, revolutionary as they not only present the
opportunity to directly manage production in terms of product performance, they offer
the impetus to reform the pharmaceutical industry. These visions have been largely
ignored to date.
Cogdill and Drennen took notice when they laid the foundation for relating
manufacturing quality and clinical performance of a drug product.20 They described the
combination of probabilistic risk assessment (PRA) and Monte Carlo simulation (MCS)
to relate elements such as raw material quality, product design, population statistics,
dosing guidelines, and patient compliance estimates with pharmacokinetic (PK),
pharmacodynamic (PD), and in vitro-in vivo correlation (IVIVC) models to remold
quality in terms of risk. The objective was to translate manufacturing and drug product
attributes into estimates of risk of toxicity and inefficacy. Given the appropriate
modeling, the interpretability of risk can be enhanced by transforming the metric from a
nominal (i.e., acceptable or unacceptable) or categorical (i.e., low, medium, high) to a
continuous (probabilistic) response. Moreover, the proposed platform departs from the
current series of univariate measures that do not effectively account for covariance
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among observations by harnessing multivariate data to simultaneously model the
confounding factors that influence product performance. The model-based platform
could then be used, for example, to define CQA hyperspaces bounded by risk or set
manufacturing performance targets (e.g., Cpk) based on tolerable risk. With estimates of
risk of toxicity and inefficacy, product and process design could then focus on
minimizing overall risk to the patient. Risk to patients is both an effective gauge of
quality and a more detailed means of communicating quality to consumers. This has the
potential to redefine the marketplace, in effect reallocating purchasing power to the true
customer (i.e., the patient), allowing him/her to make informed, risk-based decisions with
the guidance of clinicians.
In addition to altering the manner in which consumers perceive pharmaceutical
products, this novel methodology transforms the system in which products could be
released and approved. The current system typically requires a series of sequential tests
(e.g., content uniformity, assay, dissolution), which if the sampled units are within the
specifications, the product is determined to be acceptable for release to the general
public. Under the new paradigm, the confounding factors (e.g., uniformity, release rate,
clinical performance) would be modeled (with respect to risk) simultaneously, effectively
supplanting the need to set numerous specifications. Product release and approval,
therefore, would be based on limits of tolerable risk to patient safety. This is consistent
with the QbD approach of defining product specifications according the desired product
(clinical) performance (Table 1.1).
Dickinson et al. published an article shortly after Cogdill and Drennen concerning
dissolution testing and its link to clinical performance within the QbD paradigm.21 The
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objective was to demonstrate that in vitro dissolution testing is sensitive to
manufacturing, formulation, and in vivo (bioavailability) changes such that the method
could be used to assure that the safety and efficacy of newly tested products mirrors that
observed in the preceding clinical assessments. A functional relationship between the
pharmacokinetics and pharmacodynamics of a drug is truly required to effectively model
clinical performance. As the authors highlighted, however, this relationship is not always
available during the development stages. Thus, pharmacokinetic modeling was used as a
surrogate for analyzing safety and efficacy. Ultimately, the relationship between
manufacturing and composition variables and clinical performance was proposed to be
used to set the boundaries of the operational design space for in vitro dissolution. The in
vitro dissolution test, therefore, would be capable of assessing the influence that product
changes have on clinical performance.
The authors proposed five strategic components for establishing a methodology
capable of harnessing in vitro dissolution testing for evaluating clinical performance.21
1. Using a priori knowledge of the product under development and/or comparable
products, perform a risk assessment to identify the various risks to clinical quality.
2. Develop a dissolution method that is sensitive to process and product variables
that are expected to influence dissolution of the drug. The method should be
physiologically relevant.
3. Ascertain from the in vitro and in vivo data the impact that changes to these
variables have on clinical performance.
4. Define the dissolution specifications that ensure clinical performance.
5. Control dissolution within the limits of the design space to ensure clinical quality.
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Following a risk assessment to prioritize the product and process variables most
likely to affect safety and efficacy, four different dosage forms comprised of an
unidentified model drug were investigated based on their likelihood to alter the
dissolution release profile (which should affect the pharmacokinetics, and consequently,
safety and efficacy). Following in vitro and in vivo analyses (in human volunteers), the
authors observed comparable in vivo performances amongst the four formulations,
despite their dissimilar dissolution profiles. Consequently, the authors did not attempt to
establish an IVIVC, but concluded that it was not required to define a clinically relevant
design space since in vitro dissolution testing was able to distinguish the formulation and
manufacturing differences. Several different approaches to defining the dissolution
specifications were presented. The first is in agreement with the FDA guidance22 for
situations where a Level A IVIVC has been established. When this is the case, Cmax or
AUC should not deviate more than ± 10 %. When the pharmacokinetics of the drug are
not appreciably effected by variability in dissolution, as was the case for the model drug
selected by Dickinson et al., the authors advocate that a “safe space” can be indentified
where the change in pharmacokinetic parameters is minimal over a defined range of
dissolution conditions (e.g., t50, t90). Lastly, a combination of a safe space and an IVIVC
can be specified to allow the pharmacokinetic parameters to be controlled within ± 10 %
deviation. Efforts such as these will reduce the burden of clinical trials, effectively
promoting more efficient pharmaceutical development and manufacturing.21
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1.3.2 Theophylline
1.3.2.1 Background
Theophylline (Figure 1.4) was formally introduced for the treatment of status
asthmaticus (i.e., acute asthma) in 1937 following six years of investigational therapy
during which Drs. Herrmann and Aynesworth observed relief in several patients.23 It
was, however, administered to humans as early as 1904, where it was noted to cause
acute poisoning.24 Since its introduction, theophylline has been used more frequently for
chronic cardiorespiratory disorders25 and, to a lesser extent, for the treatment of neonatal
apnea.26 A xanthine derivative, theophylline is prescribed for the management of acute
and chronic bronchospasms linked to asthma and chronic obstructive pulmonary disease
(COPD). Despite being largely supplanted by newer bronchodilators (e.g.,
corticosteroids, beta-2 adrenergic agonists), theophylline is beneficial for certain patients,
including those who fail to adhere to or cannot meet demanding dosing schedules, and
those who experience inadequate relief from available alternatives. It is one of the most
commonly prescribed medications worldwide for the management of airway diseases due
to its low cost. While it is generally regarded as a third-line treatment, theophylline is
sometimes the only affordable alternative to inhaled corticosteroids.27 Additionally, its
anti-inflammatory and immunomodulatory effects have generated added attention to the
drug’s clinical potential.25 Theophylline is also frequently utilized as a model drug for a
variety of research foci, including investigations into the disparity in clearance
mechanisms between neonates and adults28 and the evaluation of physiologically-based
PK models. 29,30
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Figure 1.4. Chemical structure of anhydrous theophylline, C7H8N4O2, CAS registry number 58-55-9.

Theophylline has been almost universally classified as a bronchodilator, but its
capacity to manage chronic asthma cannot be fully explained by its modest
bronchodilator activity. Although the molecular mechanisms of action for theophylline
are still in question, the general consensus is that the immunomodulatory, antiinflammatory, and bronchoprotective effects collectively contribute to its pharmacologic
actions. Theophylline nonselectively inhibits phosphodiesterase, which is responsible for
cleaving phosphodiester bonds, such as those found in cyclic 3’,5’-guanosine
monophosphate (cGMP) and cyclic 3’,5’-adenosine monophosphate (cAMP). At
therapeutically relevant concentrations, theophylline induces an increase in intracellular
cGMP and cAMP concentrations, which results in bronchodilation and inhibition of
inflammatory and immune cells. Theophylline also acts as a nonselective antagonist of
adenosine receptors at these concentrations. Although adenosine has virtually no effect
on airway smooth muscle of non-asthmatic individuals, it elicits bronchoconstriction in
asthmatic patients. Theophylline has also been noted to reduce fatigue in diaphragmatic
muscles, enhance mucociliary clearance, block the decrease in ventilation that occurs
with sustained hypoxia, and lessen microvascular leakage of plasma into the
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airways.25,27,31 Further information regarding the potential mechanisms of action is found
in the articles by Barnes27 and Barnes and Pauwels.31
1.3.2.2 Absorption, Distribution, Metabolism, and Excretion
Theophylline is a water-soluble drug that is rapidly and completely absorbed
when administered in solution or as fast dissolving uncoated tablets.25,28 Selected
controlled- or extended-release dosage forms, however, are not 100 % bioavailable;
certain products have reported fractions of the dose absorbed systemically of as low as
0.42.32 Absorption occurs throughout the gastrointestinal tract, and the extent of
absorption has been reported to be comparable in the stomach, the small intestine, and the
colon.33 Others, however, have observed greater quantities of theophylline absorbed in
the small intestine when compared to the stomach and colon.34 Theophylline is
distributed primarily in extracellular fluid with a volume of distribution of approximately
0.45 to 0.5 L/kg. It is roughly 40 % protein bound (largely to albumin), but due to agerelated variability, the range is reported to be 40 – 60 %.35 Despite the variability,
measurements of total serum concentrations are said to accurately reflect the unbound
fraction.36 Theophylline is typically considered to be rapidly removed from the body; the
plasma half-life in adults is 7 – 9 hours.35 While this may be accurate for the majority of
the population, dramatic fluctuations in the elimination rate have been observed and the
average half-life has been reported to be 1.2 – 65 hours.37
It is generally accepted that serum concentrations of 10 – 20 mg/L define the
therapeutic range of theophylline.25,38,39 Researchers, however, have observed responses
at concentrations as low as 5 mg/L,26,31 and thus, have suggested altering the therapeutic
window to 5 – 15 mg/L to avoid potentially toxic events,35 which are more probable at
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higher serum concentrations. Others are content to report the therapeutic window as 5 –
20 mg/L.40,41 Toxic effects of theophylline include nausea, vomiting, abdominal cramps,
diarrhea, headache, arrhythmias, tremor, agitation, hypothermia, seizures, brain damage,
and mortality.25,42,43 Despite viewpoints that the severity of toxic events was correlated to
the drug level, it is apparent that typical toxic symptoms associated with lower serum
concentrations (e.g., nausea, vomiting) do not necessarily precede severe adverse
reactions (e.g., seizure, death).38
Although theophylline has been used to manage cardiorespiratory conditions for
over 70 years, the dose-response relationship remains unclear. Most references indicate
that theophylline is primarily (~90 %) metabolized via the liver and the remainder is
excreted unchanged in the urine.35 While this is reasonably accurate for the general
population, certain sub-groups (e.g., neonates, those with liver diseases) eliminate
theophylline differently. Disposition, metabolism, and excretion of theophylline are
dependent on a variety of factors and its metabolic pathway interacts with that of
caffeine, which is also a xanthine derivative. Caffeine and theophylline are structural
analogues that differ by a single N-methyl group and both molecules undergo hepatic
metabolism via similar saturable mechanisms.28
The following discussion focuses on the metabolism and excretion of
theophylline, and the relevant conversions between the two analogues. For particulars
regarding the elimination of caffeine, please refer to the article by Ginsberg et al.28 The
predominant mechanism of removal for theophylline in adults is metabolism via the
cytochrome P450 (CYP) 1A2 enzyme (Figure 1.5). The three resultant metabolites are 3methylxanthine and 1-methyluric acid (via N-demethylation), and 1,3-dimethyluric acid
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(via 8-hydroxylation); theophylline is converted to the intermediary product 1methylxanthine, which is ultimately oxidized (via C8-oxidation) to 1-methyluric acid by
xanthine oxidase. 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine
constitute 45 – 55 %, 15 – 20 %, and 10 – 15 %, respectively, of the urinary metabolites
in adults.35 While metabolism is almost universally attributed to CYP1A2, other CPY
enzymes (e.g, CYP1A1, CYP2E1, CYP3A4) and flavin-containing monooxygenases
(FMO) have been established as minor contributors to the biotransformation of
theophylline. For example, several studies indicated that CYP2E1 and CYP3A4, in
addition to CYP1A2, contribute to the oxidative metabolism of theophylline to 1,3dimethyluric acid.44 Further, metabolism of theophylline by both CYP1A1 and CYP1A2
has been observed.28,44 Given that only minor quantities of CYP1A1 are expressed in the
liver, these findings suggest that a certain amount of theophylline is metabolized
elsewhere. It is common modeling practice, however, to restrict metabolism to the liver
only. Caffeine, on the other hand, counteracts the elimination of theophylline as one of
its primary metabolic pathways yields theophylline (Figure 1.5).28 Since the metabolism
of caffeine to theophylline elevates blood levels of the latter, consumption of caffeine is
often times restricted or even prohibited during treatment with theophylline.
Consumption of soda, tea, and coffee has been reported to yield theophylline serum
concentrations of less than 3 mg/L.42
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Figure 1.5. Diagram of the major metabolic pathways for theophylline and caffeine. CYP represents
cytochrome P450 and FMO is the acronym for flavin-containing monooxygenases.

While predominant in adults, the CYP1A2 metabolic pathway is under-developed
in neonates and infants. Consequently, theophylline elimination is altered in newborns.
To begin with, roughly 50 % of the theophylline dose is excreted unchanged in the urine
of neonates. Despite the fact that renal elimination is enhanced, it is not as efficient as
metabolism via CYP1A2, which results in a net decrease in theophylline clearance in
neonates as compared to adults. This is manifest by the three- to five-fold increase in the
half-life of theophylline in neonates (20 – 34 hours compared to 7.3 hours in adults).
Secondly, upwards of 40 % of the theophylline is metabolized via 8-hydroxylation in
newborns (presumably by means of CYP2E1 and/or CYP3A4), which has been reported
to be less than that in adults. Finally, approximately 5 – 10 % of the theophylline is
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converted to caffeine and excreted in the urine, which has been observed in both neonates
and infants.35 This mechanism has never been detected in adults, suggesting that it is
perhaps a compensatory pathway found only in neonates.28,35 Metabolic enzyme activity
comparable to that in adults is not normally observed until approximately 3 years of
age.44
Inter-patient variability is perhaps best epitomized by the extreme disparity in
theophylline clearance.43,45 This is substantiated by the work of Jusko et al. who
observed clearance values ranging from 4 – 143 mL/hr/kg in 200 individuals with diverse
physiological, pathophysiological, environmental, and behavioral characteristics.46
Factors other than age (e.g., sex, diet, concomitant drug therapies, recreational drug use,
obesity, illness, pregnancy) also obfuscate the disposition and elimination of
theophylline.26,42,43,46,47 For example, polycyclic aromatic hydrocarbons found in tobacco
smoke have been shown to induce several drug-metabolizing enzymes (i.e., CYP1A1,
CYP1A2, and CYP2E1), which ultimately increase the clearance rates of theophylline by
upwards of 80 % in smokers as compared to nonsmokers.48 Elevated clearance rates
have also been observed in smokers weeks to months following abstention. Individuals
subjected to second-hand smoke also have enhanced theophylline clearances. In addition
to the direct influence on enzymatic biotransformation, smoking has physiologic
manifestations, such as vasoconstriction, which decreases blood perfusion to the liver,
ultimately reducing the elimination of theophylline. Therefore, the safety and efficacy
profiles for smokers are distinct, and their dosage regimens must be adjusted
accordingly.48
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1.3.2.3 Dosing
Numerous attempts have been made to define theophylline dosing regimens for
given sub-populations,37,41,42,49 but none have been proven to be applicable to the general
population; when tested in independent sub-populations, most patients required dose
adjustments to bring their serum levels within the defined therapeutic range.43,45,47,49
Though Bayesian forecasting methods50,51 appear to be most accurate, these dosing
regimens do not supplant the need to closely monitor serum concentrations to ensure
proper administration.49 To date, no universal dosing method has been generated for
theophylline.
Due to the unpredictable nature of dosage requirements, individualized dosage
regimens have been posited as a reasonable method of safely dosing patients with
theophylline.35,39,49,52 “It is important to realize that there are wide interindividual
differences in theophylline clearance and in the degree of its interaction with other
agents. Therefore, data in the literature should be regarded only as a general guide, and
careful observation for adverse drug reactions and blood level monitoring have to be
conducted in most patients.”35 Individualized methods, however, are restrictive in that
they necessitate estimations of serum concentration to ensure proper dosing. Hurley et
al. demonstrated in a randomized clinical trial that in contrast to dosages based on serum
theophylline concentrations alone, utilizing each patient’s estimated theophylline
clearance enhanced the accuracy of dosing.53 Irrespective of the dosing scheme,
extensive inter-patient pharmacokinetic variability coupled with the narrow therapeutic
window complicate the administration of theophylline.
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Several research groups have attempted to model the clearance of theophylline as
a result of the significant challenges that inter-patient variability poses to clinicians for its
accurate dosing. Chiou et al. introduced a method to rapidly estimate the total body
clearance of theophylline following constant-rate intravenous (IV) infusion that requires
two plasma samples and a reasonable estimate of the apparent volume of distribution.37
This method was demonstrated using rabbits as test subjects. Similarly, Powell et al.
assessed three routines for modeling total body clearance in healthy volunteers and
patients suffering from airway obstruction who were administered theophylline via
constant-rate IV infusion.45 These methods required up to seven blood samples for the
analysis of theophylline concentration.
In addition to modeling the clearance, Powell et al. also studied the effects of
various (potentially confounding) factors on the clearance and volume of distribution,
including sex, age, race, smoking habits, bronchitis, asthma, pneumonia, congestive heart
failure, and severity of bronchial obstruction in 31 healthy volunteers and 26 patients.
They found that sex, age, race, and the diagnosis of asthma or chronic bronchitis per se
had no significant effect on clearance, whereas smoking, severe congestive heart failure,
pneumonia, and severe bronchial obstruction resulted in significant changes.
Additionally, the authors observed that, with the exception of patients who had severe
congestive heart failure or pneumonia, changes in theophylline clearance during the
course of the therapy were minor; no change as a function of time was observed in the
healthy volunteers. In contract to clearance, the volume of distribution was not correlated
with any of the factors examined. The authors suggested that these data supported the
argument that changes in half-lives for a given disease state are a result of alterations in
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clearance rather in the volume of distribution. Thus, with the exclusion of those patients
whose clearance is expected to drastically change throughout the course of treatment,
they conclude that a single theophylline concentration should be adequate for the entire
IV theophylline therapy.45
Jusko et al. also performed an extensive retrospective study to model the
environmental and pathophysiologic factors that affect theophylline clearance in 200
patients and normal volunteers, including age, sex, liver disease, congestive heart failure,
obesity, renal function, history of drug, tobacco, marijuana, caffeine, or alcohol use, and
pregnancy.46 The history of drug use included consideration of oral contraceptives,
barbiturates, benzodiazepines, phenothiazines, and tricyclic antidepressants. Clearance
was modeled using a previously developed nonlinear algorithm.54 The authors noted that
other factors (e.g., marked dietary changes, respiratory viral illness, thyroid dysfunction,
acute steroid administration, low arterial PO2, recent ingestion of charcoaled foods) could
affect the disposition of theophylline; however, they were either not acknowledged as
factors at the time this study was performed or these data were unavailable. All but 8 of
the subjects were Caucasian; therefore, differences attributable to race were not
examined. Of the factors assessed, age, liver disease, smoking status, and congestive
heart failure significantly altered clearance.
Additionally, Jusko et al. sought to characterize the variability in theophylline
clearance within the sample population. Analysis of variance was used to determine the
order, priority, and interactions of the factors that correlated with theophylline clearance
to yield the maximum statistical discrimination between groups.55 Clearance estimates
were subdivided into mutually exclusive subgroups based on the reduction of
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unexplained variance (p < 0.01). If a factor was previously accounted for, but had the
potential to mediate the effects of factors yet to be considered, it could be reintroduced
for assessment. Ultimately, the authors generated a clearance cascade, which illustrates
the mean and standard deviation of total body theophylline clearance for each subgroup.
This cascade can be reduced to a linear dosing nomogram to aid physicians in effectively
targeting steady-state theophylline serum concentrations. The authors concluded that
variability due to phenothiazines, tricyclic antidepressants, severe renal impairment, or
oral contraceptives in nonsmokers could not be discounted as these categories were
inadequately represented. Furthermore, they cautioned that many of the
drug/disease/history/physiologic associations had not yet been verified in a prospective
clinical trial.46
By means of 16 patients experiencing airway obstruction, Gilman et al.56
compared the methods of Powel et al.45 and Jusko et al.,46 and a weighted least-squares
Bayesian approach and the method of Chiou et al.37 for the estimation of theophylline
clearance following administration of aminophylline via IV infusion. Percent error was
used to quantify the predictive error. Patients suffering from acute congestive heart
failure, cirrhosis of the liver, pneumonia, sepsis, or severe malnutrition, or those who had
taken erythromycin or cimetidine were excluded. The authors concluded that the Jusko et
al. method out-performed that of Powel et al.; however, the patients were categorized
into only 7 of the possible 16 terminal nodes of the Jusko et al. clearance cascade.
Moreover, the Bayesian method was found to be more precise and less biased than the
Chiou et al. routine; however, the requirement of selecting a prior model for the
individualized expectations of pharmacokinetic parameters and their corresponding

40

variances limits the applicability of the Bayesian method when these models have not
been adequately developed.
The most accepted dosing schedules for theophylline require administration one
(i.e., q.d.), two (i.e., b.i.d.), or three (i.e., t.i.d.) times per day; however, regimens that
necessitate multiple daily dosages are believed to exacerbate patient non-compliance.
However, previous reports have shown that once-daily dosing of theophylline increases
the likelihood of observing serum concentrations outside the therapeutic window.32,57-59
This finding has lead researchers to advise twice-daily dosing, which has been shown to
result in less extensive peak/trough fluctuations, thus increasing the probability of
maintaining concentrations within the desired range. Despite the (supposed) reduced risk
of an inefficacious or toxic event associated with twice-daily dosing, researchers contend
that higher clinical efficacy is attained with once-daily dosing.58,60,61 Additionally, it has
been stressed that fluctuations in clinical effects that closely parallel the oscillations in
serum concentration, which would advocate twice-daily dosing, have not been
substantiated in published studies.58

1.3.3 Mathematical Modeling and Numerical Simulation
The terminology modeling (or model) and simulation are occasionally used
interchangeably so as to suggest they share a common definition. While they both are
abstract representations of real-world systems, each has a distinct meaning and it is
important to differentiate between them. These terms are used throughout the remainder
of this dissertation according to the definitions provided by Peter Bonate, noting that the
original definition of simulation is expanded.62 A model signifies any mathematical
construct generated using fundamental processes or data that relates inputs to outputs,
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whereas simulation is the exploitation of models to examine the long-term impact that
variability [or uncertainty], treated as an input to the model, has on a system. The term
simulation is broadened to include assessments of uncertainty. Table 1.2, which was
adapted from Bonate’s work, contrasts the two expressions.62
Table 1.2. Comparison and contrast of the terms modeling and simulation. Adapted from Bonate, PL.
2000. Clinical trial simulation in drug development. Pharmaceutical Research 17(3):252 – 256.

Modeling
Sensitive to assumptions
Sensitive to black-box criticisms
Uses data
Useful method for data summarization

Relates inputs to outputs
Random variability is a nuisance variable
Looks back in time
Can identify which variables are more
important than others
Cannot be replicated

Simulation
Sensitive to assumptions
Sensitive to black-box criticisms
Builds upon models based on data
Useful method to summarize complex
inter-relationships between variables
Incorporates random variability [or
uncertainty] into a model and assesses its
effects long-term
Random variability can be incorporated
in the simulation
Looks forward in time
Can indentify which variables are more
important than others
Can be replicated

1.3.3.1 Monte Carlo Simulation
Mathematical models provide users the opportunity to manipulate inputs to
examine outputs, which offers greater insight into the functionality of processes and
systems. Models are categorized according to the flexibility of their inputs; when all are
fixed, the model is said to be deterministic, whereas when some or all of the terms are
characterized by a certain level of random variability, the model is stochastic. Simulation
harnesses models to observe an outcome or a prediction based on a given set of
parameters (i.e., inputs). Stochastic modeling techniques that utilize random variability
are typically referred to as MCS. Stanislaw Ulam and John von Neumann are credited
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with coining the expression Monte Carlo, which came during their work on the atomic
bomb at Los Alamos in 1946. Rugen and Callahan make the distinction, however, that
Ulam developed the approach earlier while playing solitaire.63 Though the phrase is a
reference to the gambling casinos in Monaco, it was initially used to simulate random
neutron diffusion in fissile material.63-65
The Monte Carlo method is a numerical technique used to solve mathematical
functions by random sampling. Although the theory of random sampling was established
long before the Monte Carlo method, MCS was not practical until the advent of
computers. The universal approach of the Monte Carlo method is simple; MCS
iteratively samples a set of random model parameters from their underlying distributions
(which are generated a priori), performs a number of deterministic computations using
the inputs, and stores the resultant outputs. Thus, a program is constructed to conduct a
number of independent, random trials, the results of which are accumulated at the
conclusion of each iteration. The Monte Carlo method is applicable to any system that is
affected by random factors. Unlike deterministic functions, MCS has the distinct
advantage of estimating the sensitivity or robustness of a system to random variation or
error through the propagation of uncertainty. This uncertainty allows stochastic elements
of a system to better represent practical observations, which can lead to more precise
conclusions and/or actions.64,65
The Monte Carlo method utilizes random variables, which implies that for any
given trial, the value assumed for a given input is unknown. The term “random,”
however, has a more specific meaning in the context of MCS in that the range of
potential values the variable can assume, along with the probabilities of these values are
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known a priori. Truly random numbers or distributions are cumbersome since it is often
desirable to reproduce calculations performed on a computer; in order to repeat trials
using random numbers, the numbers would need to be stored during each trial. Thus,
MCS is typically conducted with what are known as pseudo-random numbers, which are
values generated to approximate a particular distribution (e.g., uniform, normal) using
mathematical formulae that simulate random numbers. Rather than having to test the
validity (or randomness) of the random numbers at the start of each trial, pseudo-random
number generators need only be tested once to confirm their ability to generate a
sequence of numbers that approximates the properties of random values. The pseudorandom numbers can then be re-generated if need be using the same “seed” or point at
which the algorithm began generating values.64,66
Pseudo-random number generators do have one significant limitation; the total
number of values that can be generated using any given seed is finite. Eventually,
identical values will be re-generated as the pseudo-random number generator cycles.
Therefore, the user must verify that the sequence of pseudo-random values generated is
large enough for the specific application such that earlier trials do not become correlated
with later trials as a result of re-sampling. This ensures that the simulation is truly
stochastic. Pseudo-random number generators are restricted by the number of bits (n) the
computer possesses such that a sequence, often times referred to as the period, of pseudorandom numbers can be no longer than 2n. Newer algorithms, however, have
circumvented this issue, utilizing numerous generators for the seed and the integer
generator such that periods of 264 (Marsaglia's Ziggurat algorithm) and 219,937 – 1
(Mersenne Twister algorithm) are attainable.64,66
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The results of any MCS trial are dependent upon the number of times the system
is perturbed. The model(s) must be tested a sufficient number of times such that the
parameters sampled are representative of the general population. If the sampling is
inadequate, the output will be misleading since certain input conditions that are likely to
occur will not have been considered. While it is not possible to offer a general rule of
thumb as to the required number of iterations, the simulation should iterate enough times
to allow the output to stabilize. Ensuring that the change in the estimate drops below a
defined threshold for a set number of consecutive iterations is one approach to verifying
stabilization.64,65
1.3.3.2 Pharmaceutical Applications of Monte Carlo Simulation
Since its formal introduction, the number of applications that harness MCS has
grown substantially. Monte Carlo simulation is utilized in many scenarios, including the
general fields of manufacturing, economics, and science.63 While a thorough review of
all the applications of MCS is well outside the focus of this dissertation, the following
discussion offers a brief overview of its major uses within the pharmaceutical industry.
Additional detail regarding MCS is provided in section 1.3.7.
Monte Carlo simulation is a versatile tool that supports numerous aspects of the
drug discovery and development process. The preliminary tasks of generating models
and defining simulation inputs a priori force companies to identify the components that
are well understood and, likewise, the elements that are uncertain or missing altogether.
Although MCS is used throughout the drug discovery and development process,67 its
greatest impact as it relates to pharmaceutics is perhaps in the area of clinical trials,
commonly referred to as clinical trial simulation.67,68 To start with, MCS can be used to
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study the economic investments necessary to conduct these trials, with the obvious
objective of minimizing the total cost.62 Poland and Wada utilized PK, PD, and
economic models along with MCS to study the effects of the dosing regimen (i.e., onceversus twice-daily administration) and patient compliance on the efficacy of an
antiretroviral drug in Phase II trials.69 The authors concluded that despite enhanced
patient adherence to the once-a-day dosing schedule, the marginal increase in long-term
efficacy did not warrant the change from twice- to once-daily administration in view of
the delayed time-to-market, additional monetary investments, and technical uncertainties
associated with the new product. This is an excellent example of how MCS helped
circumvent additional clinical trials that would have undoubtedly increased development
expenses.
Many other facets of clinical trials can benefit from MCS. Although their explicit
objectives may not have included minimizing financial investments, there is a consistent
economic implication in the following cases. For example, MCS is used to approximate
the initial dose in humans for phase I studies. This can be of particular benefit in
allometric scaling efforts where PK parameters have been well-characterized (typically as
averages) within the confines of animals, but transferability to humans is uncertain.
Simulation can help elucidate which parameters have the largest effect on scaling the
dose to humans by propagating variability through the models. Moreover, MCS is
beneficial for determining the dose for phase II and III studies where the test subjects are
typically patients rather than healthy volunteers. Therefore, fewer adverse events are
anticipated from optimizing the dose in silico rather than in vivo, which inevitably
increases the likelihood that the particular drug will receive approval for marketing.62

46

With a predictive PK model, single- and multiple-dose plasma versus time
profiles can be generated with the aid of MCS, which can then be used to optimize the
dose and the dosing schedule to ensure plasma concentrations are within the desired
therapeutic range. Gomeni et al. took a similar (but extended) approach where they used
PK and PD modeling in conjunction with MCS to assess the effects of PK absorption and
disposition parameters (e.g., fraction of dose available), and inter-individual variability
on percent receptor occupancy, which had been identified as a surrogate for efficacy.70
The authors were able to identify the variables that had the largest influence on receptor
occupancy, which enhanced their company’s understanding of the unidentified drug and
helped direct future development efforts.
As evidenced by the work of Poland and Wada, and Gomeni et al., models
representing various components fundamental to clinical trials (e.g., PK and PD) can be
integrated with MCS to investigate the effects of various inputs (e.g., patient compliance,
inter-individual variability) on the clinical effectiveness of a given treatment. This offers
the user the unique opportunity to explore numerous circumstances, some of which are
not ethical in a clinical trial setting. For instance, MCS can be used to investigate the
therapeutic outcome of patients missing a given percentage of their doses, which is not
acceptable in situations where the patient would potentially experience significant
discomfort or harm. The ability of simulation to efficiently address the “What if”
questions in silico rather than in vivo underscores its utility.
Dutta and Reed utilized MCS to investigate the effects of patient compliance on
plasma concentrations of valproic acid during treatment with 12-hour enteric-coated
divalproex sodium tablets.71 PK simulation is an ideal platform to assess the effects of
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missed doses, and patient/clinician compensations for the omissions, seeing as how
withholding medication from patients suffering from epilepsy or acute mania is unethical.
Valproic acid, one of the two APIs in divalproex sodium tablets, has a narrow therapeutic
window of plasma concentrations of 50 – 100 mg/L. Given its narrow therapeutic range
and short elimination half-life of 6 – 16 hours, patient compliance is critical to the safety
and effectiveness of this modality; low plasma concentrations can result in seizures
whereas high plasma levels run the risk of inducing clinical toxicity.
The authors wanted to examine the PK effects of missing one or two doses in
conjunction with three different temporary dosing regimen adjustments: (1) one missed
divalproex dose compensated for by doubling the dose at the next scheduled dose
administration (12-hour replacement), (2) two consecutive missed divalproex doses offset
by administering a doubled dose 6 hours following the first missed dose (18-hour
replacement), and (3) two consecutive missed divalproex doses counteracted by tripling
the dose at the next scheduled dose administration (24-hour replacement). Moreover,
they were interested in the confounding effects (i.e., drug-drug interactions) of hepatic
enzyme-inducing antiepileptic drugs on valproic acid plasma concentrations. To
accomplish this, adjustments were made for certain individuals to simulate the shortened
elimination half-lives and elevated clearances observed for patients taking antiepileptic
medications.
Population mean PK parameters for dose, bioavailability, absorption lag-time,
first-order absorption rate constant, steady-state volume of distribution of unbound drug,
protein binding parameters (i.e., the number of binding sites for the two classes of
binding sites and their corresponding binding association constants), elimination half-life,
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and clearance of free drug were taken from the literature. Different doses, elimination
half-lives, and clearances were implemented for patients with enzyme induction versus
those uninduced. The age range of the hypothetical patients was restricted to 11 – 64
years and body weight was assumed to be 70 kg. Patients not taking other enzymeinducing antiepileptic drugs were administered 562.5 mg every 12 hours (i.e., 16
mg/kg/day), whereas induced subjects were administered 1125 mg (i.e., 32 mg/kg/day).
Log-normal distributions representing 20 % inter-patient variability were generated for
clearance, volume of distribution, albumin concentration, and the protein binding
parameters using the population averages. Patients, in effect, were generated by
randomly sampling the underlying distributions for the parameters estimates, which were
then used to simulate plasma concentration-time profiles. Predicted plasma
concentrations were subjected to 10 % residual error to include real-world variability. A
total of 1000 patients were tested.
The resultant valproic acid plasma concentration-time profiles (Figure 1.6) were
analyzed to quantify the effects of the missed doses and hepatic enzyme induction in
terms of the change in steady-state maximum and minimum concentrations (Cmax and
Cmin, respectively). The simulated profiles illustrate the dramatic fluctuations in valproic
acid plasma levels that accompany one or two missed doses and the three temporary
dosing regimen adjustments. Although there was no actual link to the PD outcomes, the
authors assumed that the lower limit for clinical efficacy was 50 mg/L, below which the
likelihood of a breakthrough seizure is greatly enhanced, and that plasma concentrations
greater than 100 mg/L increased the probability of toxicity. Using these criteria, the
authors concluded that the probability of inefficacy (i.e., seizing) is greatly enhanced
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when as little as one dose is omitted, especially for those taking antiepileptic medications.
Uninduced patients are at low to modest risk for toxic events, even when the dose is
tripled. Induced patients, however, are likely to experience transient toxicity due to
elevated plasma concentrations. Given their observations, Dutta and Reed recommended
a modified dosing regimen for non-compliant patients who miss one or two divalproex
doses. For patients treated with concomitant antiepileptic medications, an omitted dose
should be offset if the individual recalls the miss up to 12 hours later, noting the risk of
adverse events. If the same patient recalls the omission 18 or 24 hours later, the
patient/clinician is advised against full-dose compensation (i.e., either doubling or
tripling the dose depending on the time) due to risk of clinical toxicity. In these
instances, the clinician is encouraged to consider a partial dose replacement approach in
conjunction with a return to the scheduled dosing regimen. As for uninduced patients,
they should replace the dose upon recalling the miss, even if two consecutive doses are
omitted. The authors also pointed out that the simulation could be revised to model
young pediatric and/or geriatric patients with better estimates of their PK parameters (i.e.,
population-specific variability).71
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Figure 1.6. Simulated valproic acid (VPA) plasma concentration-time profiles of epileptic patients at
steady-state (SS) following the miss of one or two scheduled divalproex doses, with replacement 12, 18, or
24 hours later followed by continuation of scheduled dosing regimen. (a) VPA concentration-time profiles
in the mean simulated patient administered 562.5 mg q 12 hours. (b) and (c) VPA concentration-time
profiles in the mean simulated patient administered 1125 mg q 12 hours with hepatic enzyme-inducing
medication. Panel (c) is the same data shown in (b) with the addition of the inter-patient and residual
variabilities in VPA concentration-time curves. The error bars of (c) represent standard deviation (SD).
Solid line (0-24 h) to dotted line represents baseline steady-state profile (no missed doses) for the mean
simulated patient, and the solid line (24-72 h) represents the predicted mean change after omitting two
doses, with replacement 24 h later and resumption of scheduled dosing (triple dose).

Watanalumlerd et al. employed MCS and PK modeling to study the effects of
gastrointestinal transit on plasma concentration-time profiles of an orally administered
combined immediate-release and enteric-coated amphetamine pellet formulation in the
fed and fasted states.72 Compartmental PK were assumed with first-order absorption of
the immediate-release pellets, zero-order gastric emptying rate in the fed condition or
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first-order gastric emptying rate in the fasted condition of enteric-coated pellets into the
intestine, first-order absorption of the drug after being released from the enteric-coated
pellets, and first-order elimination. Once absorption occurs, it is assumed that the PK can
be described by a one-compartment model. The PK equations included terms for the
gastric emptying time as well as the lag time of gastric emptying. The PK parameters for
amphetamine (i.e., absorption rate constant, elimination rate constant, apparent volume of
distribution, and the fraction of the drug absorbed) were obtained by fitting plasma
concentration data obtained from the available literature. Constant doses of 20 and 30
mg were administered for the fed and fasted states, respectively.
Given that the primary focus of this work was to investigate the effects of gastric
emptying, only the terms for gastric emptying time and the lag time of gastric emptying
were varied during the simulations. The means and standard deviations for gastric
emptying time and lag time of emptying were also taken from literature. Separate
estimates were available for the fed and fasted states, and a total of four lognormal
distributions were generated for the time parameters. Variability of 30 % was
implemented for lag time in the fasted state since an estimate was not accessible; this
resulted in a range comparable to the other gastrointestinal transit parameters. Each
simulated plasma concentration-time curve portrayed the mean of 500 trials, and the
variability was captured in one of two ways: (1) by displaying standard deviation error
bars or (2) by plotting the 25th, 50th, and 75th percentiles, for each simulated time point.
Two lines representing the minimum and maximum simulated concentrations for each
time point were also provided.72
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The accuracy of the simulated plasma concentration-time profiles was assessed by
comparing the percent difference between the actual and predicted time to the maximum
concentration (Cmax). A difference of 2.8 % was observed in the fed state, while an 8.4 %
difference was observed for the fasted condition. The simulations confirmed the authors’
suspicion that the combined formulation, in both the fed and fasted states, would not
yield a double-pulsed release profile typical for two immediate-release doses
administered at different times because the dosage system remained intact as it passed
through the gastrointestinal tract. Rather, the profiles were characteristic of a typical peroral sustained release formulation. This work confirmed that PK modeling of combined
immediate-release and enteric-coated pellets should consider the effects of gastric
emptying and gastrointestinal transit.72
While the majority of the above examples incorporate several components of the
drug development process as they relate to clinical trials, the work of Watanalumlerd et
al.72 exemplifies that any given element can be studied independent of its counterparts.
Integration is, however, a logical extension of studying each component independently.
Simulation is expected to enhance the efficiency of the drug development process by
generating a greater understanding of the drug itself and its safety and efficacy within
patients. In doing so, the significant cost associated with producing innovative medical
products is likely to be reduced. Simulation can also be harnessed to analyze and reduce
the intrinsic risk of pharmaceutical products.
1.3.3.3 Probabilistic Risk Assessment
Probabilistic risk assessment is a systematic method to quantitatively characterize
the risk of a given system. Assuming the risk is detectable, it consists of two
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components, probability and severity. Probability describes the likelihood of occurrence
for an adverse event, whereas severity expresses the magnitude of the outcome. When
conducting a PRA, risk is expressed through a risk model, a function comprised of the
various terms known or thought to impact adverse events. At least one of the inputs to
the risk function is described by its probability distribution as opposed to a scalar (e.g.,
central tendency); methods that only use single values as inputs are referred to as point
estimate techniques.65
Depending on the underlying objectives, PRA is used to evaluate the variability
and/or uncertainty of risk estimates. Variability is defined as the true heterogeneity of a
variable or a response for a sample or population, while uncertainty is the error associated
with the parameters or models. For example, parameter uncertainty may arise due to
questionable model inputs, which may be a consequence of the representativeness of the
data for a given sample population. Model uncertainty could be a result of ambiguity in
the estimated model coefficients or perhaps the structure of the model used for the risk
function (e.g., linear versus nonlinear). It is important to note that uncertainty can be
reduced (e.g., acquire additional or improved data), whereas variability is inherent to a
population. Variability, however, can be better characterized with more data, but cannot
be reduced or eliminated. The output of a given PRA trial is the observed range of
probability distributions, which, depending on the input distributions, characterize
variability or uncertainty. The results of PRA can be used to better allocate resources
(e.g., personnel, finances) and establish performance objectives to mitigate risk. Thus,
PRA is an effective means of weighting initial investments based on potential returns.65
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One of the main objectives when conducting a PRA is to determine the
distribution(s) of possible risk scores. This illustrates the range of threats the assessor
can expect. It is also essential to understand which factors have the largest impact on
risk. This is accomplished through a sensitivity analysis, which is a systematic method to
delineate the dependency of the risk estimates on variability or uncertainty in the risk
factors. It is used to quantify the relative contribution of each model input to risk and to
understand important sources of variability or uncertainty. This is imperative since subtle
changes to one factor may have a significant effect on the risk estimate, whereas other
factors may be relatively insensitive to large fluctuations.65
Sensitivity analyses can range from extremely simple techniques to those that
utilize relatively complex mathematical and statistical approaches. The latter are more
common since numerous sources of variability and uncertainty tend to simultaneously
affect the risk estimate. Simple techniques might include determining the range of
possible values or quantifying the percent of total risk for each factor. More complex
approaches might include multiple linear regression or some other statistical analysis to
assess the percent variance in the risk estimate explained by each factor.65
A common metric used in sensitivity analyses is the sensitivity ratio, which is
sometimes referred to as the elasticity equation. The sensitivity ratio (SR) is expressed as
⎛ Y2 − Y1 ⎞
⎜⎜
⎟ ⋅100 %
Y1 ⎟⎠
⎝
SR =
⎛ X 2 − X1 ⎞
⎜⎜
⎟⎟ ⋅100 %
⎝ X1 ⎠

(1.2)

where Y1 is the baseline output obtained using baseline values for the input variables, X1
is the baseline point estimate for the input variable X, X2 is the new value of the input
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variable X after the change, and Y2 is the new output after changing the value of one of
the input variables X to X2. For PRA, the input is a specific value for a given risk factor
and the output is the risk estimate. Risk estimates are most sensitive to factors that yield
the highest absolute value of the SR and least sensitive to those with the lowest absolute
value of the SR. Although popular and instructive, the SR has limited applicability. The
SR approach assumes independence of the input variables. Therefore, if two or more
inputs interact, varying one input while another is held constant can misrepresent the
actual impact on risk. When this is the case, confounding variables must be allowed to
vary simultaneously.65
Another metric commonly used in sensitivity analyses is the coefficient of
determination (R2). With this method (i.e., simple linear regression), the square of the
correlation coefficient (r) between the various input values for a given factor and the
result risk estimates is reported; the correlation coefficient itself is powerful because it
indicates whether the factor is positively or inversely correlated to risk. Factors with an
R2 close to 1.0 have are highly sensitive whereas those close 0.0 are nearly insensitive.
The coefficient of determination for the risk factors can also be represented as the
percentage contribution to total variance of risk. Numerous other statistical approaches,
such as the Spearman rank correlation and multiple linear regression, are also valid for
performing sensitivity analyses. The sensitivity analysis methods ultimately employed
will depend on the level (i.e., discrete or continuous) of the input and output variables and
the form of the underlying risk model (i.e., linear or nonlinear).65
Sensitivity analyses performed on inputs to certain risk models, in particular those
that are nonlinear, have the potential to be highly dependent upon the values used to
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perturb the model. For that reason, it is beneficial to examine a broad range of values for
the inputs to delineate their impact on risk. Inputs characterized as random variables can
be described by a specified probability distribution. As such, the inputs can assume
values within this distribution and, therefore, can be easily studied using MCS.65
Likewise, MCS can be used to evaluate the uncertainty in input variables or model
parameters.
1.3.3.4 Monte Carlo Simulation and Probabilistic Risk Assessment
Probabilistic risk assessment has long been used as a standalone gauge of adverse
events. Wreathall and Nemeth suggest that this technique has (conceivably) been used
most frequently within the commercial nuclear power industry;73 this is not to say,
however, that PRA was not used earlier by other industries. Beginning in the early
1970s, the US Atomic Energy Commission sought to estimate the number of accidents
that could potentially result in the discharge of radioactive materials. While PRA itself
can be used to analyze a system (as can MCS), several guidance documents underscore
the utility of employing it with MCS. The National Aeronautics and Space
Administration (NASA) details their use of PRA in conjunction with MCS to help direct
decisions to ultimately augment safety and program performance.74 Similarly, the
Environmental Protection Agency (EPA) has applied PRA and MCS to analyze
ecological risk for the support of risk-based decisions since 199775 and proposed
equivalent approaches for analyzing risk to human health in 2001.65 The 2001 EPA
Superfund guidance illustrates how to use MCS to estimate exposure and risk, and
discusses the role of PRA in their decision making process. The time, resources, and
expertise required to effectively perform PRA are noted as drawbacks to this technique.
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While this may be true, the potential benefits and savings realized by such a program well
outweigh these requirements.
Inputs to PRA risk expressions can assume different values based on their locale
within the population; as such, these inputs are said to be random variables. A
continuous variable can be described by its associated probability density function or
cumulative distribution function, whereas a discrete variable can be characterized by its
corresponding probability mass function. These functions describe the probability of the
parameter assuming a given value. When defining or selecting the appropriate values or
distributions for input parameters, there often is an underlying level of ambiguity
regarding these data. For example, in situations where data either do not exist or have yet
to be collected, estimates are often drawn from previous assessments or suitable
literature. More appropriate data can be incorporated into the PRA if and when they
become available. Thus, it is the responsibility of the individual(s) executing the
assessment to defend the assumptions that were made and properly communicate their
implications and constraints.65
Once the risk equation(s) have been defined and the corresponding input
distributions have been characterized, MCS can be used to repeatedly extract input
parameters at random to evaluate their influence on risk. In other words, each iteration
tests a potential real-world scenario (e.g., 80 kg, 65 year old asthmatic male with
congestive heart failure dosed with a theophylline tablet coming from a batch that was
found to have unacceptable content uniformity) to better understand the risk associated
with the particular set of conditions. With the estimated risk distribution, it is then
possible to determine if appropriate action is necessary. Results of PRA trials and the
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actions that follow are dependent on not only the individual or organization conducting
the assessment, but also the rationale behind its initiation. For example, the output may
indicate that the underlying distribution for a given parameter (e.g., content uniformity of
an active pharmaceutical ingredient) needs to be narrowed to lower the probability of
observing toxicity in patients.64,65
Risk assessment is frequently used to estimate the potential hazards associated
with various substances, including pharmaceutical compounds. For example, molecules
that are identified as potentially carcinogenic, mutagenic, and/or teratogenic are typically
entered into a risk assessment program to characterize the relative risk between dose and
response (e.g., development of a tumor). In order to accomplish this, it is necessary to
estimate the probability of the expected outcome as a function of the dose administered.
The elucidation of this relationship, however, fails to deconvolve the underlying
pharmacokinetic and pharmacodynamic mechanisms that contribute to the undesirable
response. Therefore, integration of PK knowledge has been proposed as a means to
enhance the power of the risk assessment.76
Kodell et al. conducted a probabilistic dose-response assessment using tumor
dose-response data from a 2-year rodent bioassay to investigate several methods of
integrating PK and PD knowledge within a dose-response model.76 The authors used
MCS to study the impact of linking various combinations of PK and PD models on the
assessment of risk. Further, MCS was exploited to randomly generate rodent tumor
responses based on doses sampled from an assumed PK dose distribution. They
concluded that the use of PK data, which related administered dose to in vivo levels,
reduced the uncertainty associated with assessment of tumor risk. They also determined
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the PK models of various complexities did not affect the variability in the risk estimate.
This was attributed to the binary model for tumor response (i.e., tumor or no tumor).
Although the study by Buur et al. does not involve the administration of a drug
with the intent to treat humans, many of the concepts and methods utilized within are
directly applicable to the pharmaceutical industry.77 The authors performed a risk
assessment when they used probabilistic modeling and MCS in conjunction with a
physiologically-based PK model to predict the withdrawal times of sulfamethazine
residues in swine tissue. The FDA regulates the period of time that must elapse before
feed animals can be harvested for consumption following the administration of certain
agents to mitigate the risk of adverse reactions in humans (i.e., withdrawal time).
Sulfamethazine is an antibiotic used for the treatment and prevention of several diseases
commonly contracted by pigs. Sulfonamide drugs are of significant interest to regulatory
officials since they are known to cause a variety of allergic reactions in humans.
The authors utilized a published physiologically-based PK model and numerous
published values for the parameters of interest (e.g., hepatic clearance rates, rate of
absorption, percent plasma protein binding). A sensitivity analysis was conducted to
determine the parameters that significantly affected the pharmacokinetics of
sulfamethazine; specific details regarding the statistical approaches employed were not
provided. Lognormal distributions for the statistically significant parameters (inputs to
the PK model used to predict tissue and plasma concentration) were generated using the
widest dispersion estimates published so as to output the most conservative withdrawal
time estimates. These distributions, therefore, represented the variability within the
general swine population. Insensitive parameters were not utilized during the subsequent
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MCS analyses. Each MCS trial iterated 1000 times to yield a single withdrawal time.
The withdrawal time was estimated as the upper limit of the 95th percent confidence
interval of the time necessary for 99 % of all tissue and plasma concentrations of the
1000 trials to decrease below the specified threshold. A series of 100 trials were
conducted for specific tissues of interest. The validity of the simulation architecture was
assessed by comparing the predicted plasma and tissue concentration profiles to
published mean concentration-time data sets; it was determined that the predicted
concentrations corresponded well with the reported values. The authors concluded that
the mandated withdrawal time of 15 days should be revisited in lieu of the considerable
public health risk that persists well after this time window. Although the authors
acknowledge that their methodology most likely yields more conservative estimates than
those that might actually be observed, they underscore the fact that their simulation
architecture can be updated as additional data which better approximate the true
parameter distributions are acquired.77

1.3.4 In Vitro-In Vivo Correlation (IVIVC)
1.3.4.1 Background
Pharmacokinetic and pharmacodynamic models are generated using clinical data
acquired with the assistance of healthy volunteers and ailing patients. While testing in
humans is a critical component of the drug development process for a new drug
application (NDA), there is a distinct need for a method capable of assessing the clinical
effectiveness and reproducibility of medical products within an artificial environment.
This is especially relevant in the case of abbreviated new drug applications (ANDAs) for
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generic drugs, where clinical studies to establish safety and effectiveness are generally
not required. Knowledge obtained during pharmacokinetic, and to a certain extent
pharmacodynamic, modeling is used to help establish a relationship between in vitro and
in vivo performance. Predictive relationships between in vitro and in vivo product
performance decrease development costs, reduce unnecessary burden to test subjects, and
expedite product release, all of which underpin public health objectives of the FDA.
In vitro-in vivo correlation is the mathematical architecture for relating in vitro
drug release profiles to absorption in vivo. The main purpose of IVIVC is to demonstrate
in vivo bioavailability through in vitro analyses. Dissolution testing is the conventional in
vitro test employed by the pharmaceutical industry to assess drug release profiles in view
of the fact that drug dissolution and release from the dosage form are acknowledged as
key elements to clinical performance; dissolution was formally recognized as a sensitive
and reproducible surrogate for assessing bioequivalence in 1993. Dissolution testing
supports manufacturing quality control programs, the determination of product release
characteristics, and certain regulatory considerations.22,78,79
Dissolution testing monitors the extent or rate of drug release as a function of
time. The United States Pharmacopeia (USP) defines 4 different apparatus (1 – 4), the
basket apparatus, the paddle apparatus, the reciprocating cylinder, and the flow-through
cell, for general dissolution testing.80 For certain compounds, individual monographs
dictate the specific requirements for dissolution analyses. The FDA encourages the use
of apparatus 1 or 2 for the establishment of an IVIVC; however, apparatus 3 and 4 may
be employed when the dissolution properties cannot be ascertained with the former
setups. Equally important to the setup is the analytical method utilized to monitor drug
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release. Ultraviolet-visible (UV/Vis) spectroscopy or high pressure liquid
chromatography (HPLC) are the two most common analytical techniques used to
measure API concentration within the dissolution media. Given the overall significance
of dissolution testing, the methodology and its associated specifications are often justified
through IVIVC efforts. In addition to its role in instituting scale-up and postapproval
changes (SUPAC), establishing biowavers, and setting dissolution specifications,79
IVIVC has also been associated with enhanced product quality.78
Clinical data are traditionally available early on in the drug design and
development process. IVIVC efforts commence during the initial stages of development
and can continue late into the life cycle of a product. Numerous prototype formulations
and dosage forms, with various in vitro and in vivo characteristics, are typically
considered during product development. Although the majority of IVIVCs reported in
literature are for per oral dosage forms, research is underway to establish correlations for
other delivery vehicles (e.g., transdermal patches, biodegradable parenteral depot
systems).78,79 The IVIVC begins by proposing an in vitro target to meet a desired in vivo
performance profile or specification; the targets are subject to change, however, as the
product characteristics are finalized to achieve the intended performance. The desired
performance profile may also be modified. As more and more data are generated, the
IVIVC is refined to accurately reflect the relationship it seeks to describe.
1.3.4.2 Classification of IVIVCs
Numerous approaches to IVIVC modeling are defensible. Moreover, IVIVCs of
disparate complexities are suitable depending on the given application. Both the USP
and the FDA have released documents intended to help direct participants in constructing
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an IVIVC appropriate to their needs. The FDA published a guidance on IVIVC in 1997
entitled Extended Release Oral Dosage Forms: Development, Evaluation, and
Application of In Vitro/In Vivo Correlations.22 Likewise, a chapter titled In vitro and In
vivo Evaluations of Dosage Forms can be found within the USP.81 Within these
documents, four different levels of IVIVC are acknowledged: A, B, C, and Multiple
Level C (certain articles recognize a fifth level, D;78 however, since it is a rank ordering
and, therefore, not a true correlation, level D will not be considered within this work).
The levels are defined based on the amount of data used to establish the relationship,
which directly determines the interpretability of the IVIVC function.
Level A correlations are the most powerful IVIVC and are advocated by the
FDA.22 As Level A correlations use all in vitro and in vivo data, they represent a pointto-point relationship between the in vitro dissolution response and the in vivo input rate,
where the latter is typically expressed as the in vivo release of the drug from the delivery
vehicle. Linear correlations, regardless of whether the in vitro and in vivo curves are
directly superimposable or are rendered so by the implementation of a scaling factor, are
the most common Level A correlations. Nonlinear solutions, however, are not incorrect
and therefore, should not be overlooked in situations where linear correlations are
infeasible. Once the association between the in vitro dissolution rate and the in vivo input
rate is understood, the relationship must be extended to include the portion of drug
absorbed in vivo (the relationship is not, however, extended to the therapeutic outcome).
Ultimately, Level A correlations should be completely predictive of a drug’s in vivo
performance (e.g., plasma drug concentration). This type of correlation can be used to
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justify a change in the manufacturing route, site of production, incoming raw materials,
and/or for certain minor formulation amendments.
Level B correlations are similar to Level A in that they use all in vitro and in vivo
data; however, they are not defined point-by-point. Rather, Level B correlations are
based on statistical moment analyses, particularly the first moment. For Level B
correlations, the mean in vitro dissolution time is related to the mean in vivo residence
time or the mean in vivo dissolution time. It is critical to note that dissimilar in vivo
curves can produce comparable mean residence times. Since Level B correlations do not
model absolute plasma time curves, they alone cannot be used to justify the same changes
that can be addressed with Level A correlations.
Level C correlations relate one dissolution metric (e.g., t50%, t90%) to one
pharmacokinetic parameter (e.g., Cmax, Tmax, AUC). Considering that a Level C is a
single point correlation, it does not communicate the complete in vivo plasma profile.
Since only a partial relationship between dissolution and absorption is ascertained, a
Level C is the weakest of all the correlation levels. The applicability of a Level C
correlation is analogous to a Level B correlation. While neither establish bioequivalence,
both may be useful in product design, particularly in optimizing formulations.78
Multiple Level C correlations relate several dissolution time points, preferably a
minimum of three representing initial, intermediate, and ending time values, to one or
more pharmacokinetic parameters. Each time point should be related to the same
variable when more than one pharmacokinetic parameter is implemented. A multiple
Level C correlation established using time points representative of the entire dissolution
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profile can serve as evidence for a biowaver. More often than not, a Level A correlation
is feasible if a Level C correlation has been established.
1.3.4.3 Approaches to IVIVC Modeling
Deconvolution and convolution are two common methodologies employed to
construct IVIVCs. The former is a two-stage modeling technique, whereas the latter
involves a single stage. The first stage of deconvolution entails modeling of the in vivo
absorption or dissolution time profile. This can be accomplished using a number of
pharmacokinetic techniques such as the Wagner-Nelson or Loo-Riegelman methods, or
general non-compartmental schemes.82 Once the in vivo time profile has been estimated,
the second stage of the deconvolution method is to determine the relationship between
the in vivo profile and the in vitro dissolution profile. The goal is to establish a point-topoint relationship between the corresponding in vitro and in vivo parameters acquired at
the same time. This can be done by way of a simple linear relationship or a more
intricate sigmoidal (e.g., Hill) function. Deconvolution methods suffer from restricted
modeling flexibility (due to the numerous constraints imposed by the methods of stage
one) and do not convey drug plasma concentrations (as they model fraction dissolved
versus fraction absorbed), which severely limit the interpretability of the IVIVC.22,83
Conversely, convolution directly relates the in vitro dissolution profile to the in
vivo drug plasma concentration time profile through a convolution integral
t

C (t ) = r (t ) ∗ Cδ (t ) = ∫ Cδ (t − τ )r (τ )dτ

(1.3)

0

where C represents the drug plasma concentration, r is the in vivo input rate, τ is the
dosing time, t is the current time, and Cδ is the instantaneous absorption of a unit quantity

66

of drug, which can be estimated from IV bolus, oral solution, suspension, or rapidly
releasing (in vivo) immediate release dosage forms. In other words, total plasma
concentration C(t) is the summation (i.e., integral) of the remaining fractions Cδ(t-τ) of
the infinitesimal contributions r(τ)dτ occuring at time τ.22,83 The fundamental objective
of convolution-based IVIVC methods is to determine the functional relationship that
connects the in vivo input rate (r) to the in vitro dissolution rate (rdis) such that
r = f (rdis , t )

(1.4)

The most parsimonious convolution-based IVIVC model involves a linear relationship
r (t ) = a0 + a1 ⋅ rdis (t )

(1.5)

where the scale (a1) and offset (a0) coefficients are 1 and 0, respectively. This has been
termed the basic convolution-based IVIVC method.83 While this is an ideal scenario, the
scale and offset coefficients may often be different than 1 and 0, respectively. Due to
factors that frequently prohibit instantaneous uptake in vivo (e.g., time necessary to
transport to absorption site) and factors that yield differences in units of measurement
(e.g., fraction of the dose absorbed), time and amplitude scaling in addition to lag-time
coefficients are often beneficial to model performance, which can be achieved using the
equation
r (t ) = sr ⋅ rdis (t 0 + s1 ⋅ t )

(1.6)

where s1 and sr are the time and amplitude scaling factors, respectively, and t0 is the
absorption lag-time term, or the time at which the drug is first absorbed systemically.
Scaling and offset coefficients should only be applied in situations where they can be
justified mechanistically and enhance the predictive power of the model.83
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While deconvolution- and convolution-based methods have been applied for some
time,22 a novel method known as direct, differential-equation-based IVIVC was proposed
by Peter Buchwald in 2003.83 Although the direct, differential-equation-based IVIVC
method is analogous in many ways to the convolution technique, it is unique in that it
harnesses differential equations, which are linked to a basic pharmacokinetic model that
describes the system under consideration. Plasma concentration, therefore, is
mathematically expressed by a functional pharmacokinetic model that describes the effect
of the body on the drug itself. The assumption is made that absorption, distribution, and
elimination of the drug can best be modeled using compartmentalized pharmacokinetics.
For ease of demonstration, the following discussion will assume a one-compartment
model; however, multi-compartment models can be used during differential-equationbased IVIVC.
The fundamental architecture of differential-equation-based IVIVC expresses in
vivo drug plasma concentration as

dC
= r (t ) − kC
dt

(1.7)

where k represents the elimination rate constant, and C, r, and t are as were previously
defined. In terms of pharmacokinetic modeling, the in vivo input rate (concentration per
time) for a one-compartment open model with, for example, exponentially decreasing
input with an absorption rate κ, can be expressed using the common formulae

r (t ) =

κD0
V

⋅ e −κt ⇒ C =

κD0κ
⋅ (e −kt − eκt )
κVκ − k

(1.8)

where D0 represents the initial dose and V is the volume term. For the purposes of
IVIVC, however, the in vivo input rate (r) is related to rdis through a function analogous to
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that used in the convolution method (Equation 1.4). This assumes, however, that
dissolution, not absorption, is the rate limiting step.
Buchwald83 proposed an amended model that includes φabs, a time-dependent
absorption factor that takes into consideration fluctuations in absorbance as the dosage
system traverses the gastrointestinal tract

r (t ) = ϕ abs (t ) ⋅ sr ⋅ rdis (t 0 + s1 ⋅ t )

(1.9)

The time-dependent absorption factor can be as straightforward as a low-pass filter (φabs
= 1 if t ≤ tcut ; φabs = 0 if t > tcut) or can be something more complex such as a sigmoidal
step-down function

ϕ abs =

e −η (t − tcut )
1 + e −η (t − tcut )

(1.10)

where η is the steepness of the cut-off and tcut is the last time point at which absorption
occurs. To minimize the number of parameters that must be optimized, η can be set to a
constant value. Due to its extensive surface area, the small intestine is the primary site of
absorption for many drugs. The mean small intestine transit time has been reported to be
3 (±1) hours.84-87 Taking into consideration the range of gastric emptying times, minimal
systemic uptake would be expected beyond 4 to 10 hours post administration; drugs that
absorb well within the colon (i.e., certain highly-permeable molecules) would extend the
aforementioned absorption window. Thus, the application of a time-dependent
absorption factor is justifiable for many controlled release delivery systems. Buchwald
reported enhanced IVIVC performance when a sigmoidal absorption function (tcut = 6.4
hours) was used in conjunction with scaling and offset factors.83
A total of two equations are necessary to establish an IVIVC for a onecompartment pharmacokinetic model (Equations 1.7 and 1.9). Each additional
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compartment incorporated in the pharmacokinetic model will require one additional
differential equation to describe the change in concentration as a function of time within
that compartment. Estimations of rdis at numerous time points are required to numerically
solve the IVIVC equations. The dissolution rate can be estimated by fitting the in vitro
dissolution profiles with a flexible, continuous function, such as a sigmoidal, quadratic,
or exponential (e.g., Weibull) expression. The instantaneous dissolution rates are then
acquired via the analytical derivative of the fitted function.83
The direct, differential-equation-based IVIVC method is restrictive in that it
assumes compartmental-based pharmacokinetics. It does, however, yield an estimation
of the elimination rate constant (k), which can be verified for accuracy using clinical data.
Moreover, it circumvents the need to convolve or deconvolve mathematical expressions,
and it directly relates the in vitro dissolution profile to the in vivo drug plasma
concentration time profile.
1.3.4.4 Predictability of IVIVCs
The validity of an IVIVC is demonstrated by its predictability. Recalling that the
key objective of an IVIVC is to generate a predictive mathematical function that relates

in vitro and in vivo performance, validity is centered on the degree of prediction error.
Validity can be assessed via the data used to construct the IVIVC (referred to as internal
predictability) or data independent of those used to generate the model (referred to as
external predictability). Predictability assessments via internal and/or external methods
are dependent on the intended use of the IVIVC and the therapeutic index of the drug;
estimations of internal variability should be performed for all IVIVCs. Narrow
therapeutic index drugs require external estimations of prediction error. Greater detail
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regarding the requirements of internal versus external predictability can be found in the
FDA guidance.22 Regardless of the method used, predictability must demonstrate that the
IVIVC model can accurately predict in vivo performance from in vitro data comprised of
various release rates and manufacturing conditions. Generally, this should be
accomplished using a minimum of three different formulations with release rates that
vary by, for example, 10 % for each formulation, which should yield a commensurate
distinction in in vivo performance. Prediction error can be assessed as the average
absolute prediction error (% PE) and typically must be less than 10 % to demonstrate
predictability for both internal and external estimations. An adequate number of subjects
should be studied to effectively characterize in vivo performance. This has been
accomplished with as few as 6 and as many as 36 individuals, but this is not to say that
more cannot be evaluated.22 Jaber Emami conducted a thorough review of IVIVC in
2006 and noted that the majority of the literature articles failed to report (or perhaps even
assess) predictability.78
Dissolution is often used as a quality control gauge to assess batch-to-batch or lotto-lot similarity/dissimilarity. The variability of release at a given time point(s) is
commonly assessed, where the acceptance specification could be set as ± 10 % deviation
from the average profile of the clinical/bioavailability samples. The power of the
analysis is amplified if a predictive IVIVC has been established. Given that dissolution
now conveys in vivo performance, the dissolution release specifications can be
established with aid from the IVIVC to mitigate in vivo variability.22,79
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1.3.4.5 IVIVC for Theophylline Dosage Systems
Theophylline is categorized as a class I compound according to the
Biopharmaceutics Classification System (BCS).88 As a class I molecule, theophylline
exhibits high solubility and high permeability. Drug dissolution, not absorption, is the
rate-limiting step to the bioavailability of theophylline;89 when dissolution occurs rapidly,
however, the rate of absorption is then determined by the frequency of gastric emptying.
Therefore, an IVIVC is not unexpected for theophylline dosage systems, especially for
controlled release products where dissolution, not absorption, is the rate-limiting step.
El-Yazigi and Sawchuk remarked that even though the bioavailability of
theophylline had been thoroughly investigated, the potential of establishing a quantitative
IVIVC had yet to be reported as of 1985.90 This finding was the impetus for
investigating the effects of pH, apparatus, and stirring speed on the dissolution rate of
theophylline from assorted commercially available products. In doing so, the authors
modeled the cumulative percent theophylline dissolved using a first-order equation. The
covariation between the cumulative percent dissolved at various times or the first-order
rate constant was assessed against different pharmacokinetic parameters (e.g., the fraction
of the dose absorbed at a given time, dose-normalized area under the curve, peak serum
levels). Pharmacokinetic parameters were estimated from the in vivo data, which were
collected in male New Zealand white rabbits. At the time of publication, a coefficient of
determination of 0.9 or greater backed by reproducible predictions of the modeled
bioavailability parameters signified a good IVIVC. The authors reported strong Level C
correlations amongst in vitro and in vivo parameters for the dosage forms assessed under
a myriad of experimental conditions. Moreover, good agreement between the actual and
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predicted pharmacokinetic parameters was reported (for one apparatus at a specified pH
and a constant stirring rate).90
Munday and Fassihi generated IVIVCs for the commercially available controlled
release product Theo-Dur as well as their own novel controlled release delivery system
Mintab.89 All in vivo data was collected in canines. The authors used the rudimentary
deconvolution-based approach to IVIVC modeling where a one-to-one correspondence
between the in vitro and in vivo data is desired. Although the Theo-Dur tablets
demonstrated good IVIVC, poor correlation between the in vitro dissolution and in vivo
absorption of the Mintab system was observed. This was attributed to the incongruent
dissolution profiles observed across the various dissolution conditions. The authors did
not investigate alternative approaches to modeling the Mintab data. Moreover, they
neglected to comment on the predictability of the IVIVCs.89
Yu et al. investigated the in vitro and in vivo characteristics of four experimental
oral controlled release theophylline dosage systems (three different hard gelatin capsule
formulations and one tablet).91 Healthy male beagles were used to collect the in vivo
data. The in vitro dissolution profiles of the four different delivery vehicles where shown
to be unique across the various formulations and dissolution conditions. Using a
deconvolution-based IVIVC approach, the authors established a point-to-point (ratio)
relationship between the cumulative percent theophylline released in vitro and in vivo.
Although no predictability estimates were determined, the authors concluded that the
correlation between the in vitro and in vivo data was good based on the visual congruence
of the point-to-point (ratio) time profiles.91
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While the previous investigations utilized animals for the in vivo analyses,
Hussein and Friedman conducted an IVIVC study of various theophylline formulations in
both canines and humans.92 Five experimental sustained release theophylline
formulations and two commercial sustained release products (i.e., Theotrim and TheoDur) were selected. Two different dissolution media were used to model conditions
within the gastrointestinal environment. Distinct mean dissolution profiles were obtained
for each dosage system using the specified dissolution methodology. Three male and two
female dogs and six healthy humans (gender not indicated) were studied to obtain the in

vivo absorption data. The percent theophylline absorbed in both humans and canines was
estimated using the Wagner-Nelson method. Mean in vitro release and individual in vivo
absorption profiles were used in conjunction with linear regression to relate the
percentage released to the percentage absorbed at each time point sampled. The slopes (±
standard deviation) and the coefficients of determination for three of the experimental
formulations and both commercial products were reported; the remaining two
experimental formulations were only tested in vitro (no explanation provided). Based on
the variance explained through linear regression, the authors concluded that IVIVC was
feasible using bioavailability data obtained both in canines and humans. No estimates of
prediction error were reported.92

1.3.5 Pharmacokinetics
1.3.5.1 Background
The study and understanding of in vivo drug (and metabolite) levels over the
duration of treatment are key functions in the drug development process. These
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concentrations, in turn, influence the clinical outcomes of the therapy and, therefore, must
be managed so as to be both safe and effective. Aside from the intricacies of drug
delivery systems, numerous variables, including behavioral, environmental, physiologic,
and pathophysiologic factors, can influence the uptake and disposition of medical
substances. For example, concomitant drug therapies via drug-drug interactions
commonly modify the rate of removal of one or several of the drugs from the body,
which has the potential to drastically affect patient well-being. Furthermore, many drugs
perform differently when administered to infant, adolescent, adult, or geriatric patients
due to changes in organ size and function. As such, extensive studies must be undertaken
to identify these factors, as well as those associated with the intricacies of the delivery
system, and appreciate how (mechanistically) they alter the management of disease.
More often than not, these studies yield quantitative empirical models that predict drug
serum/plasma levels for groups of patients under a specific set of conditions.

Pharmacokinetics denotes the examination of the time course of drug absorption,
distribution, metabolism, and excretion (ADME) to ultimately elucidate the relationship
between dose and exposure. Pharmacokinetics can be grossly divided into two
components, an experimental and a theoretical element. The former involves the
collection and analyses of data, and the methods describing these practices, while the
latter entails the generation and validation of physiologically-based or empirical models
that express drug levels following administration. The pharmacokinetic focus of this
dissertation is predominantly on the theoretical component. Thus, the background and
application of experimental pharmacokinetics, which includes topics such as sampling of
biological fluids/tissues and the analytical methodologies for measuring drug
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concentration, will not be addressed. This work will, however, model plasma rather than
serum concentrations given that plasma has the ability to perfuse through all tissues in the
body. If a dynamic equilibrium is assumed to exist between plasma and the body tissues,
changes in drug plasma concentration thereby mirror those in the tissues.82,93
One of the major outcomes of experimental pharmacokinetics that subsequently
becomes the impetus for theoretical modeling is the drug concentration time profile,
which is an illustration of the concentration of drug in the serum/plasma determined at
precise sampling time points following the administration of one or more doses (Figure
1.7). Drug concentration time profiles reflect the substance’s absorption into systemic
circulation, distribution to the various tissues in the body, and elimination via
biotransformation and/or excretion, all of which take place simultaneously during
treatment. Countless variables affect the shape of these profiles, including the route of
administration, the dosing intervals, the amount of drug administered, the rate of gastric
emptying, and the fitness of the individual and the clearing organ(s). The profiles, or
more precisely, the data upon which the profiles were generated, are then used as inputs
to various numerical models that seek to accurately express the change in drug
concentration as a function of time. Otherwise, they can be described by scalar metrics
such as the maximum concentration (Cmax), the time necessary to reach the maximum
concentration (Tmax), the area under the curve (AUC), and/or the drug clearance rate, all
of which have particular PK significance.82,93
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Figure 1.7. Plasma concentration time profile for a dose administered every 12 hours for 15 days simulated
in silico.

The underlying PK are typically described as liner or nonlinear. Linear kinetics
are characteristic for a drug whose PK parameters are invariant with the administration of
different doses. For example, first-order kinetic equations might adequately describe the
time course of drug ADME; a plot of the AUC for the plasma concentration-time curve
versus dose would be linear. Some drugs, however, display dose-dependent (i.e.,
nonlinear) PK, and the same AUC versus dose plot would be nonlinear over certain
ranges. Many of the physiological processes responsible for ADME are conducted by
carrier-mediated or enzymatic systems, both of which are subject to saturation.
Additionally, the drug (or other concomitant drugs) may induce a physiologic or
pathophysiologic change that transforms the kinetics of the drug of interest from linear to
nonlinear. These situations are exemplified by a change in the rate of drug elimination.
For instance, the elimination rate may decrease due to the saturation of metabolic
enzymes or may increase due to the induction of metabolic enzymes. Regardless of the
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directionality, dramatic inaccuracies in the plasma levels may occur if the change is
inaccurately modeled.82
As stated, pharmacokinetic models can be empirical or physiologically-based.
Empirical models are applied to a set of data based solely on their ability to
mathematically describe the information, regardless of the underlying physiological and
pathophysiological mechanics. Alternatively, physiologically-based pharmacokinetic
models encompass the physical and biochemical functions of the body with respect to
ADME of drugs and metabolites. These models may incorporate knowledge regarding
the rate of blood perfusion for a particular organ or the various types of cells that
constitute the major organ systems that interact with the drug substance.82,93
In theory, an infinite number of models can be ascribed to the complex kinetic
processes of ADME if they are scrutinized on a cellular or sub-cellular level.
Approaches to modeling, however, normally employ a number of assumptions to
simplify these processes while concurrently retaining physiological relevance or
numerical applicability. The two most notable categories of pharmacokinetic modeling
are compartmental and non-compartmental models. Compartmental models reduce the
body down into a number of systematic or serially-related compartments that reversibly
interact with one another. Compartments are hypothetical regions that represent a tissue,
an organ, or a collection of tissues/organs that display comparable blood flow and affinity
for a given drug. Compartmental models assume that the drug is rapidly mixed and is
homogenously distributed within a compartment of a definite volume. Moreover, each
drug molecule has the same likelihood of exiting the compartment. Rate constants are
used to express the transfer of drug between compartments and differential equations
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describe the change in drug concentration over time. The instantaneous concentration of
drug in the body is, therefore, the summation of concentrations in each of the contributing
compartments. Compartment models are open in view of the fact that drug can be
eliminated from the system.82,93
There are two general forms of compartmental pharmacokinetics. The first is
known as the catenary system, which is structured as a series of coupled compartments
(analogous to box cars on a train) where input occurs in the first compartment and drug
can only be transferred to and from adjacent compartments. Since this format does not
effectively characterize the manner in which plasma interacts with tissues/organs,
catenary models are used infrequently. The other form of compartmental
pharmacokinetics is referred to as the mammillary system, which consists of, at a
minimum, one central compartment. They can also incorporate numerous peripheral
compartments, all of which have direct (and potentially coincident) access to the central
compartment. Mammillary models are the most common structure for compartmental
pharmacokinetics.82,93
Non-compartmental pharmacokinetics makes no assumption regarding the nature
of the distribution of a drug, whereas compartmental modeling presumes that substances
are distributed amongst one or more compartments. Non-compartmental PK makes use
of statistical moments (e.g., area under the moment curve (AUMC), AUC), which are
mathematical descriptions of a discrete distribution of data. A statistical moment of
concentration-time data describes the probability density function, which represents the
true relationship between concentration and time. A non-compartmental approach to
modeling is preferred by some as it is not centered on the same assumptions as
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compartmental pharmacokinetics, which traditionally applies empirical models that have
no physiologic relevance. Non-compartmental modeling can be of particular benefit in
situations where a single compartment model fails to adequately characterize an entire
population (e.g., a fraction of the patients are characterized by a two-compartment model,
while the remainder are more accurately described by a three-compartment model).
Nevertheless, non-compartmental models use differential equations to express the change
in concentration (in the body as a whole) over time.
The following discussion and accompanying formulae are a straightforward
example of a one-compartment open model. While more complex functions, some of
which are nonlinear (e.g., Michaelis-Menten kinetics), exist, the reader is referred to any
advanced pharmacokinetic textbook for greater detail. One-compartment open models
are particularly useful for drugs administered via IV bolus injection, where the drug is
introduced into systemic circulation (nearly) instantaneously. A one-compartment model
following IV bolus administration is fundamentally characterized by three terms, the drug
in the body (DB), the apparent volume of distribution (VD), and the elimination rate
constant (k). The apparent volume of distribution is the volume in which the drug is
assumed to be homogeneously distributed, and the elimination rate is the collective total
of the joint processes of biotransformation and excretion. The apparent volume of
distribution does not correspond to a true anatomic space; rather, it signifies the volume
of the sampling compartment used to estimate the amount of drug in the body, hence the
annex “apparent.” Since the human body is more or less at constant volume, it is
common practice to use an invariable estimate for the VD. However, certain physiologic
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conditions, such as edema, which results in increases to total body water, can invalidate
this assumption.82,93
The differential equation that describes a one-compartment model with
instantaneous uptake is

dDB
= − kDB
dt

(1.11)

where DB and k are as previously defined. Following integration, the drug in the body at
any time (t) is expressed as

DB = DB0 e − kt

(1.12)

where DB0 is the amount of drug in the body at time t = 0. Mathematically, DB is
estimated as

DB = V D C p

(1.13)

where Cp represents the concentration of drug in the plasma. Given these relationships,
the first-order decrease in plasma drug concentration is expressed as
C p = C p0 e − kt

(1.14)

where C p0 is the concentration of drug in the plasma at time t = 0 once the drug has
equilibrated within the body. The VD is estimated using the expression
VD =

dose DB0
= 0
C p0
Cp

(1.15)

where the dose is administered via IV bolus injection and C p0 is estimated by
extrapolating the plasma concentration versus time curve back to the y axis.82,93
Clearance is the pharmacokinetic term for the overall rate of removal of drug

from the body. It does not identify the underlying elimination mechanism(s); rather,
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clearance is purely a numerical expression of the volume of fluid containing drug that is
removed from the body per unit time. Although clearance is typically expressed with
respect to volume, removal can also be conveyed in terms of mass, fraction, or
concentration per unit time. Many drugs are removed from the body via a first-order
process (i.e., the rate of removal is only dependent upon the plasma concentration).
When expressed as volume per unit time, clearance is assumed to be constant for a firstorder process, which is a direct result of assuming a constant VD; just as was true for VD,
certain physiologic circumstances can invalidate this assumption. As such, clearance (Cl)
from the body is expressed as
Cl = − kVD

(1.16)

where k is the first-order elimination rate constant. The negative sign indicates that drug
is being removed from the body. Although the instantaneous rate of drug removal from
the body (i.e., amount per unit time) will decrease as concentration declines, clearance
(i.e., volume per unit time) will remain constant so long as elimination is characterized by
first-order kinetics. The concept of clearance can be incorporated within the expression
of plasma concentration for a one-compartment open model to yield
C p = (D0 / VD ) e − (Cl / VD )t

(1.17)

where D0 denotes the initial IV dose. Analogous equations exist for alternative routes of
administration and for multi-compartment models. Moreover, the concept of clearance is
also applicable in non-compartmental pharmacokinetics.82,93 Extensive discussion
regarding the estimation of clearance (e.g., renal excretion and biotransformation rate
constants) can be found in pharmacokinetic textbooks and the literature. The reader is
referred to these general references for greater detail.
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1.3.5.2 Pharmacokinetic Models of Theophylline
Accurate dosing of theophylline has remained a significant challenge since its
first applications in the early 20th century. Imprecision can largely be attributed the
extensive inter-patient variability for the PK of theophylline. Consequently, substantial
effort has been devoted to better understanding the underlying relationship between dose
and exposure.
Ginsberg et al. investigated the utility of a physiologically-based PK model for
discriminating PK differences in neonates and adults. This study was performed using
two model drugs, caffeine and theophylline, both of which are know to have disparate PK
in neonates and adults. Both drugs were selected since caffeine demonstrates a more
dramatic difference as a function of age, despite the fact that caffeine and theophylline
are eliminated via similar pathways (refer to section 1.3.2.2). Since the underlying PK
mechanisms and the significant confounding factors are, by and large, poorly established
for neonates when compared to adults, the authors were particularly interested in
investigating the transferability of in vitro metabolic parameters determined in
mammalian cells transfected with CYP c-DNAs to whole liver metrics. This is an
attractive method since the whole liver metrics can then be adjusted for the differential
expression levels observed between neonates and adults.
To accomplish this objective, a 5-compartment physiologically-based PK model
was generated (i.e., liver, kidney, fat, and rapidly and slowly perfused tissues). Hepatic
metabolism was modeled using published in vitro Michaelis-Menten constants (i.e., Vmax
and Km) for the major metabolic pathways of caffeine and theophylline (i.e., CYP1A1,
CYP1A2, CYP2E1); all other transfer equations were linear. The Michaelis-Menten
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constants were scaled to account for the size of the liver, the amount of microsomal
protein per gram of liver tissue, the aggregate concentration of CYP enzymes per
microgram of microsomal protein isolated from the tissue, and the relative amount of
each CYP enzyme to the total microsomal CYP quantity for a specific age range.
Metabolism in organs other than the liver was not modeled and the fate of the
metabolites, with the exception of conversion of theophylline to caffeine in neonates
(assumed to be first-order), was not considered. Renal elimination was expressed as a
first-order process. Although several of the model coefficients (i.e., the MichaelisMenten constants) were adjusted from the published values to optimize model
performance, the authors concluded that the model described the differential PK
reasonably well based on the comparison of predicted metabolite and drug levels with
urinary excretion data. Adjustments were deemed necessary since the in vitro system did
not mimic the compensatory pathways that are present in vivo (e.g, conversion of
theophylline to caffeine, no incorporation of FMO). The authors also noted that
metabolism in newborns should be adjusted for gestational variations and postnatal age
during the first weeks of life. This study underscores the importance of neonatal PK data.
Scaling of theophylline data from adults to newborns would overlook the conversion of
theophylline to caffeine that takes place in this age group.28
Bjorkman exercised a similar set of objectives when he generated a generalized
physiologically-based PK model applicable across a broad range of ages.30 Unlike the
work of Ginsberg et al.,28 however, all relevant PK parameters (i.e., model inputs) were
scaled using data obtained from adults as opposed to estimating the parameters from in
vitro metabolic data. The physiologically-based model was evaluated with theophylline
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and midazolam, two drugs that display dissimilar physiochemical and PK attributes (e.g.,
lipophilicity, predominant CYP metabolic enzymes). As the unbound (i.e., free) fraction
of theophylline is known to vary with age, a constant unbound fraction of 0.56 was
assumed for adults, while plasma protein binding for infants and children was modeled
according to the age-related variability is serum albumin concentration (equation not
given in original article). Total theophylline clearance was partitioned to be 85 % hepatic
and 15 % renal, and clearance was assumed to be linear (i.e., first-order) across all age
ranges studied. For subjects from 0 – 9 years, a bi-exponential growth function was used
to assign the relative contributions of CYP enzymes to the hepatic metabolism of
theophylline, while 92 % was attributed to CYP1A2 and 8 % to CYP2E1 for individuals
10 years or older. Renal clearance for infants of 6-months was increased by 10 % owing
to the methylation of theophylline to caffeine.
The model was validated using amassed literature data. Model performance was
assessed according to the percent prediction error for the estimation of clearance (Cl),
volume of distribution at steady state (Vdss), and terminal half-life (t1/2). The median
prediction errors for Cl, Vdss, and t1/2 of theophylline were -4.0 %, 3.4 %, and 24 %,
respectively. Bjorkman concluded that the model predicted Vdss and Cl well, but noted
that inter-subject variability of the actual clearance data was considerable. This is not
surprising given the findings of studies such as Jusko et al.46 and Chiou et al.37 The error
of prediction for t1/2 was appreciably larger; inaccuracies in Cl and Vdss, however, are
compounded in half-life estimations. Additionally, Bjorkman questioned the legitimacy
of several reported half-life values cited for neonates and infants, which may be more
inexact than the predicted values. While clearance, and to a much lesser extent, terminal

85

half-life of theophylline changed as a function of age, the volume of distribution was
relatively invariant.30
While these examples are far more complex than a linear one-compartment open
model, several studies have demonstrated reasonable predictive power using this
technique. Many of the following articles have been previously addressed in literature
survey (refer to section 1.3.2) and, therefore, will not be expounded upon other than to
specify the PK modeling assumptions that were implemented. The studies conducted by
Powell et al.45 and Chiou et al.37 utilized a linear one-compartment open model to
describe theophylline concentrations. Powell et al. also assumed that clearance and
volume of distribution were constant for any given individual regardless of the
theophylline level. The authors defended their assumptions by referencing the empirical
observations of a few studies published prior to their work. The article by Gilman et
al.,56 which compared the methods of Powel et al.45 and Jusko et al.,46 and a weighted

least-squares Bayesian approach and the method of Chiou et al.37 for the estimation of
theophylline clearance, employed a one-compartment open model and assumed linear
elimination of theophylline. The authors justified the use of linear elimination based on
the several reports that theophylline failed to demonstrate saturable elimination in adults.
The mean age of the patients utilized in the Gilman et al. study was 43.5 ± 15.8 years. A
constant volume of distribution of 0.5 L/kg was implemented.
Brocks et al. performed a PK study in 34 pediatric patients ranging in age from 4
months to 14 years of age using a one-compartment open model for orally administered
theophylline.94 The authors generated predicted theophylline serum concentrations using
both the patient’s individualized volume of distribution (0.3 – 1.54 L/kg) and a
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standardized value of 0.5 L/kg, and two blood samples. The mean prediction errors
between the observed and predicted serum concentrations using the individualized and
standardized volumes of distribution were -0.509 mg/L and 1.27 mg/L, respectively. The
authors concluded that their method can be used to accurately estimate theophylline
dosages for pediatric patients, despite the fact that it does not require IV data.
Casner et al. conducted a randomized trial during which the accuracy of a PK
model for IV theophylline dosing was compared to physician dosing.95 A total of 35
asthmatic or COPD patients were followed throughout the trial (several were excluded
due to incomplete data) in one of two randomized groups; the kinetic group was dosed
according to a computerized version of the Chiou et al. method,37 while the empirical
group was dosed by physicians instructed to obtain a target concentration of 15 mg/L.
The physiologic and pathophysiologic characteristics of the two groups were comparable.
Three serum theophylline levels were determined from blood samples for each patient.
Prediction error for the two groups was estimated by subtracting the third serum level
from the target concentration. The mean absolute values were 14.8 ± 4.4 and 12.6 ± 4.1
mg/L for the kinetic and empirical groups, respectively. Despite the fact that the
computer predicted dosing was closer to the target value, the difference was not
statistically significant. Moreover, none of the clinical outcomes (e.g., number of
subtherapeutic or toxic levels, duration of time in hospital) were statistically different
between groups. The authors concluded that PK model for theophylline dosing was of no
additional clinical benefit. It is noteworthy, however, that a linear, one-compartment PK
model was able to match the skill of trained physicians.
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The investigation of Hurley et al. was similar to the preceding study of Casner et
al.; Hurley et al. conducted a randomized trial to assess the clinical differences of

computerized versus physician dosing in 91 asthmatic or COPD patients upon admission
to the hospital with acute air-flow obstruction.53 The authors also implemented a onecompartment open model; however, the physicians were not advised to attain a target
theophylline level. Patients were initially dosed according to total body weight and then
their doses were adjusted either by a computerized model (i.e., monitored group) or by a
physician (i.e., control group). Hurley et al. observed no statistically significant
difference in theophylline serum concentrations between the two groups, nor in the
number of subtherapeutic or superpotent levels. They did, however, observe a
statistically significant difference in the lower number of reported subjective side effects
(i.e., breathlessness, palpitations) in the kinetic (or monitored) group as well as a
statistically shorter hospital stay in the kinetic group (6.3 days) compared to the empirical
(or control) groups (8.7 days). Unlike Casner et al., the authors concluded that “using a
pharmacokinetic method to determine theophylline dosage for the patient with acute airflow obstruction improves the likelihood of achieving a theophylline concentration in the
therapeutic range, and may hasten the patient’s recovery.”
These are but a few of the examples of the PK models that have been generated to
study theophylline. Other researchers have also advocated the use of linear, onecompartment models for the analyses of theophylline delivery systems.32,35,41,51,52,96,97
Such models are purported to be applicable for both IV and orally administered dosage
systems.
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1.3.6 Pharmacodynamics
1.3.6.1 Background
A thorough understanding of the physiochemical properties of a drug and how
they control its ADME is imperative. Such knowledge, however, offers little insight as to
how the molecule interacts with the targeted pharmacophore to elicit a physiologic
response. Although a mechanistic understanding of the manner in which a drug docks
with the molecular target is not essential early in the development process, a sponsor
must quickly identify how patients respond to the drug at a specified dose. Likewise, it is
important to understand how the safety and effectiveness of a drug delivery system
change as it is optimized with respect to a desired exposure-response profile. Within this,
it is important to recognize that optimization will most likely affect the onset, magnitude,
and duration of drug action.
Once the pharmacokinetics of a drug are reasonably well understood, it is
important to define the minimum effective concentration (MEC) that results in the
desired endpoint and the minimum toxic concentration (MTC) that results in any adverse
(i.e., toxic) event; concentrations between the MEC and MTC delineate the therapeutic
window. Numerous drugs exhibit a proportional relationship between the administered
dose and the observed outcome. Many individuals, however, respond differently
(although not necessarily unfavorably) to the same drug administered at equivalent doses
and it is this inter-individual variability that obfuscates the underlying exposure-response
relationship. Moreover, small fractions of the population can respond negatively to a
given substance at a specified dose, despite the fact that the majority of individuals
tolerate the treatment. It is therefore important to integrate pre-clinical data with clinical

89

observations, as they become available, to better understand the relationship between
exposure and pharmacologic outcome. A thorough appreciation of the exposure-response
relationship can help to better pinpoint successful management practices for individual
patients or sub-populations a priori.48
Pharmacodynamics is the field of study devoted to the onset, intensity, and

duration of drug action following exposure. In other words, PD is a supplement to PK
that draws a parallel between the drug concentration time profile and pharmacologic
endpoints to ultimately elucidate the relationship between exposure and response. This
bridge between PK and PD helps define the optimum dosing regimen to achieve the
intended result. It follows, therefore, that the same intricacies that affect the PK of a drug
have the potential to influence the PD. More importantly, these variables can act
independently on the PD, despite the fact they showed no observable effect on the PK.
Thus, it is necessary to investigate the potential demographic, physiologic, and pathologic
factors that affect the exposure-response relationship.48
Pharmacodynamic research often involves extensive investigations into the
genetic factors that predispose individuals to respond favorably or unfavorably to a given
drug. Even in instances where the response is efficacious per se, pharmacologic
outcomes that deviate from the projected exposure-response profiles are sometimes
attributable to genetic polymorphisims of genes that encode receptors specific to the
drugs and/or metabolites. Such genetic variations have been known to alter the response
independent of any change in the PK curve.48
Adding to the significant challenge of defining an exposure-response profile is
tolerance. In certain cases, the observed pharmacologic outcome is modulated as a
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function of time, despite maintaining the same dosing regimen. This can be attributed to
several physiologic or pathophysiologic factors, including an increase or decrease in the
quantity of receptors, or an alteration in receptor affinity or signal transduction. Thus, the
exposure-response profile can be severely misconstrued if these time-dependent effects
are overlooked.48
Numerous other phenomena mask the underlying relationship between the PK and
PD of a particular drug. For instance, certain molecules elicit no effect below the MEC,
while others yield a response distinctive from that observed within the therapeutic
window; these effects are thereby exacerbated by sub-potent dosing and/or patient
incompliance. In such instances, a single exposure-response curve inadequately
characterizes the causal relationship. Furthermore, although many exposure-response
curves are linear (or can be transformed to be so) over extended ranges, others are more
appropriately described by an alternate function (e.g., sigmoid) due to disproportionate
increases or decreases in response at extreme concentrations. Selection of an
inappropriate mathematical function to characterize the exposure response relationship
can yield an erroneous PD model.
The ability to ascertain the true exposure-response relationship is dependent upon
the accuracy of the response estimate. For example, subjective endpoints (e.g., decrease
in pain) have higher degrees of uncertainty than measurable responses (e.g., decrease in
blood pressure). Responses that are dependent on an individual’s or a physician’s
perception can complicate efforts to generate an accurate PD curve. Further, certain
pharmacologic endpoints are not feasible to measure. Therefore, to increase the
practicality or lower the associated risk, surrogate PD endpoints are employed under the
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assumption that they are predictive of the actual clinical response. For example, analyses
of the antitumor effects of chemotherapeutic agents would require routine biopsies, which
pose too high of a risk to the patient. To circumvent this risk, clinicians often monitor
expression levels of white blood cells to gauge patient response.98 Use of surrogate
endpoints requires an additional level of validation to ensure that they are indeed
representative of the true pharmacologic outcome. Regardless of the endpoint employed,
the success of any therapy is dependent upon, along with other critical links, a precise
relationship between exposure and response.
1.3.6.2 Pharmacodynamic Models of Theophylline
While numerous studies have focused on understanding the complex relationship
between theophylline dose and exposure, less research has been devoted to developing
pharmacodynamic models expressing the link between exposure and response. This may
be, to some extent, justified by the fact that researchers generally agree upon the
therapeutic window that characterizes theophylline and the inefficacious and toxic events
that occur outside this range. Consistently dosing within this range, however, has proven
to be a challenge.
The pharmacologic outcomes of theophylline closely parallel serum or plasma
concentrations. Both the degree of bronchodilation and the decrease in airway
responsiveness trend with theophylline concentration.25 In fact, bronchodilation
increases linearly with logarithmic increases in theophylline concentration, within the
therapeutic range.35 Over the years of treatment with theophylline, researchers and
clinicians have concluded that theophylline concentrations of 10 – 20 mg/L are most
likely to safely provide clinical benefit, although it should be noted that levels as low as 5
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mg/L are efficacious in certain cases. Others, however, have campaigned for the lower
limit of efficacy to be established as 5 mg/L (refer to section 1.3.2). Thus, the MEC is
not unanimously acknowledged as 5 or 10 mg/L, or some concentration in between.
Concentrations in excess of 20 mg/L compromise the safety of treatment as the
likelihood of toxic side effects increase dramatically above this level. This is
demonstrated in Figure 1.8 where the toxic outcomes of 50 adult patients treated with
theophylline were documented.39 Unfortunately, the occurrence of more severe side
effects is not always preceded by mild toxic events. While certain mild side effects (e.g.,
headache nausea) may be offset by the potential clinical benefit, the fact that the onset of
more severe side effects cannot be accurately predicted has firmly established the MTC at
20 mg/L, although some have suggested this value should be reduced to 15 mg/L (refer to
section 1.3.2). Severe side effects are consistently observed at concentrations well in
excess of 20 mg/L.

Figure 1.8. Mean theophylline serum concentrations versus the frequency and severity of toxic effects in 50
adult patients. Mild toxic events included nausea, vomiting, headache, and insomnia. Potentially serious
toxic effects were limited to sinus tachycardia. Severe toxic side effects included life-threatening cardiac
arrhythmias and seizures.
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A number of studies have evaluated the effects of concomitant therapies on the
pharmacologic outcome of theophylline, but they are specific to a single drug effect and
sample population, and thus, have limited applicability. For example, Hoffman et al.
investigated the effects of total body gamma irradiation on several drugs in rats.99 They
concluded that gamma radiation did not affect the theophylline dose necessary to induce
seizures. Similarly, Hoffman et al. explored the potential for cyclosporine to potentiate
the effects of theophylline in rats.100 They observed that administration of cyclosporine
reduced the theophylline concentration required to induce seizures and suggested that
cyclosporine may increase the risk for generalized seizures during treatment with
theophylline.
A survey of the literature reveals that the majority of PD studies involving
theophylline focus on bronchodilation in asthmatic patients. One of the criteria used to
diagnose asthma as well as monitor its condition is forced expiratory volume in one
second (FEV1), which is the amount of air that an individual can forcibly expire in one
second. FEV1 is typically measured in liters using a spirometer and is reported as a
percentage of the amount of air that can be forcibly expired after full inspiration.
It has long been reported that the degree of bronchodilation (or percentage change
in FEV1) is linearly related to theophylline concentration when the concentration axis is
log-transformed. Indeed, Mitenko et al. observed this relationship in six hospitalized
asthmatic patients who were administered theophylline IV; no mathematical relationship
defining the PD model was offered.41 More recently, however, researchers have
observed findings that challenge this correlation.
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Flores-Murrieta et al. reported in 1999 that previous researchers had failed to
model the PD outcomes of theophylline in asthmatic patients presenting with different
degrees of airway obstruction.101 The authors conducted a study in 15 asthmatic patients
who were cleared of all confounding diseases. Patients were divided into two groups, the
first consisting of 2 males and 6 females (mean age 40 ± 11 years) who displayed FEV1
values of less than 50 % and the second comprised of 7 females (mean age 30 ± 12 years)
with FEV1 values between 50 and 70 % of ideal. A single 250 mg dose of theophylline
was administered via IV infusion over 30 minutes and plasma drug concentration as well
as FEV1 was measured for a total of 12 hours. Plasma concentration-time data were
modeled using a two-compartment open model consisting of a central and an effect
compartment. A two-compartment model was determined to be optimal due to the delay
between the appearance of theophylline in the plasma and bronchodilation. Plasma
concentration in the effect compartment was correlated to FEV1 via a sigmoidal Emax
expression
⎛ E ⋅Cγ
E = E0 + ⎜⎜ maxγ
γ
⎝ EC50 + C

⎞
⎟
⎟
⎠

(1.18)

where E is the pharmacologic response, E0 signifies the baseline response, Emax
represents the theoretical maximum effect that can be attained, EC50 symbolizes the drug
concentration at 50 % of the maximum effect, C is concentration at the effect site, and γ
is the sigmoidicity constant, which dictates the steepness of the curve. The optimal fits
for the response curves were determined using nonlinear regression. Emax
pharmacodynamic models were previously demonstrated to be practical for correlating
FEV1 to theophylline concentration.102
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The authors observed counterclockwise hysteresis loops in both groups when
FEV1 values were plotted against theophylline plasma concentration (Figure 1.9). This
phenomenon suggests that the relationship between bronchodilation and theophylline
concentration is indirect, possibly due to a delay in the equilibrium between plasma
concentration and the site of drug action. Both groups were able to achieve comparable
FEV1 values when treated with theophylline; however, the EC50 value was higher for the
severe patients, which increases their risk of experiencing a toxic event. The PK of the
two groups were comparable. While these results confirm the indirect relationship
observed by two other research groups,103,104 they contradict the general viewpoint that
the extent of bronchodilation is directly related to theophylline concentration. The
authors concluded that by failing to segregate patients according to baseline airway
function, earlier investigations may have overlooked the true exposure-response
relationship for theophylline.101

Figure 1.9. Plots of FEV1 verses theophylline plasma concentration to patients with severe (left) and
moderate (right) airway obstruction. The arrows indicate the counterclockwise hysteresis.
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Despite years of research and a substantial number of literature publications, it is
evident that the PD, much the same as the PK, of theophylline has yet to be fully
elucidated. The author is unaware of any large-scale study assessing the safety and
effectiveness of theophylline in a broad population encompassing the various
physiologic, pathophysiologic, and other factors known to influence its action. As a
result of these voids, theophylline remains a viable research candidate for PK and PD
investigations.

1.3.7 Pharmacokinetic/Pharmacodynamic Simulation
The individual disciplines of PK and PD are merely two of the many discrete
components situated on the continuum known as the drug discovery and development
process. Integration of these components, however, convolves their contributions and
offers knowledge that transcends each discipline to provide a more complete picture of
the drug delivery system and its impact on patient well-being. Integrated PK and PD
models bridge the relationship between dose and response. These models can then be
used to better guide the development and ultimate utility of a drug delivery system. For
example, integrated PK/PD models can be used to minimize the likelihood that a patient
will experience an adverse event following commencement of a therapy. The same
models can be used to understand how response changes between fed and fasted states or
how the pharmacologic outcomes might be affected as a result of drug-drug interactions
that alter the ADME of one or several of the concomitant drug therapies.48
Modern-day computers augment the arsenal of research tools available to
scientists and clinicians. Technological advances in the areas of hardware and software
have nearly eliminated computational deficiencies that were limiting factors several
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decades ago. Thus, personal computers are powerful enough to conduct a variety of in
silico simulations with varying underlying objectives. Numerical simulation can be

expected to take a more prominent role in the drug discovery and development process as
it compliments the FDA’s Critical Path Initiative by utilizing innovative techniques to
study the manufacturability, safety, and efficacy of candidate molecules and/or drug
products.9 Pharmacokinetics and pharmacodynamics are two pharmaceutical disciplines
that utilize computer simulation extensively.
Once a PK model has been generated, a simulation platform can be constructed to
assess the impact that random variation to the inputs has on the PK model output(s) (e.g.,
plasma concentration). The article by Gomeni et al. was previously introduced as it
pertains to MCS.70 Regarding the details of their PK modeling and simulation, the
authors first implemented a convolution approach to estimate plasma concentration.
Specifically, the in vivo delivery rate, which was modeled using the Weibull function,
and the disposition and elimination time course, which was described by a twocompartment linear model, were convolved to predict plasma concentration. The authors
then perturbed this model via MCS by randomly sampling values for the inputs (e.g.,
fraction of the dose absorbed, Weibull shape and time parameters) to better understand
their influence on plasma concentration, and subsequently, receptor occupancy. Lognormal distributions for each input parameter were generated according to a
predetermined coefficient of variation for that particular trial. The simulation evaluated
plasma concentration for a given patient 24 hours after the 7th dose to better understand
how variability of the inputs affected receptor occupancy.
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Alternatively, Peters recently illustrated how physiologically-based PK simulation
can be used to estimate PK model coefficients with two model drugs, verapamil and a
proprietary compound no longer in development, in both rats and humans.105 The
primary objective was to demonstrate that physiologically-based PK simulation of plasma
concentration-time profiles can reliably differentiate the underlying PK mechanisms,
most notably the intestinal loss of orally administered drugs from first-pass hepatic
metabolism, which are more often than not modeled in the same compartment as they are
difficult to separate within clinical data. A generalized physiologically-based PK model
comprised of a 9-compartment absorption model and a 14-compartment (i.e., 14-organ)
somatic model was constructed to account for factors such the first-pass effect, intestinal
loss, renal and biliary elimination, enterohepatic recirculation, and conversion of the
metabolites back to the parent compound.
For a given drug, the first phase began by iteratively optimizing the estimates of
clearance and the tissue partitioning coefficients of the 14 organs for IV administration
using known physiochemical properties of the drug (i.e., permeability and solubility).
Model performance was evaluated by assessing the goodness of fit for the predicted AUC
with the mean of the actual AUC values. Once the predicted profile closely mirrored the
actual IV plasma curve, the next step used the optimized clearance and distribution
parameters to simulate the plasma concentration-time profile for oral administration.
Assuming that solubility and permeability are the only two properties that determine the
shape of the profile (i.e., that clearance and tissue distribution coefficients are not
dependent upon the route of administration), differences between the actual and predicted
concentration-time curves for oral administration should be attributable to intestinal loss
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factors such as drug-induced gastric emptying delay, enterohepatic recirculation, gut wall
metabolism, chemical degration, P-glycoprotein efflux, and/or variable absorption across
the gut. These model parameters can then be modulated to reveal which factors are more
than likely responsible for any differences between profiles. Peters emphasized that this
method is functional even with inaccurate estimates of clearance and/or tissue
partitioning coefficients. Further, she highlighted that physiologically-based PK
modeling is a suitable approach for deconvolving absorption from distribution,
metabolism, and excretion phenomena for orally administered drugs. The specific factors
affecting the pharmacokinetics of the oral dosage form can then be differentiated through
additional laboratory experimentation.105
It is evident that as physiologically-based modeling and simulation progresses, the
concept of compartments is continually advancing from bodily systems or organs to
cellular structures (e.g., enzymes, transporters). This presents the opportunity to model
and simulate population variability on a cellular level, which will better elucidate how
these disparities, which could be attributed to numerous factors (e.g., genetics, disease
states, concomitant drug therapies), affect drug kinetics and action.67
A quantitative PK model is a prerequisite for predicting the clinical effectiveness
of a given drug. Once such a model is available, it can be integrated with
pharmacodynamic knowledge to study the safety and efficacy of treatment. Often times,
simulation utilizes PK and PD models simultaneously to accelerate the drug development
process. Such models are typically referred to as PK/PD models, which attempt to link
the drug dosages to the clinical outcomes. The value of a PD model is dependent upon
the merit of the corresponding PK model; a PD model that cannot accurately predict

100

pharmacologic response as a function of drug concentration has limited utility. Several
case studies that investigated the potential impact of certain variables (e.g., dosing
schedule, PK parameters, patient compliance) on the effectiveness of treatment were
reviewed earlier.
Another important advantage of PK/PD simulation is its ability to help identify
specific sub-populations that will benefit from treatment with the compound under
investigation. As a rule of thumb, any compound that lacks efficacy will fail in clinical
trials. Likewise, categorizing patients who will not respond safely or effectively to a
given therapy is vital for the sponsor, the regulatory agencies, and the general public.
With knowledge of a substance’s ADME along with explicit inter-patient characteristics,
simulation can elucidate specific patient conditions that preclude individuals from
treatment. In silico investigations of patient variability in diverse populations has been
coined population pharmacodynamics. As Michelson et al. indicates, responder
populations can be identified using simulated patients generated from hypotheses or by
fitting observed data to dose-response curves using any number of mathematical
functions that account for covariates (e.g., age, gender, health factors).106 Tools that
identify responder populations should not only increase the number of available
therapies, but should enhance the efficiency and effectiveness of clinical trials, which will
ultimately hasten the time-to-market.
Eddy and Schlessinger published what is perhaps one of the most comprehensive
examples of a simulation platform constructed to study a disease state.107 The authors
generated an extensive diabetes model and simulation platform referred to as the
Archimedes model. While the Archimedes model transcends the classification of PK/PD
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simulation, it is purposefully offered as a summary to the literature survey since it
integrates many of the elements addressed thus far. The authors indicated that the model
was too large to detail in a single manuscript, but the equations and corresponding
assumptions are available in an online appendix (http://care.diabetesjournals.org). The
Archimedes model was generated according to 3 basic criteria: (1) the model was to
include all facets of the disease or its management that were considered valuable for
investigating areas of interest, (2) the model was to be able to delineate clinically relevant
features of the disease and its management, and (3) the level of detail incorporated was to
be commensurate with its importance in the design of clinical trials. The Archimedes
model was sequentially constructed and utilized in the following five stages: (1) develop
a nonquantitative or conceptual description of the pertinent biology and pathology of
diabetes (i.e., the variables and their relationships), (2) identify studies that focused on
these variables and their underlying connection, (3) use the knowledge found in those
investigations to link these variables via mathematical functions, (4) program these
models into the simulation platform, and (5) perform numerical simulation using the
platform. Individual models were tested and debugged during phase (4) of this series.
Although the development criteria and phases were originally couched in terms of the
Archimedes model, it should be noted that they are directly applicable to alternative
simulation systems.
The Archimedes model was constructed using a system of differential equations
and was coded using an object-oriented language known as Smalltalk. At the time of
publication, it included numerous physiologic, pathologic, logistical, administrative, and
economic factors including disease risk factors, incidence and progression of the disease,
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glucose metabolism, symptoms, treatments, complications (e.g., coronary artery disease,
congestive heart failure, deaths from diabetes and its associated complications,
physiological dysfunctions as a result of disease (change in production of glucose as a
result of an increase or decrease in insulin, etc.)), and differences amongst health care
facilities (e.g., tests for pathophysiology of diabetes, re-admission rates). The structural
relationship of the variables included in the diabetes model is summarized in Figure 1.10.
The Archimedes model has the flexibility to assess three different treatment regimes (i.e.,
IV insulin, oral drugs, diet and exercise). Response to, for example, insulin is initially
modeled by an individual’s insulin factor from a distribution that characterizes the
variation of the general population. This effect is then propagated through the various
expressions that comprise the Archimedes model to account for confounding factors.
The authors validated the Archimedes model in a subsequent article using actual clinical
data from 18 trials. They concluded that the platform has the capacity to realistically
model and simulate anatomic and pathophysiologic changes, treatments, and outcomes
relevant to diabetes and its complications within the context of the available trial data.108
They also indicated that the Archimedes model has the inherent flexibility to incorporate
additional underlying knowledge regarding this disease state as it becomes available.107
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Figure 1.10. Schematic diagram detailing the structural relationship of the factors included in the
Archimedes model of diabetes. Circles represent variables and lines indicate relationships. In general, the
arrows directed into a variable represent one equation. Squares indicate other components of the model
that are too complex to be shown here and have their own corresponding diagrams consisting of tens of
variables and relationships. UKPDS and DCCT are acronyms for actual clinical trails and appear as circles
with dashed boarders. These two trails were used to help construct the elements of the model illustrated in
the figure. Reproduced from the work of Eddy and Schlessinger.

This work was founded on the central hypothesis that pharmaceutical process and
product understanding can be simultaneously utilized to model the risk that final product
quality imparts to clinical performance. The subsequent chapters, whole and in part,
address one or more of the objectives stated in section 1.2. Chapter 2 describes the
particular data, models, and assumptions used to construct the risk simulation platform,
which is the medium used to redefine pharmaceutical quality in terms of risk by linking
clinical attributes to production characteristics. Subsequently, the determination of the
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conditional risk of product variation on clinical performance for the model drug delivery
system is detailed. Chapter 3 builds upon the underlying relationships between product
variation and clinical performance to generate design spaces conditioned on quantitative
estimates of inefficacy and toxicity risk.
Multivariate data analysis and calibration are important elements of PAT and
QbD as spectroscopic techniques are often used to acquire and/or enhance product and
process knowledge. Chapter 4, therefore, demonstrates the utility of multivariate data
analysis for elucidating the effects of various product and process variables on
spectroscopic measurements. The influence of experimental design on spectroscopic
variance is also considered. Chapters 5 and 6 described the role of net analyte signal
theory and figures of merit in gauging the performance of calibration models, which will
likely be integral components of future risk simulation efforts. Not only is it important to
understand the performance of calibrations, it is critical to identify how their performance
influences the prediction of factors that ultimately affect risk.
The penultimate chapter (7) seeks to unify the preceding topics via a hypothetical
example revolving around the incorporation of PAT into a QbD production environment
to ultimately control the clinical performance of the final product. Here, non-invasive
spectroscopic techniques are strategically integrated prior to final product release to
monitor those attributes which are potentially critical to quality. The corresponding role
of process and control models in managing inefficacy and toxicity risk of the model drug
delivery system is also addressed. Lastly, Chapter 8 provides a summary of the
aforementioned work.
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This dissertation explicitly links product characteristics to clinical performance
using the proposed methodology. It is important to emphasize that these theophylline
data were used to demonstrate one (of potentially several) approaches to directly relating
product and patient characteristics. The clinical risk data were not, however, generated
with the intent to suggest that theophylline regimens should or should not be altered.
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Chapter 2: A New Definition of Pharmaceutical Quality: Assembly
of a Risk Simulation Platform to Investigate the Impact of
Manufacturing/Product Variability on Clinical Performance of a
Model Theophylline Solid Oral Dosage System

2.1 Introduction
Around the turn of the 21st century, an informal retrospective survey of the
pharmaceutical industry revealed that its progress (particularly with regard to
manufacturing) was essentially stagnant and paled in comparison to other industrial
sectors. Some individuals contend this was obvious and discussed within intellectual
circles ad nauseum. Countless more, however, were reluctant to admit or failed to detect
the issue at hand, and yet others who begrudgingly acknowledged the problem hurriedly
placed blame on an overly restrictive regulatory system that penalized innovation. This
was all set to change.
Taking initiative and holding themselves partially responsible, the FDA launched
the CGMPs for the 21st Century campaign in 2002 to, in effect, “modernize” the
pharmaceutical industry. The modernization commenced internally, and a new, riskbased regulatory architecture was created to refocus resources where they were needed
most; areas that posed the greatest risk to the public. In turn, pharmaceutical companies
were encouraged to adopt risk- and science-based approaches for drug discovery and
development. Numerous initiatives, reports, and guidances followed (e.g., PAT, QbD),
many of which promoted innovation and offered examples as to how the associated
changes fit within the contemporary regulatory environment. These documents
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underscore the need for collective change and emphasize several benefits that
manufactures would reap from innovation.
“Quality” is explicitly or implicitly addressed in all of these documents. To date,
the exact definition of quality in the pharmaceutical industry is unresolved, which is
burdensome given that one of the primary objectives of the modernization initiative is to
spur innovation to ultimately enhance pharmaceutical product quality. This uncertainty
culminated in 2004 when Dr. Janet Woodcock, Director of the CDER at the FDA
proposed re-defining pharmaceutical quality with regards to risk by linking production
characteristics to clinical attributes.19
It is well understood that the clinical performance of any therapeutic regimen is
dependent on a number of factors. For example, patient compliance dramatically
influences safety and efficacy profiles. Consequently, researchers and clinicians invest
time and energy to understand and control compliance rates. Manufacturing of the drug
products also imposes a certain degree of risk on clinical performance. Despite its
influence, little (if any) effort is devoted to quantifying the risk associated with
manufacturing processes. If quality is to be re-defined in terms of risk, probabilistic
relationships between production and clinical attributes must be established.
Cogdill and Drennen described an approach for relating manufacturing
characteristics and clinical performance of a drug product.20 They proposed the
combination of probabilistic risk assessment (PRA) and Monte Carlo simulation (MCS)
to relate elements such as raw material quality, product design, population statistics,
dosing guidelines, and patient compliance estimates with pharmacokinetic (PK),
pharmacodynamic (PD), and in vitro-in vivo correlation (IVIVC) models to remold
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quality in terms of risk (Figure 2.1). The objective was to translate manufacturing and
drug product attributes into probabilistic risk scores for toxicity and inefficacy. With
these estimates, product and process design could then focus on minimizing risk to the
patient.

Figure 2.1. Schematic of the various model components that comprise the risk simulation platform. Figure
adapted from Cogdill, RP; Drennen, JK. 2008. Risk-based quality by design (QbD): A Taguchi
perspective on the assessment of product quality, and the quantitative linkage of drug product parameters
and clinical performance. Journal of Pharmaceutical Innovation 3 (1): 23 – 29. Solid arrows represent
components that are currently linked in the platform, whereas dotted arrows signify components/concepts
that have yet to be incorporated.

This work used theophylline as a model drug to illustrate one potential method of
relating manufacturing characteristics of a solid dosage system to clinical performance in
simulated asthmatic patients displaying considerable inter-individual variability. The
objectives were to (1) describe the structure for harnessing MCS and PRA to estimate
risks of inefficacy and toxicity and (2) estimate the conditional risk of production
characteristics on clinical performance for a model solid oral dosage system.
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2.2 Materials and Methods
2.2.1 The Weibull Distribution
Waloddi Weibull formally introduced what is now referred to as the Weibull
distribution in a 1939 monograph published by the Royal Swedish Institute for
Engineering Research. As Arthur Hallinan, Jr. emphasized, there are (at least) five
different mathematical formulae used to express the Weibull distribution, all which are
equivalent following certain transformations.109 It was his opinion that the array of
formulae most likely created confusion, and, therefore, initial reservation concerning its
applicability. Nonetheless, the Weibull distribution has been used to model numerous
phenomena such as wind speed, failure (or reliability), and dissolution.16,109,110
Although originally hypothesized as a material function to describe the strength of
materials subjected to stress, the Weibull distribution is now regarded as a flexible (i.e.,
generalized) statistical distribution. The distribution was proposed as a three-parameter
distribution, characterized by a scale parameter (α), a shape parameter (β), and a location
constant (c), but it is frequently utilized as a two-parameter (c = 0), and, at times, a oneparameter distribution (α and c = 0). It should be noted that the symbols used to
represent these three parameters have varied over time, but these were intentionally
selected so as to be consistent with the most recent literature. The following formulae
will be presented according to the two-parameter functions; a location constant is
employed to adjust the point at which there is a non-zero probability. Please refer to the
article by Arthur Hallinan, Jr. for greater detail regarding the various three-parameter
Weibull expressions.109
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The cumulative distribution function (CDF), or the cumulative probability of
occurrence for a given random variable (V) is described by the two-parameter Weibull
function
f (V ) = 1 − e

⎛V ⎞
−⎜ ⎟
⎝α ⎠

β

(2.1)

where V is the vector of points to be modeled (vi ≥ 0), β is the Weibull slope or shape
parameter (β > 0), and α is the Weibull scale parameter (α > 0). Similarly, the derivative
of the CDF describes the probability density function (PDF), which is the probability
distribution of a continuous random variable. The PDF is expressed by the equation

β ⎛V ⎞
f ′(V ) = ⋅ ⎜ ⎟
α ⎝α ⎠

β −1

⋅e

⎛V ⎞
−⎜ ⎟
⎝α ⎠

β

(2.2)

where V , β, and α are as previously defined. A random variable is said to be Weibull
distributed if its CDF or PDF are adequately represented by Equations 2.1 or 2.2 (or the
equivalent one or three-parameter functions). Several methods, including the Weibull
graph technique, least-squares, and maximum likelihood, can be used to estimate the
parameters.109
The Weibull distribution is considered flexible for a number of reasons. First, it is
characterized by only 3 (or less) parameters, which is more straightforward than, for
example, the five-parameter bi-variate normal distribution. Second, it mirrors the
Rayleigh distribution and approximates the Gaussian distribution when the shape
parameter is 2.0 and 3.6, respectively; these distributions can be classified as specific
cases of the Weibull. Its ability to assume a range of values for the shape parameter,
therefore, allows the distribution to more easily compensate for real-world variability.
Finally, the Weibull distribution provides a reasonable fit to a variety of observed
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distributions, which is evidenced by the assorted phenomena it has been used to model.110
It was for these reasons that the Weibull distribution was selected to model certain data
for this work.

2.2.2 Patient Simulation
Monte Carlo simulation has been shown to be an effective method for generating
hypothetical patient populations in situations where it may be unreasonable or unethical
to utilize humans.64,111 For the work herein, MCS will be used to generate asthmatic
patients ranging in age from 10 to 90 years; patients outside of this range were not
modeled due to the lack of data pertaining to the targeted factors. The most significant
factors affecting the disposition of theophylline, as determined by Jusko et al.,46 will be
specified to effectively represent inter-patient variability. All modeling and MCS
simulations were performed using routines written in-house (Matlab, version 7.1, The
MathWorks, Natick, MA ; PLS_Toolbox, version 3.0, Eigenvector Research, Inc.,
Manson, WA). Initially, data classifying the 2007 United States (US) population by age
and gender were obtained from the US Census Bureau’s International Data Base,112 and
statistics summarizing the prevalence of asthma within the US population during 2000 2005 were obtained from the Centers for Disease Control and Prevention (CDC).113 Data
for the prevalence of asthma specific to individuals older than 65 was not further
delineated; thus, it was assumed that the prevalence (per 1000 subjects) monotonically
decreased by 1.0 for each 10-year increment exceeding 70 years. A new distribution that
approximated the asthmatic fraction of the total population within each age range was
generated from the product of the US population and age-specific asthma rates.
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An MCS routine, utilizing the exclusion method, assigned the age of each
asthmatic patient based on the aforementioned relative distribution. The maximum
number of allowable patients for each age range was determined by multiplying the
number of desired patients by the relative distribution. To generate an initial estimate of
age for a given patient, a single pseudo-random value was drawn from a uniform
distribution generated on the unit scale (i.e., “rand.m” function within Matlab), was
multiplied by the difference between the upper (i.e., 90) and lower (i.e., 10) age limits,
and was added to the lower age limit. The estimate of age was rounded to the nearest
integer. The “rand.m” function generates values between the closed interval of [2-53, 1-253

] and is theoretically capable of generating 21492 values prior to repeating itself. If the

estimate did not fall within the desired age range, the routine continued to generate
estimations by resampling the uniform distribution until a satisfactory estimate was
achieved. Likewise, if the estimate was within an age range where the maximum number
of allowable patients had already been generated, the routine iterated until an acceptable
age was attained. The distribution of age for the 100,000-patient population is
summarized in Table 2.1. On average, approximately 375,000 iterations were required to
assign the ages of the 100,000 patients.
Once the age of each patient was assigned, the gender of every patient was
determined. Gender was resolved by drawing a number from a binomial distribution,
which was generated using the “binornd.m” function in Matlab. The success probability
(p) was set to the fraction of males in a specific age range.112 A value of 1 signified a
male, whereas 0 represented a female. The distribution of gender for the 100,000-patient
population is summarized in Table 2.1.
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Table 2.1. Age and gender distributions for the simulated patient population.
Age Range
Combined
Fraction of Total
(years)
Totals
Population
Males
Females
0-4
0
0
0
0.000
5-9
0
0
0
0.000
10 - 14
5,324
5,226
10,550
0.106
15 - 19
5,305
4,927
10,232
0.102
20 - 24
4,348
4,247
8,595
0.086
25 - 29
3,781
3,692
7,473
0.075
30 - 34
3,251
3,224
6,475
0.065
35 - 39
3,583
3,410
6,993
0.070
40 - 44
3,728
3,846
7,574
0.076
45 - 49
4,117
4,246
8,363
0.084
50 - 54
3,957
4,088
8,045
0.080
55 - 59
3,443
3,714
7,157
0.072
60 - 64
2,634
2,971
5,605
0.056
65 - 69
1,901
2,153
4,054
0.041
70 - 74
1,420
1,643
3,063
0.031
75 - 79
1,034
1,415
2,449
0.024
80 +
1,187
2,185
3,372
0.034
0 - 80 +

49,013

50,987

100,000

1.000

Cumulative Fraction of Total
Population
0.000
0.000
0.106
0.208
0.294
0.369
0.433
0.503
0.579
0.663
0.743
0.815
0.871
0.911
0.942
0.966
1.000

Fraction
Male
0.000
0.000
0.505
0.518
0.506
0.506
0.502
0.512
0.492
0.492
0.492
0.481
0.470
0.469
0.464
0.422
0.352

1.000

0.490

Anthropometric reference data for the conditional distributions of total body weight (kg)
and body mass index (BMI) of the US population for all ages during 1999 – 2002 were
obtained from the National Health and Nutrition Examination Survey (NHANES),
conducted by the National Center for Health Statistics (NCHS), CDC.114 The weighted
population means, standard errors of the means, and selected percentiles by sex, race,
ethnic group, age, or age group were reported in this survey. Results, categorized by
gender, are reported per year for individuals 1 to 19 and per decade for subjects 20 years
and older. The 5th, 10th, 15th, 25th, 50th, 75th, 85th, 90th, and 95th percentiles (i.e., the value
in an ordered set of measurements for which x % of the observations lie below) were
presented provided that the NCHS determined that the estimate was reliable. Unreliable
figures were those that had a relative standard error (i.e., ratio of the standard error and
the mean) greater than 30 %. The percentiles summarizing each age range for both
weight and BMI were independently modeled using the two-parameter Weibull function
(Equation 2.1). The weight and BMI values for males and females were modeled
separately and the Weibull parameters were estimated using a least-squares approach. A
shape and scale parameter were estimated for each age range modeled; the nominal
percentiles were predicted using the reference percentile values114 and the corresponding
Weibull parameters to assess the goodness of fit. Irrespective of gender, the lowest
coefficient of determination obtained for any of the individual models for weight or BMI
was 0.951 and the median value across all models was 0.983. All anthropometric
modeling was performed prior to the MCS for generating patients.
To assign weight and BMI metrics, the appropriate Weibull parameters were
selected, first for weight and then for BMI, based on a patient’s age and gender. The age-
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and gender-categorized shape and scale parameters were used to generate a Weibull
distribution (i.e., “wblrnd.m function in Matlab), from which a single value, representing
the patient’s weight or BMI, was extracted at random. Weight and BMI estimates were
continually resampled until a value that fell within the restricted weight (20 – 130 kg) or
BMI (10 – 50) range was obtained.
With the age, gender, weight, and BMI assigned, the remaining factors affecting
the disposition of theophylline were specified. Statistics on cigarette smoking, marijuana
use, alcohol consumption, and intake of oral contraceptives were obtained from the 2006
US Health survey conducted by the NCHS, CDC.115 Statistics, reported as percent of
total population, were taken for the latest recorded year. Data were (generally) reported
for the ranges 12 – 13, 14 – 15, 16 – 17, 18 – 25, 26 – 34, and 35 years old and over. The
last age bin was modified to include the expanded ranges 35 – 44, 45 – 64, and 65 – 90
years of age. Except where noted otherwise, the CDC data for greater than 35 years were
represented identically in the three expanded age bins. For heavy alcohol drinkers, which
was recoded as the percent of those who consumed alcohol, the values for 45 – 64 and 65
– 90 were adjusted downward (i.e., 8.8 % and 5.9 %, respectively) from the 10.4 % value
reported for 35+ years based on the assumption that these individuals would pass away
sooner than those who were not heavy drinkers. Additionally, the 3.1 % value reported
for marijuana use for 35+ years was adjusted to 1.5 % for those individuals 65 – 90 years
of age. For both marijuana and alcohol use, the percentage of female users was assumed
to be 50 % of the observed rate for males; the values for heavy alcohol drinkers, however,
were identical for males and females. Regarding the intake of oral contraceptives, the
CDC data reported usage for minors in the range of 15 – 19 years. Thus, this value was
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applied to the 16 – 17 age bin, while 0 % and 20 % were assumed for 12 – 13 and 14 – 15
years old, respectively. Additionally, a value of 0 % was assumed for the 45 – 64 and 65
– 90 ranges; oral contraceptive use was not recorded after 44 years. Regardless of age, a
value of 0 % for oral contraceptive use was assumed for males. Data for cigarette
smoking aligned with the amended age bins; therefore, they were used as reported.
The probability of suffering from congestive heart failure was modeled using data
that described the prevalence of heart disease by age, which was obtained from the
National Heart, Lung, and Blood Institute (NHLBI) Data Fact Sheet.116 These data were
reproduced from the 1976 – 1980 and 1988 - 1991 NHANES surveys; however, only data
for 1988 – 1991 were used (Figure 5 of the NHLBI report). A data tracing program
written in-house was used to estimate the prevalence (%) for the age-groups sampled.
For individuals greater than 30 years of age, the probability of experiencing congestive
heart failure (CHF) was approximated using the equation

p

≈ 3.92 x 10 −3 ⋅ (age ) − 0.22 ⋅ (age) + 3.51
2

(2.3)

where p represents the probability of CHF and age is the age (in years) of the patient.
Based on age- and gender-specific discharge frequencies for CHF cases recorded during
2004,115 the resultant probability was multiplied by a factor of 0.75 if the patient was
female. Additionally, all individuals 30 years of age or younger were automatically
precluded from having congestive heart failure.
Sufficient gender- and age-specific data for the general use of barbiturates and
benzodiazepines were unavailable. Therefore, inferences for the percent of the total
population using each class of drug were made based on age and gender. These data are
presented in Table 2.2.
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Table 2.2. Gender- and age-specific data detailing the percent of the total simulated population using
barbiturates and benzodiazepines.
Age
12 14 16 18 25 35 45 65 Range
13
15
17
24
34
44
64
90
(years)
Barbiturate Use
Male
0.0
1.0
3.0
4.0
4.0
3.0
2.0
2.0
(% of total
population)
Female
0.0
0.0
1.0
2.0
3.0
3.0
2.0
2.0
Benzodiazepine
Male
0.0
2.0
4.0
5.0
7.0
15.0
20.0
15.0
Use (% of total
population)
Female
0.0
2.0
4.0
5.0
7.0
15.0
20.0
15.0

The likelihood of a patient presenting with any of the remaining factors shown to
affect theophylline disposition (i.e., cigarette smoking, marijuana use, alcohol
consumption, congestive heart failure, and intake of oral contraceptives, barbiturates, and
benzodiazepines) was independently determined by randomly extracting a value from a
binomial distribution, where p was set to the fraction of the total population that
presented with a specific factor. Each factor was categorized based on age and gender,
and therefore, p was selected based on the patient’s age and sex. For congestive heart
failure, p was merely the resultant probability estimated using Equation 2.3. An output of
1 from the binomial distribution represented a subject who displayed the given factor,
whereas 0 indicated a patient who was negative for that factor.
Once all of the factors were accounted for, theophylline clearance was
individualized for each patient according to the clearance cascade adapted from Jusko et
al.46 (Figure 2.2). It should be noted that the terminal nodes for marijuana use in

individuals less than 40 years old who did not use oral contraceptives were excluded from
the clearance cascade model. Data pertaining to the use of marijuana are subject to
misrepresentation. Therefore, eliminating the second split based on marijuana use
mitigated the uncertainty associated with accurately categorizing patients within the
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cascade model. The terminal node on the clearance cascade was determined for each
patient based on the individualized factors that predispose theophylline disposition. The
percentage of the total 100,000-patient population that fell within each node is reported in
Figure 2.2. Once it was determined which node best described a given patient, the mean
and standard deviation of that particular node (Figure 2.2) were used to generate a normal
distribution (i.e., “normrnd.m” function within Matlab), from which a single value,
representing the patient’s theophylline clearance, was extracted at random. Clearance
estimates were restricted to 5 – 180 mL/hr/kg. If necessary, the distribution was
resampled until the estimate was within the constrained range. The distribution of
clearance for the 100,000-patient population based on the factors studied is summarized
in Figure 2.3. Theophylline clearance was assumed to be constant throughout the course
of treatment.
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Figure 2.2. Clearance cascade detailing the average theophylline clearance for individuals classified
according to numerous factors. Figure was adapted from Jusko, WJ, Gardner, MJ, Mangione, A, Schentag,
JJ, Koup, JR, Vance, JW. 1979. Factors affecting theophylline clearances: Age, tobacco, marijuana,
cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol.
Journal of Pharmaceutical Sciences 68 (11): 1358 – 1366. Both the number of individuals in the original
study by Jusko et al. and the percentage of the 100,000 simulated population that fell within each node are
indicated. All terminal nodes are shaded. 0, 1, and 2 signifies the extensiveness of a given factor as
delineated in the original study. MJ = Marijuana; O.C. = Oral Contraceptive; EtOH = Alcohol; CHF =
Congestive Heart Failure; CIG = Cigarette Smoker; BENZ = Benzodiazepines; BARBS = Barbiturates.
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Figure 2.3. Frequency histograms of clearance (a) and volume of distribution (b) for the 100,000 simulated
patients. The mean, standard deviation (S.D.), and range [ , ] of each parameter are also provided.

Finally, volume of distribution was assigned by randomly sampling a normal
distribution defined by a mean volume of distribution of 0.47 L/kg and a standard
deviation of 0.03 L/kg. While previous studies have assumed one (constant) average
volume of distribution for all patients (e.g., 0.45 L/kg),46,56 the author considered this to
be more representative of the variability that would be encountered in actual patients.
The volume of distribution values for the 100,000-patient population are summarized in
Figure 2.3. Analogous to clearance, the volume of distribution was assumed to be
constant for each patient during the course of simulated therapy.

2.2.3 Model Solid Oral Dosage Form
A solid oral theophylline dosage system that was previously formulated and
processed at Duquesne University (Pittsburgh, PA) and compacted at a local
pharmaceutical company was utilized for its estimations of manufacturing variability and
clinical performance. The experimental details regarding these tablets have been
described elsewhere.117 Briefly, three separate manufacturing routes (i.e., direction
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compression, roller compaction, and wet granulation) were used to produce 300 mg
standard round bi-convex 3/8” diameter tablets on an 18-station high-speed rotary tablet
press (model HT-AP1855-U/I, Elizabeth Hata). Eighteen distinct batches were
manufactured using the direct compression and roller compaction routes, whereas 12
batches were produced via wet granulation. For the direct compression and roller
compaction (Chilsonator, model IR 220, The Fitzpatrick Company) manufacturing
methods, various combinations of anhydrous theophylline (BASF), lactose monohydrate
(316 Fast Flo, Foremost Farms), microcrystalline cellulose (Avicel PH-102, FMC
Biopolymer), and magnesium stearate (Spectrum Chemical) were processed and tableted.
Tablets produced using the wet granules (planetary mixer, model 838F, Hobart) consisted
of anhydrous theophylline, lactose monohydrate, magnesium stearate, and corn starch
(Spectrum Chemical); a starch paste was used as the binding agent. For all three
manufacturing methods, the compaction pressure was adjusted to yield target radial
tensile strengths of 8, 11, or 14 kiloponds (kp). The nominal amount of theophylline was
either 90 or 133 mg.
USP apparatus 2 (i.e., paddle) dissolution testing was performed using a Distek
dissolution system (model 2100B) at a paddle speed of 50 revolutions per minute (RPM).
The dissolution system was equipped with Hewlett-Packard UV-Vis spectrometer (model
8453) and a closed-loop automated sampler (Distek, Inc.). All dissolution testing was
performed using deionized, de-aerated water as the medium in 900 mL Peak™ glass
vessels at 37±0.1°C. The absorbance of theophylline was detected at 272 nm in 10 mm
pathlength quartz flow cells following the construction of a standard curve. In total, 12
tablets per batch for each unique manufacturing route were assessed.
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The Weibull function is often used to describe empirical dissolution data.118
Dissolution profiles (i.e., percent theophylline released) of tablets produced via the direct
compression, roller compaction, and wet granulation methods were modeled using the
two-parameter Weibull function described by Equation 2.1 where V is the vector of
dissolution time points. For dissolution modeling, the time constant (α) is often
represented as T63.2, the time at which 63.2 % of the drug is released. Once these data are
fit to a Weibull distribution, the PDF (Equation 2.2) can be used to approximate the
dissolution rate. Each dissolution curve was modeled by its reduction to a shape and a
scale parameter. The distribution of dissolution shape parameters and dissolution time
constants for the model system are presented in Figure 2.4. Two lines were fit to these
data to represent the approximate maximum and median values for the dissolution shape
parameter given the range of dissolution time constants (Figure 2.4).

2
Direct Compression
Roller Compaction
Wet Granulation

1.9
1.8

β = -0.0572*T63.2 + 1.515

1.7

β

1.6

β = -0.115*T63.2 + 2.03

1.5
1.4
1.3
1.2
1.1
1

0

1

2

3

4
5
T63.2 (hr)

6

7

8

9

Figure 2.4. The distribution of dissolution shape parameters (ß) and dissolution time constants (T63.2) for
the model theophylline solid oral dosage system. Two lines were manually fit to these data to represent the
approximate maximum and median values for the dissolution shape parameter given the range of
dissolution time constants.
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Content uniformity testing was also performed on dissolved tablets using a UVVis spectrometer (Hewlett-Packard, model 8453). Tablets were pulverized and dissolved
in deionized water. The absorbance of theophylline was detected at 272 nm in 10 mm
pathlength cuvettes at 25 °C using a standard curve independent of the one implemented
for dissolution testing. Uniformity of tablets produced from all three manufacturing
routes was assessed. In total, 10 tablets per batch for each unique manufacturing routine
were analyzed.
Dissolution time constants and content uniformity estimates were segregated by
batch to generate estimates of manufacturing variability. Intra-batch refers to the
standard deviation of mean-centered observations within a batch, whereas inter-batch
denotes the standard deviation of the mean observations across all batches (e.g., content
uniformity, dissolution time constant).

2.2.4 IVIVC Model
Hussein and Friedman modeled the release and absorption characteristics of
several novel, self-prepared, sustained-release (SR) theophylline formulations in addition
to two commercial SR products (i.e., Theotrim and Theo-Dur).92 Specific details
regarding the materials and methods can be obtained from their original publication.
Briefly, USP apparatus 1 (i.e., rotating basket) dissolution testing was performed at 100
RPM in 600 mL vessels. The first 2 hours of testing was conducted in 400 mL of
simulated gastric fluid containing pepsin, after which, the medium was replaced with 400
mL of simulated intestinal fluid containing pancreatin and was monitored for an
additional 10 hours. Theophylline concentration was subsequently determined by HPLC
analysis. Six healthy volunteers were administered each formulation in a crossover study
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observing a washout period of 3 weeks. Theophylline plasma concentrations were
estimated using an HPLC method and the percentage of the theophylline dose absorbed
was then determined using the Wagner-Nelson method.
The mean (n = 4) in vitro dissolution percent released and the mean (n = 6) in vivo
percent absorbed profiles obtained from the volunteers for the said dosage forms were
used to construct a Level A IVIVC model via a deconvolution approach (refer to section
1.3.4). These data correspond to Figures 1 and 3 of their original publication.92 Only the
values for formulations T-1, T-1-A, T-2-A, and Theotrim were modeled. A graph tracing
program was used to extract quantitative data from the figures describing the percent
released and percent absorbed at the time points sampled. Subsequently, these data were
modeled using a two-parameter Weibull function (Equation 2.1); the fitted shape and
scale parameters were used to estimate the instantaneous rates of release and absorption
for the in vitro and in vivo data, respectively (Equation 2.2). Finally, the instantaneous
dissolution rates were fitted using the Power Law to determine the IVIVC function
(Figure 2.5). The resultant nonlinear function for transforming in vitro release to in vivo
absorption was determined to be
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Figure 2.5. Plot of the in vivo absorption rate versus the in vitro dissolution release rate. The IVIVC model
was fit using a Power Law function.

RB = 0.465 ⋅ RD

0.672

(2.4)

where RB is the in vivo absorption rate, RD is the in vitro dissolution release rate, and
0.465 and 0.672 are the scale factor (unitless) and Power Law parameter (unitless),
respectively; the coefficient of determination for this function was 0.943.

2.2.5 PK Model
First-order pharmacokinetics by means of a one-compartment open model were
assumed to adequately describe theophylline plasma concentrations following
administration of the solid oral dosage form. Since multiple dosages were administered
throughout the course of therapy, the principle of superposition was applied.82
Superposition provides the opportunity to forecast plasma concentration-time curves
based on the viewpoint that drug levels from successive doses are linearly additive. The
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superposition principle assumes that the pharmacokinetics of the drug are not dosedependent and that the drug is eliminated by first-order kinetics, which are reasonable
assumptions for the administration of theophylline (refer to section 1.3.5.2). The change
in theophylline plasma concentration as a function of time was modeled using the
equation

⎛t ⎞
−⎜ ⎟
D⋅S ⋅ A⎡
−β
β −1
⎢β ⋅ α ⋅ t ⋅ e ⎝ α ⎠
=
dt
Vd ⋅ W ⎢
⎣

dC p

β

P

⎤
Cl
⎥ −
⋅ Cp
1000 ⋅ Vd
⎥
⎦

(2.5)

where Cp is the theophylline plasma concentration (mg/L), t is the time (hr), S is the
optional scaling factor (unitless), D is the dose (mg), Vd is the volume of distribution
(L/kg), W is the patient’s total body weight (kg), β is the Weibull shape parameter
(unitless), α is the Weibull time constant (hours), A is the IVIVC scale factor (unitless), P
is the IVIVC Power Law parameter (unitless), and Cl is clearance (ml/kg/hr). All
simulations were performed with S at a constant value of 1.0. This equation was derived
to characterize the change in theophylline plasma concentration based on the relationship
between the dissolution and absorptions rates and the individualized patient
pharmacokinetic parameters. The output is mg/L/hr of theophylline.
Similar to the work of Buchwald,83 theophylline input was modeled using
sigmoidal lag time and cut-off coefficients where absorption was assumed to be 100 % of
the maximum rate after 0.5 hours (i.e., lag time) and the absorption potential was reduced
to 50 % after 8 hours (i.e., cut-off) to simulated time-dependent phenomena. These
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coefficients were used to adjust the input (I) of theophylline through the following series
of equations
⎛ t ⎞
−⎜ ⎟
D⋅S ⋅ A⎡
β −1
−β
⎢
I=
β ⋅α ⋅ t ⋅ e ⎝α ⎠
Vd ⋅ W ⎢
⎣

1+ e

cutoff = 1 −

dt

⎤
⎥
⎥
⎦

P

1

lagtime =

dC p

β

(2.5b)

⎛ 15 ⎞
−(t − 0.5 ) ⎜
⎟
⎝ 0.5 ⎠

1
1 + e −(t − 8 )

= (I ⋅ lagtime ⋅ cutoff ) −

(2.5a)

(2.5c)
Cl
⋅ Cp
1000 ⋅ Vd

(2.5d)

Figure 2.6 shows the lag time and cut-off coefficients for one 12-hour dose. Equation
2.5d is analogous to the original PK model with the exception of the lag time and cut-off
terms. The numerical solution to Equation 2.5d was obtained via a Matlab-based
differential equation solver (i.e., ode23).
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Figure 2.6. Plot illustrating the lag time and cut-off absorption coefficients over a 12-hour window.
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2.2.6 PD Model
One or more probabilistic PD models are most desirable for a risk assessment tool
such as the one described herein. For example, access to several PD models that
characterize the probability of efficacy, the probability of multiple adverse events (e.g.,
headache, vomiting, seizure) and the covariance between these observations is optimal.
More often than not, said models will not be available during the initial stages of risk
assessment. Furthermore, efficacy may be characterized by various responses (e.g.,
forced expiratory volume, number of asthmatic attacks, quality of life), further obscuring
the dose-response relationship and thus, the probability of a given outcome. Therefore, it
is necessary to assume an underlying model, which can be replaced, augmented, or
combined with additional models as the level of understanding increases.
A probabilistic-based PD model detailing the general efficacy and toxicity of
theophylline was not readily available. Therefore, the authors chose to implement a
model for a hypothetical drug, which also had a therapeutic range of 10 – 20 mg/L
(labeled Figure 1.7 in the reference).93 Data points were reproduced using the tracing
program and were fitted using a sigmoid function. The PD model originally described
the probability (%) of efficacy and toxicity as a function of drug concentration. The
estimated sigmoid functions for efficacy and toxicity are provided in Equations 2.6a and
2.6b, respectively

PˆE =
PˆT =

74.77

1+ e

−[( Z − 0.96 )⋅ 9.70 ]

1+ e

−[( Z −1.40 )⋅19.40 ]

74.29
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+ 3.83

(2.6a)

+ 3.77

(2.6b)

where P̂E and P̂T are the predicted probabilities (%) for efficacy and toxicity, respectively,
and Z is the vector of log-transformed theophylline plasma concentrations (mg/L). The
PD model was adapted to describe the probability (%) of inefficacy and toxicity as a
function of theophylline plasma concentration (Figure 2.7). Inefficacy estimates were
generated by subtracting the efficacy probabilities from 100 %. No specific distinctions
were made between various inefficacious or toxic events; the risk of observing, for
example, a headache or a seizure was identically weighted.
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Figure 2.7. Pharmacodynamic model for theophylline describing the probability of observing a toxic or an
inefficacious event as a function of theophylline plasma concentration. Figure adapted from DiPiro JT,
Spruill WJ, Blouin RA, Pruemer JM. 2002. Concepts in Clinical Pharmacokinetics 3rd ed., New York:
American Society of Health-System Pharmacists, Inc. (ASHP). p 279.

2.2.7 Dosing
Each patient was subjected to an iterative dosing scheme where his/her initial
dose (D) was estimated using the equation
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D=

CT ⋅ Cl ⋅

1
⋅W ⋅ Q
1000
F

(2.7)

where CT is the target plasma concentration (i.e., the median concentration of the
therapeutic window, defined as 10 – 20 mg/L), Cl is the individual’s theophylline
clearance as predicted by the Jusko et al. model (mL/hr/kg),46 W is the patient’s weight
(kg), Q is the time interval between doses (i.e., 12 hr), and F is the fraction of dose
absorbed systemically (unitless). A constant value of 0.8 was assumed for F, which is
comparable to values reported for other oral theophylline formulations.32 Based on the
nominal amount of theophylline assumed to be in each tablet (i.e., 100 mg), the number
of tablets necessary to yield the initial dose was estimated (the number of units was
rounded to the nearest integer). Following a period of time assumed to be sufficient to
reach steady-state (i.e., 5 doses), the patient’s plasma concentration was estimated via the
PK model (Equation 2.5). If the dose was found to be inadequate, it was incrementally
adjusted (either increased or decreased depending on whether it was too low or too high,
respectively) until the iterative dosing scheme converged on a satisfactory dosage. If,
however, the dose was adequate to yield a plasma concentration between the minimum
effective concentration (MEC) and the minimum toxic concentration (MTC), treatment
was initiated and the patient was administered the said dose for the duration of the trial
period. On average, approximately 1.2 dose adjustments per patient were necessary for a
given sub-population of 1500 individuals (data from dose adjustment iterations are not
included in calculation of risk scores).
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2.2.8 Risk Simulation
All risk simulations employed a MCS routine independent of that used to generate
the patients. The simulation platform was constructed such that the user is able to specify
the age range of the population to be tested (recall that age is a covariate for all other
patient factors), as well as the manner in which the simulation terminates. For this
option, the user can specify the number of individuals to be included in the sample
population. Otherwise, the simulation can be set to iterate until specific convergence
criteria are reached. All simulations presented in this work were terminated using
convergence criteria. The user is also able to specify patient compliance and
manufacturing variability estimates, as well as details concerning the drug and its
corresponding therapy. These were determined or assumed for the model theophylline
solid oral dosage system tested herein (Table 2.3).
Table 2.3. Summary of the manufacturing variability metrics and the treatment parameters used during
simulation.
Manufacturing Metrics
Intra-Batch RSD of Dissolution Time Constant
Inter-Batch RSD of Dissolution Time Constant
RSD of Intra-Batch Content Uniformity
RSD of Inter-Batch Content Uniformity

0.06
0.03
0.03
0.01

Simulation Parameters
Length of Therapy (days)
Time Interval between Doses (hours)
Standard Deviation of Dosing Interval (hours)
Therapeutic Window (mg/L)
Rate of Compliance (% of doses taken)
Fraction of Dose Absorbed (unitless)
Dissolution Time Constant (hours)
Nominal Theophylline Amount (mg)

30
12
1
[10 - 20]
90
0.8
5.0
100.0

Given that one of the principal objectives of this work was to estimate the
conditional risk of product quality variation on clinical performance, the simulator was

132

assembled such that the user could allow or prohibit the estimates of certain factors to be
sampled according to their underlying distributions. These factors included the inter- and
intra-batch relative standard deviation (RSD) of the dissolution time constants, the interand intra-batch RSD of content uniformity, the rate of patient compliance, and the
standard deviation of the dosing interval. Thus, the risk simulation platform user was
required to set variability “flags” prior to the start of a simulation that turned the factors
“on” or “off” to assess their effect on risk. If a factor was turned off, its estimate was
consecutively set to the same value, whereas if it was allowed to vary, the estimate was
influenced by the level of variability (some would refer to this as “quality”) or rate of
adherence. For example, the scenario where each tablet contains the same amount of
active (as per the label claim) represents the highest degree of quality (minimal
variability) in terms of content uniformity.
A total of 4 variability flags were to be set by the user: inter- and intra-batch
dosage variability, patient compliance variability, and dosing variability. All, none, or a
combination of these variability flags could have been turned on during the course of a
given simulation. When the dosing time interval was subject to variation, each dosing
time was altered by the addition of a pseudo-random number drawn from a normal
distribution with zero mean and unit standard deviation (i.e., “randn.m” function within
Matlab); the random number was multiplied by the standard deviation of the dosing
interval (Table 2.3) before it was added to the particular dosing time. Otherwise, doses
were administered at their scheduled times. For simulations where patient compliance
was variable, compliance was modeled using a binomial distribution where the success
probability was set to the assumed patient compliance (% of doses taken); a value of 0
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denoted a missed dose. Patients were prohibited from missing two consecutive doses.
Noncompliance was prohibited during the patient-specific iterative dosing schedule.
Otherwise, all doses were assumed to be taken.
The remaining two variability flags pertain to the dosage form itself. For
instances where inter-batch variability was initiated, the initial dose administered to a
patient (D') was randomly selected from a normal distribution, whose mean was set to D
(Equation 2.7), and whose standard deviation was set to the inter-batch RSD of content
uniformity (Table 2.3) multiplied by D. This estimate then remained the mean nominal
dosage for that patient throughout the course of treatment (e.g., 30 days). Additionally,
the inter-batch variability flag also altered the dissolution time constant; α' was randomly
selected from a normal distribution whose mean was the nominal time constant (α) and
whose standard deviation was set as the inter-batch RSD of the dissolution time constant
multiplied the nominal α (Table 2.3). Again, α' was held constant for the duration of
therapy. When intra-batch variability was prompted, each dose administered to a given
patient was adjusted from the nominal amount (either D or D', depending on whether or
not inter-batch variability was triggered) to reflect the level of variability around the
mean for the current batch. This was accomplished by randomly selecting the current
dose from a normal distribution of mean D or D' and standard deviation of D or D'
multiplied by the intra-batch RSD of content uniformity (Table 2.3). Additionally, the
intra-batch variability flag also altered the dissolution time constant for each dose; it was
randomly selected from a normal distribution whose mean was the nominal time constant
(α or α', depending on whether or not inter-batch variability was triggered) and whose
standard deviation was set as the intra-batch RSD of the dissolution time constant
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multiplied by α or α'. Otherwise, the dose estimated using Equation 2.7 was successively
administered assuming a constant dissolution time constant when dosage form variability
was not assessed. The simulation assumed that the one-month drug supply (for each
patient) was drawn from a single batch.
The final parameter that needed to be addressed was β. The Weibull shape
parameter was estimated for each dose using the linear relationships describing the
approximate median and maximum values of β as a function of α (Figure 2.4).
Specifically, β was randomly selected from a normal distribution. The mean of the
normal distribution was set as the median value of β and the standard deviation was set to
the standard deviation of β, which was estimated using the 99.9 % confidence interval for
a normal distribution and the difference between the maximum and median shape
parameters for a given time constant. The minimum allowable value for β was 1.01.
With all of the parameters set, the program commenced by first excluding those
patients not meeting the age criteria, that is if the criteria differed from 10 – 90 years.
Each patient was randomly selected from the sub-population and dosed accordingly.
Once the appropriate dose was determined for each patient, he/she was administered
treatment. Throughout the course of the therapy, a patient’s theophylline plasma
concentration was monitored by integrating Equation 2.5. Plasma concentrations were
estimated 6 times per hour. These data were stored and superimposed over the course of
treatment. A frequency histogram summarizing theophylline plasma levels was
generated for each patient; responses were segregated (i.e., binned) into 0.25 mg/L
intervals.
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Probabilistic estimates of observing inefficacious and toxic events were
predetermined for theophylline concentrations ranging from 0 to 100 mg/L at 0.25 mg/L
increments using the PD sigmoid functions (Equations 2.6a and 2.6b). Using these
concentration-based likelihoods, risk estimates (or scores) were generated after each
patient was treated. First, the plasma concentration histograms were aggregated (i.e.,
data within each concentration bin were amassed for all patients tested). Next, the
aggregated plasma concentration data was transformed into a CDF. Provided that both
the PD functions and the pooled CDF were generated using the same concentration axis,
plots of the inefficacy risk scores versus the aggregated CDF data and the toxicity risk
scores versus the aggregated CDF data were generated. These plots were used to
interpret the percentage of the population that had a risk score at or below a given value
(i.e., the likelihood of observing an adverse event within a sample population given the
observed plasma concentrations). Example plots for inefficacy and toxicity are shown in
Figure 2.8a and Figure 2.8b, respectively. These plots illustrate that 95 % of the sample
population had an inefficacy risk score less than or equal to 25.62 % and a toxicity risk
score of less than or equal to 8.01 % for the given trial simulation. In other words, 95 %
of the population was treated such that there was a maximum likelihood of 25.62 % and
8.01 % for observing an inefficacious or toxic event, respectively.
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Figure 2.8. Plots of inefficacy (a) and toxicity (b) risk scores versus the fraction of observations for the
sample population tested. These data were interpolated (solid lines) to determine the percentage of the
sample population (95 %) that had a risk score less than or equal to a given value. The sample population
was treated such that there was a maximum likelihood of 25.62 % and 8.01 % for observing an
inefficacious or toxic event, respectively.

Rather than reporting multiple risk scores for both inefficacy and toxicity, it was
desirable to summarize the risk to a sample population with a single risk score for each
adverse event. Thus, the empirical CDF/PD function plots were interpolated to yield a
single risk score corresponding to a CDF probability of 0.95 for both inefficacy and
toxicity. A risk score summarizing those tested was generated for each addition of a
patient. The number of iterations conducted was not fixed; rather, the risk simulator
continued to test additional patients until the risk scores for inefficacy and toxicity both
stabilized below a certain oscillation threshold. Stability of risk assessments was
assessed by calculating the absolute fractional change of the median risk score (Δ)
observed by adding one additional patient to the sample population using the equation
⎡
⎛ n ⎞
⎛ n−1 ⎞⎤
abs ⎢median⎜⎜ RS ⎟⎟ − median⎜⎜ RS ⎟⎟⎥
i
i
⎢⎣
⎝ i =1 ⎠
⎝ i =1 ⎠⎥⎦
Δ=
⎛ n ⎞
median⎜⎜ RS ⎟⎟
i
⎝ i =1 ⎠
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(2.8)

where RS indicates the risk score for the ith observation and n represents the number of
patients assessed. Patients were consecutively tested until the variability of the risk
estimates for both inefficacy and toxicity were below the difference threshold of 10-4.
Furthermore, the absolute change was required to retain a value below the threshold for
250 consecutive patients before the simulator converged on the risk estimates; these
criteria were required for both inefficacy and toxicity. Therefore, two risk scores, one for
inefficacy and one for toxicity, were generated for each trial simulation.

2.2.9 Experimental Design
A 2x2x2x2x2x2 full factorial design was generated in Matlab using the
“fullfact.m” function to assess the effects of manufacturing variability and patient
compliance on clinical performance (Table 2.4). Two levels for each factor were tested,
which corresponded to the presence or absence of variability (i.e., factor on or off,
respectively). The six factors assessed were the inter- and intra-batch RSD of the
dissolution time constants, the inter- and intra-batch RSD of content uniformity, the rate
of patient compliance, and the standard deviation of the dosing interval. A value of 1
signified the presence of variability, whereas 0 represented its absence. Each row in the
design represents an independent risk simulation trail. The full factorial experimental
design was performed in triplicate, which required a total of 192 simulations. The
simulation run order for each replicate of the design matrix was randomized. The age
range for patient inclusion was not altered from that of the general population.
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Table 2.4. Summary of the 2x2x2x2x2x2 full factorial experimental design. A value of 1 signifies the
presence of variability, whereas 0 represents its absence.

Trial
Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

IntraBatch β
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0

InterBatch β
0
0
1
1
0
0
1
1
0
0
1
1
0
0
1
1
0
0
1
1
0
0
1
1
0
0
1
1
0
0
1
1
0
0
1
1
0
0
1
1
0

IntraBatch
Content
Uniformity
0
0
0
0
1
1
1
1
0
0
0
0
1
1
1
1
0
0
0
0
1
1
1
1
0
0
0
0
1
1
1
1
0
0
0
0
1
1
1
1
0
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InterBatch
Content
Uniformity
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
1

Patient
Compliance
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0

Standard
Deviation
of Dosing
Time
Interval
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1

Trial
Number
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64

IntraBatch β
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1

InterBatch β
0
1
1
0
0
1
1
0
0
1
1
0
0
1
1
0
0
1
1
0
0
1
1

IntraBatch
Content
Uniformity
0
0
0
1
1
1
1
0
0
0
0
1
1
1
1
0
0
0
0
1
1
1
1
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InterBatch
Content
Uniformity
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1

Patient
Compliance
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

Standard
Deviation
of Dosing
Time
Interval
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

A 2x2x2x2 full factorial design was also generated to assess the effects of
manufacturing variability excluding all influences from patient compliance and dosing
time variability (Table 2.5). Again, two levels for each factor were tested where a value
of 1 signified the presence of variability and 0 represented its absence. The four factors
assessed were the inter- and intra-batch RSD of the dissolution time constants, and the
inter- and intra-batch RSD of content uniformity. All runs were performed in triplicate,
which required a total of 48 simulations. The simulation run order for each replicate of
the design matrix was randomized. The age range for patient inclusion was not altered
from that of the general population.
Table 2.5. Summary of the 2x2x2x2 full factorial experimental design.
IntraInterBatch
Batch
Trial
IntraInterContent
Content
Number
Batch β
Batch β
Uniformity Uniformity
1
0
0
0
0
2
1
0
0
0
3
0
1
0
0
4
1
1
0
0
5
0
0
1
0
6
1
0
1
0
7
0
1
1
0
8
1
1
1
0
9
0
0
0
1
10
1
0
0
1
11
0
1
0
1
12
1
1
0
1
13
0
0
1
1
14
1
0
1
1
15
0
1
1
1
16
1
1
1
1
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2.2.10 Statistical Analyses
Sensitivity analyses were conducted on the results of the two DOEs using
standard least-squares regression and an effects screening approach to determine the
factors that had a significant influence on the risk to inefficacy and toxicity. This
approach calculated the type III sums of squares. The inputs (Tables 2.4 and 2.5) were
coded as nominal and the responses were coded as continuous. A full factorial model
was initially generated to consider all potential interactions. Thereafter, fractional
factorial models were assessed. Standard least-squares regression was also used to
determine the final models for inefficacy and toxicity; both the inputs and responses were
coded continuous. The significance level (α, not to be confused with the Weibull scale
parameter) for all analyses was 0.05. All statistical analyses were conducted in Matlab
(version 7.1, The MathWorks, Natick, MA) or JMP (version 8.0.1, SAS Institute Inc.,
Cary, NC). The risk scores for inefficacy and toxicity were analyzed independently.

2.3 Results and Discussion
2.3.1 Relationship between Toxicity and Inefficacy
It is important to understand the underlying relationship between inefficacy and
toxicity in view of the fact that one of the fundamental objectives of the drug
development process is to minimize the incidence of both adverse events. This can be
accomplished using the PD model(s). Figure 2.9 illustrates the probabilistic relationship
between inefficacy and toxicity, both of which are functions of theophylline
concentration; Figure 2.9 is merely a 3-dimensional representation of the PD data that
appear in Figure 2.7. As might be expected, the likelihoods for inefficacy and toxicity
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are invariant at concentrations well below the MEC; the probability of experiencing an
inefficacious event is high at low concentrations, whereas the probability associated with
toxic events is minimal. As theophylline levels approach that which has been reported to
have clinical effects (~ 5 mg/L), however, the probability of inefficacy sharply declines
and does not begin to stabilize until roughly the mid-point of the therapeutic range.
Conversely, the probability for toxic events is relatively constant until the middle of the
therapeutic window, at which point the likelihood dramatically increases. The
probability of inefficacy is nearly at its lowest value beyond the middle of the therapeutic
range, indicating that patients continue to experience clinical outcomes (e.g.,
bronchodilation) while enduring the adverse event(s). The PD model also reveals that the
probability of inefficacy will never be below approximately 22 %, which suggests that
the drug will not offer clinical benefits for certain patients.
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Figure 2.9. Plot of toxicity probability versus inefficacy probability versus theophylline concentration.
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Figure 2.9 also illustrates that there are concentration ranges for which the two
adverse events are inversely related to one anther. In particular, the probabilities for
inefficacy and toxicity are linearly related with a correlation coefficient of –0.976 over 20
– 25 mg/L. Comparable negative correlations can be found locally over other
concentration ranges. This is important since, depending on where patients are dosed, the
interpretation of risk, for example, in a sensitivity analysis, has the potential to be
analyzed in terms of either outcome without consideration of the other. Indeed, this
should be verified before one of the two metrics is disregarded. While it is generally
desirable to dose patients midway between the MEC and MTC, drug levels may
consistently reside more close to one or the other. In this instance, a comparable change
in both metrics may have more clinical relevance for one adverse event than it does for
the other; this is more likely when the drug levels are near concentrations for which the
relationship between inefficacy and toxicity deviates from linearity.

2.3.2 Dissolution Time Constant Optimization
The theophylline tablets produced from the three manufacturing routes resulted in
various dissolution profiles. Thus, it was necessary to select an appropriate dissolution
time constant that characterized the release of theophylline for the model dosage form
prior to determining the conditional risk of product quality on clinical performance.
Dissolution time constants ranging from 1 to 7 hours were assessed at 0.5 hour intervals
since the majority of the tablets modeled yielded dissolution time constants in this range
(Figure 2.4). Variability in the six manufacturing and patient compliance factors was
prohibited during these trials. Each time constant was assessed in triplicate and the risk
scores for inefficacy and toxicity are shown in Figure 2.10a and Figure 2.10b,
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respectively. Ultimately, a dissolution time constant that minimized the risk to inefficacy
and toxicity was desirable. Due to the local inverse relationship between inefficacy and
toxicity, the minimum risk for inefficacy occurred at a time constant where risk of
toxicity was the greatest. Therefore, a time constant of 5.0 hours was selected to
characterize the model theophylline dosage form as this value favorably reduced the
likelihood of toxic events observed at shorter time constants and concurrently minimized
the increase in inefficacious events observed at longer time constants. These risk scores
effectively represented the baseline risk from which variations in clinical performance
were assessed. The remaining simulations were run using the parameter values indicated
in Table 2.3 according to the experimental designs illustrated in Tables 2.4 and 2.5.

Figure 2.10. Plots of inefficacy (a) and toxicity (b) risk scores versus various dissolution time constants
tested in different age-restricted sample populations.

2.3.3 2x2x2x2x2x2 Full Factorial Experimental Design
The following screening and modeling efforts utilized standard-least squares
regression. The general approach to linear modeling assumes that the response is
continuous over the range of negative infinity to positive infinity. This assumption can
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be particularly problematic for proportional responses (e.g., probabilities), since, due to
model error, the predictions can be outside of the anticipated range (e.g., 0 to 1 or 0 to
100). Therefore, the estimates and standard errors were examined for consistency and
accuracy to substantiate the use of linear regression. The validity of the other
assumptions of linear regression (e.g., homoscedasticity, linearity, normality) was also
verified. Additionally, predictor variables were analyzed for multicollinearity.
The resultant inefficacy and toxicity risk scores for the 2x2x2x2x2x2 full factorial
experimental design are summarized in Figure 2.11; quantile and other statistical metrics
are also presented in Table 2.6. Risk scores for both inefficacy and toxicity were
approximately unimodally distributed; the assumption of normality, therefore, is not
unreasonable. Accordingly, transformations were deemed to be unnecessary. Simple
linear regression revealed that the scores for inefficacy and toxicity were negatively
correlated (r = -0.997). The inverse relationship was a direct result of the PD model and
the dosing regimen; 95 % of the patients were dosed such that the CDF was consistently
interpolated at theophylline concentrations of 20 – 25 mg/L (recall the inverse
relationship of the PD model in this concentration range, which is illustrated in Figure
2.9). Given their inverse relationship, the discussion is predominately focused on
toxicity. The corresponding inverse statistical relationships for inefficacy were
confirmed.
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Figure 2.11. Frequency histograms of the resultant inefficacy (a) and toxicity (b) risk scores for the
2x2x2x2x2x2 full factorial experimental design (n = 192). The mean, standard deviation (S.D.), and range
[ , ] of each adverse event are also provided.

Table 2.6. Summary statistics for the 2x2x2x2x2x2 full factorial experimental design.
Percentile
100.0%
99.5%
97.5%
90.0%
75.0%
50.0%
25.0%
10.0%
2.5%
0.5%
0.0%
Percentile
100.0%
99.5%
97.5%
90.0%
75.0%
50.0%
25.0%
10.0%
2.5%
0.5%
0.0%

Metric
maximum

quartile
median
quartile

minimum
Metric
maximum

quartile
median
quartile

minimum

Inefficacy
Probability (%)
Metric
26.461
Mean (%)
26.461
Std Dev (%)
26.369
Std Err Mean (%)
26.281
Upper 95% Mean (%)
26.135
Lower 95% Mean (%)
25.979
Number of Observations
25.785
25.629
25.538
25.468
25.468
Toxicity
Probability (%)
8.336
8.336
8.184
7.998
7.703
7.373
7.137
6.934
6.820
6.707
6.707

Metric
Mean (%)
Std Dev (%)
Std Err Mean (%)
Upper 95% Mean (%)
Lower 95% Mean (%)
Number of Observations
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25.962
0.236
0.017
25.996
25.928
192

7.428
0.387
0.028
7.484
7.373
192

Sensitivity analyses were conducted to determine which factors had a significant
impact on the risk of an adverse event. Figure 2.11 illustrates that the ranges of risk
scores were narrow for both adverse events. Nevertheless, the full factorial screening
revealed that three main effects, intra-batch RSD of content uniformity, rate of patient
compliance, and standard deviation of the dosing interval, significantly influenced
probability of experiencing a toxic event. In addition to these main effects, the first-order
interaction between the rate of patient compliance and the standard deviation of the
dosing interval was identified as significant. Two other higher order interactions were
significant; however, they were determined to be spurious based on the insignificance of
the other main effects that comprised the interaction terms. It is important to note that the
same three main effects were determined to be significant for inefficacy. The interaction
between the rate of patient compliance and the standard deviation of the dosing interval,
however, was not strong enough to significantly alter the likelihood of an inefficacious
event. This demonstrates the sensitivity of the risk simulation platform to asymmetric
risk, a phenomenon that would go undetected with a standard “quality” metric such as
Cpk, which does not account for clinical outcomes. Two additional higher order
interactions were also significant for inefficacy; they were determined to be spurious as
well.
Following the full factorial screening exercise, a 2nd degree fractional screening
was carried out to re-assess the main effects and first-order interactions. Analogous to
the previous screening study, three main effects, intra-batch RSD of content uniformity,
rate of patient compliance, and standard deviation of the dosing interval, as well as the
first-order interaction between the rate of patient compliance and the standard deviation
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of the dosing interval significantly influenced the probability of toxicity. Likewise, intrabatch RSD of content uniformity, rate of patient compliance, and standard deviation of
the dosing interval significantly influenced the probability of inefficacy.
Subsequently, standard least-squares regression was used to compare several
potential linear models. Ultimately, the final model for inefficacy included three main
effects, intra-batch RSD of content uniformity, rate of patient compliance, and standard
deviation of the dosing interval, while the model for toxicity included these three main
effects and the first-order interaction between the rate of patient compliance and the
standard deviation of the dosing interval. Intra-batch RSD of content uniformity and
standard deviation of the dosing interval functioned to an increase in the probability of
toxicity, whereas patient compliance decreased the likelihood of experiencing a toxic
event.
Studentized residuals were, where appropriate, analyzed to verify that the
assumptions of linear regression were valid for these data. One such plot, studentized
residuals versus sample number, is provided in Figure 2.12. Additionally, plots of
studentized residuals versus the predicted response values were examined, which did not
suggest that these data were heteroscedastic (plots not shown). Abnormal patterns were
not observed in any of the residual plots, which further substantiates the use of linear
regression. The studentized residuals were also used to indentify outliers. The largest
(absolute value of the) studentized residual for the toxicity model was 2.97, and a total of
11 residuals were above 2.0. Likewise, the largest (absolute value of the) studentized
residual for the inefficacy model was 2.81 and, in all, 11 residuals were above 2.0.
Therefore, no observations were removed for either model. The experimental design was
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intentionally replicated to assess lack of fit. Testing of both models revealed that the null
hypothesis, which stated that the model fit these data, could not be rejected. The final
models for inefficacy and toxicity are summarized in Tables 2.7 and 2.8, respectively.
The predicted versus measured plots for the two clinical outcomes, which also illustrate
the appropriateness of the straight-line model, are shown in Figure 2.13.

Figure 2.12. Plots of studentized residuals versus sample number for inefficacy (a) and toxicity (b) for the
finalized linear models of the 2x2x2x2x2x2 experimental design.

Figure 2.13. Predicted versus measured plots for the inefficacy (a) and toxicity (b) linear models. The unit
line is shown in black.
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Table 2.7. Final model results for inefficacy for the 2x2x2x2x2x2 experimental design.
Inefficacy
Summary of Fit
2

R
R2 Adj
Root Mean Square Error
Mean of Response
Observations

0.86851
0.86641
0.086
25.962
192
Analysis of Variance

Source
Model
Error
Total

D.F.
3
188
191

Sum of Squares
9.225
1.397
10.621

Mean
Square
3.075
0.007

F Ratio
413.917
Prob > F
1.54E-82

Lack of Fit
Source
Lack of Fit
Pure Error
Total Error

Term
Intercept
Intra-Batch CU Variability
Patient Compliance
S.D. Dosing Time

D.F.
4
184
188

Sum of Squares
0.020
1.377
1.397

Parameter Estimates
Estimate
Std Error
26.059
0.012
-0.061
0.012
0.234
0.012
-0.366
0.012
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Mean
Square
0.005
0.007

t Ratio
2094.647
-4.931
18.792
-29.399

F Ratio
0.664
Prob > F
6.17E-01
Max Rsq
0.87038
Prob > |t|
0.0
1.79E-06
4.97E-45
3.13E-72

Table 2.8. Final model results for toxicity for the 2x2x2x2x2x2 experimental design.
Toxicity
Summary of Fit
2

R
R2 Adj
Root Mean Square Error
Mean of Response
Observations

0.86239
0.85944
0.145
7.428
192

Source
Model
Error
Total

Analysis of Variance
Sum of
D.F.
Squares
4
24.726
187
3.946
191
28.672

Mean
Square
6.182
0.021

Source
Lack of Fit
Pure Error
Total Error

Lack of Fit
Sum of
Squares
D.F.
3
0.059
184
3.887
187
3.946

Mean
Square
0.020
0.021

Parameter Estimates
Estimate
Std Error

Term

t Ratio

F Ratio
292.969
Prob > F
2.38E-79

F Ratio
0.926
Prob > F
4.29E-01
Max Rsq
0.86443

Intercept
Intra-Batch CU Variability
Patient Compliance
S.D. Dosing Time

7.270
0.100
-0.381
0.597

0.021
0.021
0.021
0.021

346.746
4.783
-18.160
28.489

Prob > |t|
1.37E264
3.49E-06
3.85E-43
6.06E-70

Patient Compliance x
S.D. Dosing Time

-0.116

0.042

-2.755

6.44E-03

To further scrutinize the final models, the 95 % confidence intervals for the
expected mean value were grouped by all possible combinations of the independent
variables (Table 2.9). Examination of the mean 95 % confidence intervals revealed that
no two intervals overlapped across all possible input combinations. This was the case for
both inefficacy and toxicity. Lack of overlap further underscored the significant change
in risk scores induced by intra-batch RSD of content uniformity, rate of patient
compliance, and standard deviation of the dosing interval. The data in Table 2.9 were
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also used to generate plots of the predicted probabilities for inefficacy and toxicity
adjusted for intra-batch content uniformity variability, patient compliance, and the
standard deviation of the dosing interval (Figure 2.14). The interaction between the rate
of patient compliance and the standard deviation of the dosing interval for the toxicity
model is clearly demonstrated by the non-parallel nature of the lines in subplots c and d;
subplots a and b substantiate the lack of interaction for the inefficacy model.

Figure 2.14. Plots of the predicted mean probabilities for inefficacy (a,b) and toxicity (c,d) adjusted for the
effects of intra-batch content uniformity variability, patient compliance, and dosing time standard
deviation. Asterisks denote the upper and lower values of the mean confidence intervals whereas the open
circles represent the mid-point of the intervals.
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Table 2.9. 95 % confidence intervals for the expected mean value grouped by all possible combinations of
the independent variables. The acronym CI stands for confidence interval.
Inefficacy

Intra-Batch
Content
Uniformity
Variability
0
0
0
0
1
1
1
1

Patient
Compliance
0
1
0
1
0
1
0
1

Predicted
Inefficacy
Mean 95 % CI
Lower Upper
26.034 26.083
26.268 26.317
25.668 25.717
25.902 25.951
25.973 26.022
26.207 26.256
25.607 25.656
25.841 25.890

Dosing
Time
Standard
Deviation
0
0
1
1
0
0
1
1
Toxicity

Intra-Batch
Content
Uniformity
Variability
0
0
0
0
1
1
1
1

Patient
Compliance
0
1
0
1
0
1
0
1

Dosing
Time
Standard
Deviation
0
0
1
1
0
0
1
1

Patient
Compliance
x Dosing
Time
Standard
Deviation
0
0
0
1
0
0
0
1

Predicted
Toxicity Mean
95 % CI
Lower Upper
7.195
7.287
6.872
6.964
7.850
7.942
7.411
7.504
7.295
7.387
6.972
7.064
7.950
8.043
7.512
7.604

2.3.4 2x2x2x2 Full Factorial Experimental Design
Due to the overpowering variance explained by patient compliance and dosing
time variability, a second experimental design was executed to evaluate the effects of
manufacturing variability when patient compliance was 100 % and all doses were
administered precisely at the scheduled dosing times. This was done to ensure that the
two patient factors (at the levels assessed) did not mask subtle, yet important,
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manufacturing effects. The resultant inefficacy and toxicity risk scores for the 2x2x2x2
full factorial experimental design are summarized in Figure 2.15; quantile and other
statistical metrics are also presented in Table 2.10. Data were analyzed in a manner
comparable to that in the 2x2x2x2x2x2 experimental design. As was observed in the
2x2x2x2x2x2 experimental design, the scores for inefficacy and toxicity were negatively
correlated (r = -0.999). Likewise, the inverse relationship was a direct result of the PD
model and the dosing regimen; 95 % of the patients were dosed such that the CDF was
consistently interpolated at theophylline concentrations between 20 and 25 mg/L (recall
the negative correlation between inefficacy and toxicity within this range).
Consequently, the discussion is predominately focused on toxicity. The corresponding
inverse statistical relationships for inefficacy were confirmed.

Figure 2.15. Frequency histograms of the resultant inefficacy (a) and toxicity (b) risk scores for the
2x2x2x2 full factorial experimental design (n = 48). The mean, standard deviation (S.D.), and range [ , ] of
each adverse event are also provided.
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Table 2.10. Summary statistics for the 2x2x2x2 full factorial experimental design.
Percentile
100.0%
99.5%
97.5%
90.0%
75.0%
50.0%
25.0%
10.0%
2.5%
0.5%
0.0%
Percentile
100.0%
99.5%
97.5%
90.0%
75.0%
50.0%
25.0%
10.0%
2.5%
0.5%
0.0%

Metric
maximum

quartile
median
quartile

minimum
Metric
maximum

quartile
median
quartile

minimum

Inefficacy
Probability (%)
Metric
26.200
Mean (%)
26.200
Std Dev (%)
26.196
Std Err Mean (%)
26.125
Upper 95% Mean (%)
26.086
Lower 95% Mean (%)
26.025
Number of Observations
25.962
25.911
25.897
25.897
25.897
Toxicity
Probability (%)
7.507
7.507
7.507
7.483
7.401
7.301
7.208
7.151
7.048
7.043
7.043

Metric
Mean (%)
Std Dev (%)
Std Err Mean (%)
Upper 95% Mean (%)
Lower 95% Mean (%)
Number of Observations

26.024
0.077
0.011
26.046
26.002
48

7.305
0.119
0.017
7.340
7.270
48

The results of the 4-factor experimental design were similar to those of the 6factor design; intra-batch content uniformity was the only manufacturing factor that
significantly affected risk of toxicity, even when deviations from the dosing regimen
were not permitted. As was observed previously, intra-batch content uniformity was
positively correlated with the change in toxicity risk scores and negatively correlated with
inefficacy. Linear regression, however, did not yield models of considerable predictive
power (R2 ≈ 0.26), which was most likely a consequence of the large standard deviation
relative to the narrow range of the resultant risk scores (Table 2.10). Nonetheless, intra-
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batch content uniformity is important in explaining the variation in inefficacy and toxicity
risk scores.
It is important to note that the conditional risk, regardless of whether or not
patients are compliant, is dependent upon the manufacturing estimates tested. For
example, assume that the RSD of content uniformity (both inter- and intra-batch) is
comparable to the estimates assessed (Table 2.3), but, due to poor control during
tableting, the estimates for dissolution time variability are worse. Lack of control during
tableting could result in highly variable compression pressures, which, in turn, would
sequentially yield erratic (1) radial tensile strengths, (2) dissolution profiles, and (3)
exposure-response profiles. These changes would undoubtedly affect the portion of
variability explained by the inter- and intra-batch dissolution time constant factors.
The conditional risk is also expected to vary from product to product. While
dissolution variability (at the level tested) did not significantly impact clinical
performance for the model solid oral dosage system, it may very well significantly
influence, for example, an immediate release tablet. For instance, moderate dissolution
variability could result in sub-therapeutic levels at the critical time period following
administration (e.g., 30 minutes), which would most likely result in clinical inefficacy.
These effects were not as pronounced in the model system, most likely because the
factors were assessed once patients were at steady-state. Dissolution variability,
therefore, was not large enough to induce an adverse event.
In addition to product-dependence, risk to clinical performance is also dependent
on the production method. A substantial change in the manufacturing route, such as from
direct compression to wet granulation, is likely to considerably alter drug dissolution

157

(Figure 2.4), and, therefore, clinical performance if the change is not optimized with
respect to the desired QTPP. The adjustment, however, does not need to be so dramatic
to have an effect on the patient. A switch in the blending protocol from a v-blender to a
bin blender is likely to affect the inter- and intra-batch content uniformity if the PCCPs
are not optimized with regard to the QTPP. Likewise, a formulation modification from
intra- to extra-granular addition of the granulating binder has the potential to alter drug
dissolution, and ultimately, inefficacy or toxicity. For these very reasons, changes in the
manufacturing protocol should be investigated with regard to their impact on clinical
performance. This can be accomplished by directly linking the process to clinical
performance via a design space.

2.3.5 Risk Simulation: A Piece of the Modernization Puzzle
The risk simulations were conducted at the point in time where actual metrics of
the manufacturing characteristics were available (Table 2.3). Nonetheless, this was not
designed to imply that a risk assessment can only be initiated once the manufacturing
variability metrics are accessible. Given an approach such as the one described herein, a
risk assessor has the opportunity to assume values for parameters and/or attributes he/she
believes have the potential to influence risk. Since these are approximations, uncertainty
can then be propagated through the platform to gain a better understanding of which
factors significantly affect risk. As the actual values become available, they can be
incorporated, and the risk assessment can then be repeated.
Similarly, finalized/optimized components of the risk simulation platform (Figure
2.1) are not necessary to conduct the assessment. This work was completed using a
hypothetical PD model. That does not mean, however, that the additional assessments
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cannot be carried out once a legitimate probabilistic PD model of theophylline is
generated. Moreover, gender- and age-specific estimates for the usage of barbiturates
and benzodiazepines were assumed. As actual data become available, the patient
population can be re-generated, at which point the risk simulations can be repeated.
Components, whether they are as substantial as the PK or PD model, or as small as a
single coefficient in a model, can be replaced as better estimates, or the finalized
elements, are arrived at. The risk simulation platform was constructed to be modular to
provide this flexibility. This iterative procedure can be implemented throughout the drug
development process to enhance product and process understanding.
One of the objectives of the Critical Path Initiative is to accelerate the time-tomarket of innovative, safe, and effective medical products by changing the approach to
product development. Sponsors are encouraged to utilize innovative techniques to
investigate the manufacturability, safety, and efficacy of candidate molecules and/or drug
products.9 This objective can certainly be expanded to include approaches that examine
the impact that changes, such as those instituted through comparability protocols, have on
the manufacturability, safety, and efficacy of currently marketed products. The
multivariate risk simulation platform used in this work provides the opportunity to
simultaneously study the effects of manufacturing, compliance, and physiologic and
pathophysiologic states on the safety and efficacy of drug delivery systems. This is true
for new chemical entities and previously marketed drugs alike.
The multivariate risk simulation platform also serves as a resource allocation tool,
which can help fulfill the public health objective of offering affordable medications. For
example, analysis of the model drug system revealed that intra-batch content uniformity
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was the only manufacturing factor assessed that significantly influenced the probability
of an adverse event. Risk simulation, therefore, identified intra-batch content uniformity
as a CQA. While the other factors are not to be disregarded (beyond the range
evaluated), it would be unreasonable to a invest large sum of resources into further
reducing the precision of manufacturing such that dissolution variability consistently
passed strict specifications seeing as how the current level of variability did not
significantly alter clinical performance. Such an investment would needlessly inflate the
overall product cost. The manufacturer should still be cognizant of the insignificant
factors, however, since additional levels of variability in one or more of the
inconsequential variables could elicit a significant change in clinical performance. This
could be accomplished by monitoring and controlling their variability within the limits of
acceptable risk to clinical performance (i.e., quality, as it is redefined). Resources
should, on the other hand, be devoted to understanding and controlling the PCCPs for
intra-batch content uniformity such that risk of adverse events is minimized.
Up to this point, the utility of the risk simulation platform has largely been
couched on harnessing explicit patient and product knowledge to evaluate clinical
performance (i.e., quality) as it relates to pharmaceutical production. As was discussed in
the literature survey (refer to section 1.3.3.2), simulation has played an important role in
clinical trials. A risk simulation approach such as this one also has the potential to
contribute greatly in this area. Despite the fact that conditional risk was investigated
using the general population, the risk simulation platform can also delineate subpopulations that display disparate risk levels (Figure 2.10). This supports the selection of
participants for inclusion in clinical trials, with the ultimate objective of reducing the
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likelihood of the drug being toxic or ineffective. Although drugs that are capable of
being safely and effectively administered to the general population are desirable, certain
patient factors often preclude individuals from taking a given medication. These subpopulations must be quickly identified so as to allow safe treatment. The gamut of
patient factors that interact to affect drug action will not always be available initially;
however, data from drugs of the same class or defensible estimates can be used as starting
points. Subsequent clinical trial data can then be integrated within the simulation
platform to better understand the conditions that predispose patients to adverse clinical
outcomes. Once validated, these data can then be used to carefully market the product.
Whether launching a clinical trial or beginning treatment in a doctor’s office, the
risk simulation platform can facilitate arriving at a safe and effective individualized dose
based on the volunteer/patient’s ascertainable factors (e.g., age, gender, BMI, smoking
and drinking status, known concomitant drugs). Together with the acting physician’s
expertise, the likelihood of adverse events can be minimized before the individual is ever
administered the drug. With the appropriate data, this methodology would eliminate the
oftentimes cyclic dose (by weight or some other dosing nomogram), monitor
(serum/plasma levels), and adjust (as needed) approach which unquestionably jeopardizes
the health of the individual if the first attempt is inaccurate. Admittedly, any uncertainty
present in the risk simulation platform would also endanger the individuals. The
platform, however, could be validated through a randomized clinical trial (simulation
supervised versus unsupervised dosing) thereby mitigating the effects of unmodeled
variance.
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Thus far, the inter-relationship of the risk simulation components was utilized
none other than to generate risk scores. These links are illustrated by the solid arrows in
Figure 2.1. The risk scores, however, can be harnessed to oversee and/or optimize certain
components (dotted arrows). For example, the dosing guidelines (whether for the general
population or select sub-populations) can be adjusted to minimize the risk of adverse
events. Furthermore, feedforward and feedback manufacturing controls can be instituted
(via process and control models) to control PCCPs such that the desired level of clinical
performance is attainted. Similarly, raw material variability can be integrated such that
the process can be adjusted to compensate for risk imparted by incoming components.
Chapter 3 uses the risk simulation platform to generate a design space for the model solid
oral dosage system that is bounded by risk scores. Once the design space has been
created, control models can be developed to ensure that production is maintained at a
level of acceptable risk. Since risk scores are continuous, one or more acceptance
thresholds must be arrived at. This should be a multidisciplinary decision that weighs
factors such as feasibility, cost to the consumer, and risk-to-benefit ratios.

2.4 Conclusions
A risk simulation platform that integrated population statistics, drug delivery
system characteristics, dosing guidelines, patient compliance estimates, production
metrics, and PK, PD, and IVIVC models to investigate the impact of manufacturing
variability on clinical performance of a model theophylline solid oral dosage system was
described. This work was predicated on requests to re-define pharmaceutical quality in
terms of risk by linking production characteristics to clinical attributes. Manufacturing
precision was characterized by inter- and intra-batch content uniformity and dissolution
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variability metrics, while clinical performance was described by a probabilistic PD model
that expressed the probability of inefficacy and toxicity as a function of theophylline
plasma concentrations. At the levels assessed, both patient compliance variables, percent
of doses taken and dosing time variability, significantly impacted risk of inefficacy and
toxicity. In addition to these factors, intra-batch content uniformity variability elicited a
significant change in risk scores for the two adverse events, and, therefore, was identified
as a CQA. This is the first in a series of chapters that demonstrate how pharmaceutical
quality can be recast to explicitly communicate risk as it relates to clinical performance.
Future research will focus on constructing a design space that directly links critical
process parameters to quantitative estimates of inefficacy and toxicity risk. Thereafter,
control models can be developed to supervise production such that clinical performance
of the final product is within the hyperspace.
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Chapter 3: Performance-Based Quality Specifications: The
Relationship between Process Critical Control Parameters, Critical
Quality Attributes, and Clinical Performance

3.1 Introduction
The quality of pharmaceutical products is currently evaluated through a series of
independent tests (e.g., USP <711> and <905>) that do not explicitly communicate the
clinical consequences of product variability. Univariate specifications disregard potential
multivariate and nonlinear interactions that affect risk of clinical performance.20 For
example, a clinical inter-dependence between API content and drug release is expected to
exist for solid oral dosage systems. Super-potent tablets with elevated release rates
compromise patient safety due to increased drug levels in the blood. Furthermore, such
product poses a specific (toxic) risk to patients whose drug clearance rates are suppressed
(e.g., alcoholics with severe liver damage). Therefore, under the current testing
paradigm, it is conceivable that in-specification (i.e., passing) product could, in certain
patients, pose a greater clinical risk than product determined to be out-of-specification
(Figure 3.1). If quality were to be redefined by linking production characteristics to
clinical attributes, however, specifications for product release could be then be
established on the basis of clinical risk.
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Figure 3.1. Schematic illustrating final product release testing with USP <905> and <711>. Given the
specifications, only tablet A would pass the release tests, despite the fact it may very well pose a greater
risk than tablet B. OOS stands for out-of-specification. Figure reproduced from the work of Cogdill and
Drennen.

Besides failing to directly communicate clinical consequences, these tests
dichotomize quality as satisfactory or unacceptable, despite the fact that the unit-to-unit
quality can be disparate in a passing lot. While equally weighting the risk of all samples
in and of itself diminishes their utility, the validity of these very tests, which are used to
gauge the quality of pharmaceutical products, is now being questioned. A recently
published article evaluated the sensitivity of the USP <905> test for content
uniformity.119 To conduct the investigation, lots containing varying degrees of nonconforming material were simulated in silico. Lots of different distributions (i.e., normal,
log normal, bimodal, and uniform) were also tested. The authors concluded that USP
<905> “is relatively insensitive to detecting non-conforming material.” Furthermore,
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despite that fact that the simulated lots contained considerable portions of out-ofspecification material, the test did not consistently fail these lots until the percentage of
defects was in excess of 20 %. This underscores the potential ineffectiveness of the USP
<905> and the corresponding final product specifications in gauging quality. Similar
arguments, such as the one framed by Tsong et al.,120 have also questioned the sensitivity
of USP <711> for detecting lots where considerable portions of the tablets are out-ofspecification.
Under the current (empirical) paradigm for product development, specifications
are often established on the basis of achievable levels of process reproducibility long
after the production method is selected from feasibility and profitability criteria. For
instance, a particular production facility might be equipped for, and decidedly
experienced in (and, therefore, biased towards) wet granulation methods. The drugspecific process would have been inevitably transferred from R&D to production, at
which point a considerable level of process understanding is available. The final product
specifications would more than likely be set in parallel with (or following) the scale-up
efforts. These specifications seek to maximize production yield while concurrently
minimizing foreseeable undesirable outcomes (e.g., product recalls, adverse patient
reactions). Since the majority of these outcomes have profound direct (rework costs,
legal fees) and indirect (brand image) monetary connotations, companies often prefer to
impose excessively strict specifications to mitigate the effects of process and/or product
uncertainty (i.e., their effect on clinical performance). Thus, there exists a need to
directly link process and product variability to clinical performance to maximize safety,
effectiveness, and affordability.
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In contrast to the empirical paradigm, a first-principles approach to product
development would determine the acceptable limits of clinical performance before
consideration of the production method. Process development would commence only
after the performance-based quality specifications were defined. In other words,
production would be tailored to achieve the clinical specifications without prior
knowledge of process reproducibility. The idea of a first-principles approach might be
further extended to begin with a particular disease state and a preliminary understanding
of the patients with said condition. Next, a pharmacophore would be optimized for a
specific receptor, which collectively elicit pharmacologic action. Using available patient,
PK, and PD knowledge, acceptable levels of clinical performance would then be
proposed, but should be flexible to integrate incoming clinical data (i.e., uncertainty in
initial knowledge). The tolerable limits for clinical performance will then be used to
condition the manufacturing process and evaluate product quality. Ideally, a drug
delivery system and its associated manufacturing process would be selected on its ability
to achieve the highest levels of clinical performance; however, companies may very well
be restricted by prior investments (e.g., purchase of specific production equipment). The
process, irrespective of the delivery system ultimately implemented, can be optimized
with respect to clinical performance. Once the delivery system has been identified, the
CQAs, or the physical, chemical, biological, or microbiological properties or
characteristics that affect clinical performance (i.e., quality), can then be identified.
Thereafter, the process variables that ultimately impact clinical performance (i.e., PCCPs)
can be isolated. The first-principles approach to product development is summarized in
Figure 3.2.
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Figure 3.2. Schematic diagram illustrating the first-principles approach for product development.

Design space has assumed a predominant role in the pharmaceutical industry. It
is, therefore, appropriate to discuss the impact that recasting quality in terms of clinical
performance has on components associated with the idea of design space. In its current
form, design space is considered “the multidimensional combination and interaction of
input variables (e.g., material attributes) and process parameters that have been
demonstrated to provide assurance of quality.”12 As the appendices in ICH Q8R1
illustrate, the hyperspace is defined by PCCPs, which thereby condition the CQAs.
Consequently, the design space is specific to a unit operation or a single production
process. It defines the operational range of process parameters known to influence
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(surrogates of) product quality (e.g., dissolution). Design space can be thought of as the
link between PCCPs and CQAs (Figure 3.2). MacGregor and Bruwer recently suggested
such an architecture where design space would characterized the combination of CQAs
that offered product whose quality was compliant with specific safety and efficacy
requirements; however, they did not propose a means to directly connect CQAs and
clinical performance (i.e., quality).121
If quality was to be considered in terms of risk by linking production
characteristics to clinical attributes, design space would be, as MacGregor and Bruwer
have alluded to, an n-dimensional interaction of inputs that have been demonstrated to
ensure clinical performance. CQAs would remain fundamental to the design space;
however, they would become inputs to, rather than outputs of, the hyperspace. The
definition of a CQA would effectively remain unchanged, but the physical, chemical,
biological, or microbiological properties or characteristics would be directly related to
clinical performance (e.g., inefficacy or toxicity risk scores) rather than indirectly linked
via surrogate indicators of quality (e.g., moisture content, dissolution, friability). The
identification and utilization of a CQA, therefore, would reflect the re-standardization of
“quality.” Likewise, the definition of a PCCP would not need to be amended.
Conceptually, however, a PCCP would be intimately related to clinical performance
rather than the surrogate marker. Performance-based quality specifications (PBQS),
therefore, are proposed to be the link between CQAs and clinical performance (Figure
3.2). As such, they can be used to define a design space centered on quantitative
estimates of clinical performance.
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Following the first-principles approach (Figure 3.2), construction of the design
space would be hierarchical. At the outset, the underlying relationship between product
attributes (e.g., API content, drug release rate) and clinical performance would define the
space. If the drug delivery system has already been identified (e.g., uncoated tablet), a
risk simulation platform (reference Chapter 2) could conceivably be used to generate the
initial hyperspace before a single unit is ever produced. Nevertheless, once the
production method has been identified, process and product knowledge, in conjunction
with experimental design, risk assessment, simulation, and, if desired, PAT, could be
harnessed to identify the attributes that are critical to clinical performance (i.e., CQAs).
In contrast to the current design space methodology, a hyperspace that defines the
relationship between CQAs and clinical performance is extremely powerful since it is not
specific to a given process. Theoretically, one of several processes (e.g., direct
compression, wet granulation, roller compaction) could be integrated within the design
space since, within reason, the CQAs remain invariant from process to process. While
partial transferability between, for example, production lines for an extended release solid
oral dosage form is feasible, universal transferability (e.g., direct integration of process
knowledge for a transdermal drug delivery system) would most likely be unachievable
since different CQAs would be expected to influence clinical performance. Transfer of
the process-independent design space to a specific production line would be
accomplished by identifying the process parameters that affect clinical performance, and,
subsequently generating process models that effectively serve as transfer functions
between the PCCPs and CQAs. The final design space, which would then be subject to
regulatory discretion, would illustrate the underlying relationship between PCCPs and

170

clinical performance. Control models could also be integrated to adjust the process (for
incoming raw material variability, in-process product variability, environmental
fluctuations, etc.) such that clinical performance of the final product lies within the
design space.
It is apparent that re-defining pharmaceutical quality in terms of risk by relating
process and patient characteristics to clinical performance is beneficial for the
manufacturer, the regulator, and the patient alike. While the revamp is long overdue,
standardizing such a fundamental concept alters current pharmaceutical quality
initiatives. This work addressed the design space modifications that accompany the new
definition of pharmaceutical quality. The objectives were to (1) illustrate the potential
drawbacks of the current paradigm for solid oral dosage form release testing, (2) generate
artificial design spaces for a model theophylline solid oral dosage system that are
conditioned on quantitative estimations of inefficacy and toxicity risk, and (3) address the
potential of a release paradigm where the quality of pharmaceutical products can be
evaluated with regards to clinical performance.

3.2 Materials and Methods
3.2.1 Risk Simulations
The risk simulator, which has been described previously (refer to Chapter 2), was
used to conduct in silico studies. Several modifications were made to the simulator to
alter its functionality. However, unless noted otherwise, the theophylline regimen was
not adjusted. In the previous studies, the mean Weibull dissolution time constant was
optimized to minimize global risk. The underlying Weibull dissolution time constant
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distribution was then generated using this mean and estimates of the inter- or intra-batch
RSD. The resultant distributions were randomly sampled to yield the test parameter for
the current simulation iteration; a new time constant was sampled for each dose
administered. Since the purpose was not to evaluate constrained manufacturing
scenarios, but rather to perturb the simulation inputs beyond the levels tested in the initial
risk assessments, particularly for dissolution variability given that it did not have a
significant impact on clinical performance (reference Chapter 2), the dissolution time
constants were fixed for each risk simulation trial.
Additionally, rather than randomly sampling the variability in theophylline
uniformity from its underlying distributions, deviation from label claim was specified for
each risk simulation trial. For a given risk simulation trial, individual patient doses were
estimated using an iterative dosing scheme (refer to section 2.2.7). All doses
administered for a given trial, however, were adjusted to deviate by the same percentage
from the nominal amount. Analogous to the previous studies, each simulation trial
consecutively tested patients until the variability of the risk estimates for both inefficacy
and toxicity were below the difference threshold of 10-4. Furthermore, the absolute
change was required to retain a value below the threshold for 250 successive patients
before the simulator converged on the risk estimates. All doses were assumed to be taken
at their scheduled times; treatment was administered every 12 hours for 30 days. The age
range for the general population was not restricted. A total of 288 independent
simulation trials were run.
Data pertaining to 12 distinct wet granulation batches of the model theophylline
tablets were utilized to conduct these simulations (refer to section 2.2.3). As was

172

described earlier, 12 and 10 units per batch were sampled for dissolution and content
uniformity testing, respectively. Prior to dissolution or content uniformity testing, a
reflectance spectrum for both sides of each tablet was acquired over the wavelength range
of 1100 – 2498 nm at a 2 nm increment, averaging 32 scans (FOSS NIRSystems 5000-II,
Vision version 2.00, FOSS NIRSystems, Inc., Laurel, MD). Each dissolution profile was
modeled using a two-parameter Weibull function, which yielded a shape and scale
parameter. Data corresponding to tablets that underwent content uniformity testing were
used to construct calibration models for the prediction of theophylline.
Calibration models were constructed using NIR reflectance data, expressed in
absorbance units, of the 120 tablets (240 spectra) and amount of theophylline (%) as
determined via UV-Vis spectroscopy (refer to section 2.2.3). Partial least-squares
regression122 was used via the SIMPLS algorithm123 to relate spectroscopic response to
theophylline amount. Preprocessing routines, including standard normal variate (SNV)
scaling, detrending, derivatives, and combinations of the preceding were tested.124 The
most favorable data pretreatment method was selected based on a minimization of crossvalidation error. Contiguous block cross-validation with a block size of 5 was used to
generate the temporary cross-validation models. For all preprocessing routine(s)
employed, spectroscopic data were mean-centered while reference data were scaled to
zero mean and unit variance. Model rank was chosen as the point where a rapid decline
in the incremental variance captured was observed, cognizant of the expected feasible
limit of dimensionality based on the factors varying within the design. Detrending (firstorder) was determined to be the optimal data pretreatment method. Two latent variables
were necessary to adequately model these NIR absorbance data for the prediction of
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theophylline. This calibration model was subsequently applied to the 288 spectra of the
144 tablets subjected to dissolution testing in order to predict their theophylline levels
(i.e., testing data set); predicted amounts were compared to the nominal levels for each
tablet as per the original design.117 Predicted and reference values were used to
determine the root-mean-standard error (RMSE). The RMSE for cross-validation
(RMSECV), calibration (RMSEC), and testing (RMSET) were calculated using the
formula
n

RMSE =

∑ (y
i =1

− yˆ i )

2

i

n

(3.1)

where y i is the measured amount, ŷi is the predicted amount, and n is the number of
samples for the data set under consideration. Summary statistics for the calibration
model are provided in Table 3.1.
Table 3.1. Calibration summary statistics for the prediction of theophylline.
Data Type
Method
Preprocessing
Latent Variables
Component

NIR (Reflectance)
PLS
First-Order Detrending
2
Theophylline

R2CAL

0.980

R2CV

0.948

R2TEST
RMSEC (%)
RMSECV (%)
RMSET (%)

0.982
0.96
1.57
1.04

BiasCV (%)

-0.248

BiasTEST (%)

-0.250

Projection of the spectra of the tablets subjected to dissolution testing onto the
calibration model provided theophylline amounts. These data supplement the available
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information content (i.e., Weibull shape and scale parameters) for these tablets. Predicted
theophylline percentages for the same tablet varied slightly due to minor inconsistencies
(e.g., positioning, heterogeneity, constituent packing) detected between the two tablet
surfaces. While the theophylline percentages were unique for a given tablet, the Weibull
scale and shape parameters were identical for duplicate scans. Therefore, 288 distinct
responses were available for the 144 tablets.
With the percent theophylline and Weibull scale and shape parameter data now
available, each distinct response was used as an input set for a given risk simulation trial.
Specifically, predicted theophylline percentages were compared to the nominal values to
calculate the percent deviation from label claim; this percentage was then used to adjust
each patient’s dose once it was individualized using the iterative dosing scheme. The
Weibull parameters and deviation from label claim were constant throughout a given
simulation; the inputs were updated with values corresponding to a new tablet (or the
reverse side of the same tablet) only once the current trial met the convergence criteria.
Thus, the only element varying within a given trial was the pool of patients tested; all
patients received tablets that displayed identical content uniformity and dissolution
characteristics.

3.2.2 USP Testing
Several USP monographs for theophylline products have been published in the
USP-NF.125 Tests for uniformity and dissolution draw on the general chapters <905> and
<711>, respectively, where the individual monographs indicate the specifications for
each test for a particular product. A monograph for theophylline tablets is available;
however, it is limited to immediate-release products. Since the model drug delivery
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system is an extended-release tablet, specifications were extracted from its closest analog,
the monograph for extended-release capsules; where appropriate, the specifications for
products labeled for dosing every 12 hours were used. This assumption is justified given
that the specifications outlined in the monograph ought to have been optimized in terms
of biopharmaceutical performance. Since theophylline is highly soluble and highly
permeable, comparable dissolution curves should yield similar safety and efficacy
profiles for the two delivery systems. As stated in the monograph, extended-release
capsules are to contain between 90 and 110 percent of the labeled amount of anhydrous
theophylline. All content uniformity analyses were conducted using this criterion.
Theophylline content was determined using the aforementioned calibration model. Given
that dissolution of the model tablets was conducted in deionized water (refer to section
2.2.3), dissolution profiles were evaluated using Test 10; none of the other 9 tests are
applicable.126 Acceptance criteria for the percentage of label claim dissolved at the
specified times are summarized in Table 3.2. All dissolution testing was conducted using
these criteria according to USP <711>.80
Table 3.2. Acceptance criteria for the percent label claim of theophylline dissolved at the specified times
according to USP Test 10 for 12-hour extended-release capsules.
Time
Amount Dissolved
(hours)
(% Label Claim)
Designation
1

6 - 27

Q1

2

25 - 50

Q2

4

65 - 85

Q4

8

> 80

Q8

Dissolution profiles (% theophylline released versus time) of the 144 tablets
manufactured via the wet granulation method were evaluated according to the criteria
outlined in Table 3.2 using a program written in-house. The program determined the

176

percent theophylline dissolved (i.e., Q1, Q2, Q4, and Q8) at the specified times (i.e., 1, 2,
4, and 8 hours) for each tablet. Once these data were available, each tablet was evaluated
according to USP <711> under the assumption that the one tablet was representative of a
uniform lot (i.e., all tablets within the given lot had identical Q1, Q2, Q4, and Q8 values).
Level once acceptance criteria for extended-release dosage forms states that all Q values
for each unit tested must fall within the stated ranges. Furthermore, all units tested must
have a Q value greater than the amount specified for the final test time.80 Since the lots
are assumed to be uniform, proceeding to level two testing upon failure of level one or
level three upon failure of level two will not alter the test outcome. Thus, the tablets
were only subjected to level one testing according to the criteria outlined in Table 3.2.
Given that the risk simulator was constructed to process Weibull parameters
estimates rather than Q values, least-squares regression was used to relate the dissolution
time constants (T63.2) of the 144 tablets manufactured via the wet granulation method to
Q1, Q2, Q4, and Q8; linear as well as polynomial fits were evaluated. The predictive
models for Q1, Q2, Q4, and Q8 are summarized in Table 3.3; RMSEC was determined
using Equation 3.1. Since T63.2 is a reasonable surrogate for Q1, Q2, Q4, and Q8, at least
inasmuch as the scenarios tested, USP <711> results for the model system were displayed
in terms of T63.2. Reported specifications for T63.2 only encompass tablets (lots) that
passed USP <711> according to the criteria outlined in Table 3.2.
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Table 3.3. Summary of the predictive models for Q1, Q2, Q4, and Q8 with T63.2 as the predictor.
Dissolution Time
(hours)
Designation Transformation
Equation

RMSEC
(%)

R2CAL

1

Q1

1/Q1

1/Q1 = 0.00017*T63.23 - 0.0031*T63.22 + 0.026*T63.2 – 0.0030

2.58

0.874

2

Q2

None

1.91

0.987

4

Q4

1/Q4

Q2 = -0.34*T63.23 + 6.65*T63.22 - 45.58*T63.2 + 129.75
1/Q4 = 1.68x10-5*T63.24 - 0.00037*T63.23 + 0.0028*T63.22 – 0.0054*T63.2
+ 0.013

1.80

0.993

8

Q8

None

Q8 = 0.28*T63.23 - 4.60*T63.22 + 15.88*T63.2 + 84.53

1.29

0.987
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3.3 Results and Discussion
3.3.1 USP <905> and <711> ‘Testing’
The scores for inefficacy and toxicity for the 288 trials were negatively correlated
(r = -0.8785), which is not as strong as that which was observed in the risk assessments
(reference Chapter 2). The reduction in covariance between inefficacy and toxicity is a
consequence of assuming uniform production; lots which deviate to a greater extent from
nominal result in theophylline plasma concentrations that are consistently off-target, and,
therefore, outside the concentration range where inefficacy and toxicity are inversely
related. Due to the lack of (complete) correspondence, results were depicted for both
adverse events.
While it would have been straightforward to assign artificial values for
theophylline content and the Weibull dissolution parameters, it was particularly desirable
to ascertain the true relationship between these factors seeing as how they are
confounding. Thus, to avoid testing a combination of inputs that were potentially
impractical, production tablets from 12 different batches were used to estimate
theophylline content and the Weibull parameters. The 144 tablets manufactured via a wet
granulation method were delineated into 288 distinct responses where each response
included percent theophylline (hence, deviation from nominal or label claim), the
Weibull shape and scale parameters, and Q1, Q2, Q4, and Q8. These data afford the
opportunity to evaluate the tablets, which were assumed to each represent a uniform
production lot, according to the USP tests for content uniformity and dissolution.
Likewise, these data can be harnessed to investigate the impact that specific

179

manufacturing scenarios have on clinical performance. In other words, the risk simulator
can be used to project the clinical consequences of producing lots displaying various
content uniformities and dissolution characteristics.
The results of the 288 simulation trials were arranged according to the input
values for theophylline, expressed as percent deviation from nominal, and the Weibull
dissolution time constant. Figure 3.3 displays plots of the resultant inefficacy and
toxicity risk scores versus API deviation from nominal (synonymous to deviation from
label claim). The lower and upper specifications limits for content uniformity, as
outlined in the individual monograph for extended-release theophylline capsules, are also
depicted. All of the 288 lots tested were well within the acceptance limits for content
uniformity. Similarly, Figure 3.4 displays plots of the resultant inefficacy and toxicity
risk scores versus the Weibull dissolution time constant. The lower and upper
specification limits for dissolution are also depicted. For the conditions assessed, tablets
with dissolution time constants between 3.10 and 3.77 hours resulted in Q1, Q2, Q4, and
Q8 values that met the acceptance criteria outlined in Table 3.2. In total, only 62 of the
288 lots passed USP <711>.
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Figure 3.3. Plot of risk scores for inefficacy (a) and toxicity (b) versus theophylline amount, expressed as
percent deviation from nominal (i.e., label claim). The bold vertical lines indicate the lower and upper
specification limits for content uniformity analysis as per USP <905>.

Figure 3.4. Plot of risk scores for inefficacy (a) and toxicity (b) versus the Weibull dissolution time
constant. The bold vertical lines indicate the lower and upper specification limits for dissolution analysis as
per USP <711> and the individual monograph for theophylline extended-release capsules.

USP tests for content uniformity and dissolution were conducted in sequential
fashion, which is in line with the current approach for solid oral dosage form release
testing. Combining the outputs of the USP tests and the risk simulations exposes one of
the potential pitfalls of the current system. As Figure 3.3 illustrates, samples that met the
criteria for content uniformity, criteria which are intended to ensure the safety and
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efficacy of the final product, display disparate levels of clinical performance. The
maximum risk scores observed in the risk assessments, for which content uniformity was
identified as a CQA, were 26.46 % and 8.34 % for inefficacy and toxicity, respectively,
well below many of the scores obtained during these studies. Despite considerable
differences in clinical performance, tablets sampled from any of the simulated lots would
have been taken as acceptable. It is quite presumptuous to uniformly categorize all 288
scenarios. Figure 3.4 offers a similar prospective on the current approach to final product
testing. Although the lots which passed USP <711> had relatively low risk scores for
inefficacy, the toxicity risk scores were exceptionally high, the majority of which were
above the maximum risk score observed in the risk assessments (reference Chapter 2).
Albeit an artificial construct, these data emphasize the potential disconnect between final
product specifications and clinical performance. This underscores the importance of
defining quality in terms of risk by linking production characteristics to clinical
attributes.
Another potential shortcoming of the current approach to final product testing lies
in its univariate approach. As previously noted, a clinical inter-dependence between API
content and drug dissolution is likely. These data support such an interaction. As Figure
3.3 illustrates, lots that were low in theophylline content posed a higher risk for
inefficacy, whereas lots that were in excess of label claim presented a greater likelihood
of toxicity. Similarly, Figure 3.4 depicts the clinical impact of various dissolution time
constants; smaller dissolution time constants (corresponds to faster release rates) result in
lower probability of being inefficacious, while larger dissolution time constants
(corresponds to slower release rates) pose a reduced risk of toxicity. The impact on the
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risk scores is exacerbated when the effects of content uniformity and dissolution are
considered simultaneously. Take, for instance, the group of toxicity risk scores that
correspond to dissolution time constants between 1 and 2 hours (Figure 3.4b). Although
a low dissolution time constant generally yields a high probability of toxicity, time
constants between 1 and 2 hours resulted in a considerable range in risk scores. This can
be explained, at least in part, by the interaction between content uniformity and T63.2;
super-potent tablets with short dissolution time constants posed a greater toxic risk than
did sub-potent tablets. Although this interaction is reflected in the multivariate risk score,
it is not accounted for in the univariate specifications utilized in USP <905> and <711>.
This begs the question, how good are the current specifications at ensuring quality?
It is not entirely appropriate to question the validity of final product specifications
on the basis of risk score magnitudes without ascribing some level of clinical significance
to the scores themselves. While conclusions regarding the clinical significance of a risk
score should be drawn by a multidisciplinary team comprised of clinicians, scientists,
process engineers, statisticians, etc., thresholds defining low, medium, and high risk were
instituted to further underscore the potential drawbacks of assessing final product quality
under the current paradigm. Inefficacy risk scores less than or equal to 25.979 %, greater
than 25.979 % and less than or equal to 26.461 %, and greater than 26.461 % were
classified as low, medium, and high risk, respectively. Likewise, toxicity risk scores less
than or equal to 7.373 %, greater than 7.373 % and less than or equal to 8.336 %, and
greater than 8.336 % were classified as low, medium, and high risk, respectively. The
median risk scores from the 2x2x2x2x2x2 full factorial experimental design (refer to
Chapter 2) were used to delineate low and medium risk, while the maximum observed
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risk scores for inefficacy and toxicity were used to distinguish medium and high risk for
the two adverse events. Figure 3.5 illustrates the combined effect of theophylline content
and T63.2 after the scores were categorized according to low, medium, and high risk. The
acceptance criteria for USP <905> and <711> are also defined. Figure 3.5a illustrates
that these criteria are likely much too strict (more so for <711>) when considering
inefficacy, and are inaccurate for assurance of safety. The criteria would ideally take into
consideration both adverse events, and, therefore, would need to be optimized to
simultaneously mitigate the likelihood of inefficacy and toxicity. Depending on the riskto-benefit ratios determined by the multidisciplinary team, the two adverse events are
likely to be disproportionally weighted when optimizing the criteria. For instance, certain
toxic events (e.g., headache) might be acceptable (to both the clinician and the patient),
thereby reducing the sensitivity of the test criteria to specific fluctuations in toxicity risk
scores as a result of the corresponding increase in efficacy.

Figure 3.5. Plots of theophylline content versus Weibull dissolution time constant for inefficacy (a) and
toxicity (b) with the clinical outcomes categorized according to low, medium, and high risk. The
acceptance limits for USP <905> and <711> are indicated by the bold rectangle.
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3.3.2 Design Space
In light of the deficiencies which limit assessments of final product quality, risk
simulation has been used to delineate the relationship between the CQAs of the model
drug delivery system and its clinical performance (i.e., PBQS). The relationship between
theophylline content, T63.2, and inefficacy and toxicity risk is depicted in Figure 3.6. As
the following discussion addresses, the PBQS can then be used to generate a design space
where the incoming CQAs have been conditioned on estimates of inefficacy and toxicity
risk. To be consistent with the examples previously shown, clinical thresholds were
instituted to generate the design spaces. Inefficacy risk scores less than or equal to
25.979 %, greater than 25.979 % and less than or equal to 26.461 %, and greater than
26.461 % were classified as low, medium, and high risk, respectively. Likewise, toxicity
risk scores less than or equal to 7.373 %, greater than 7.373 % and less than or equal to
8.336 %, and greater than 8.336 % were classified as low, medium, and high risk,
respectively.

Figure 3.6. Contour plots depicting the relationship between theophylline content and the Weibull
dissolution time constant for inefficacy (a) and toxicity (b). The color bars represent the ranges of the risk
scores (%).
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Two artificial design spaces (independently) conditioned on quantitative estimates of
inefficacy and toxicity risk are presented in Figure 3.7. The example design spaces were
confined to combinations which resulted in low risk scores. Although the design spaces
were restricted to three dimensions (projected onto a two-dimensional contour plot) to
facilitate viewing, the reader should make note that the hyperspace can be n-dimensional.
The design spaces can be adjusted to reflect a multidisciplinary team’s conclusion
regarding acceptable risk using the data represented in Figure 3.6. Validation should
confirm that design space appropriately discriminates clinical risk.

Figure 3.7. Simulation based design spaces for a model theophylline extended-release tablet conditioned on
inefficacy (a) and toxicity (b) risk scores. Dark blue, sea green, and burgundy signify low, medium, and
high risk, respectively.

Although dissolution variability was not identified as a CQA during the risk
assessment, it was included as an input to the design space. At first glance, it might
appear as though the results of the risk assessment were discounted in view of the fact
that T63.2 was an input to the design space. The results of the risk assessment, however,
must not be taken at face value. While dissolution variability was not critical to quality
(at α = 0.05) within the experimental design, it interacts with content uniformity, which
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was critical to clinical performance. If T63.2 were not monitored, it may unknowingly
drift to a level that would, when combined with the effects of in-specification content
uniformity, unfavorably impact clinical performance. Thus, it is imperative that T63.2 be
included in the design space. This is true for all non-critical parameters that interact
(within ranges reasonable for a given process) with CQAs.
Furthermore, there is no direct penalty (e.g., cost, model complexity) for
including T63.2 in the design space given that the architecture of the risk simulator (Figure
2.1) predetermined the mathematical relationship between the T63.2 and inefficacy and
toxicity risk. Integration of an attribute not previously studied in the risk assessment
would, however, invalidate the PBQS. This underpins the need to combine the
information gained from the risk assessment with knowledge of the process and product.

3.3.3 A New Release Paradigm
A design space conditioned on probabilistic estimates of clinical performance has
significant regulatory implications; the advantages currently promoted (e.g., reduced
comparability protocol reporting) are still applicable. Although hyperspaces that utilize
CQAs as inputs are informative, those which directly link PCCPs to clinical performance
(i.e., those which are specific to a process) are likely to offer the greatest regulatory
flexibility; this is largely a function of their direct interpretability regarding the process
itself. Once the PBQS are established, efforts to generate process models can commence;
data upon which process models are developed may, in fact, already be available. These
models could serve as transfer functions between the PCCPs and CQAs, effectively
linking a given process to clinical performance. Control models, therefore, can be
instituted to oversee process parameters such that clinical performance is maintained
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within the design space. Although material attributes (e.g., API particle size distribution)
were not included in the artificial construct, they are by no means precluded from such an
approach. Material attributes can be integrated into the risk assessment as well as the
process and control models.
Thus, a design space constructed from PCCPs (as well as material attributes) and
estimates of clinical performance can be, coincident with the current intentions of the
initiative, subjected to regulatory review. The appropriate validation data, which should
include actual clinical trial and production data, can be used to demonstrate the predictive
power of the risk simulator, the process and control models, and, ultimately, the processspecific design space. Regulatory approval would, therefore, create a potential platform
for real-time product release. In essence, final product conforming to the design space
need not be re-evaluated for assurance of quality. The design space, which has its own
integrated specifications, thereby, serves as the ultimate final product release test. In
spite of the best design of experiments, there always exists the potential for introduction
of unmodeled variance (e.g., change in raw material supplier, shift in production sites).
Therefore, the design space (and all of its associated models) must be continually
managed, and updated as necessary.

3.4 Conclusions
In silico simulations were conducted to generate inefficacy and toxicity risk
scores for 288 uniform lots of extended-release theophylline tablets displaying explicit
content uniformity and dissolution variability. These data were used to demonstrate
potential weaknesses of the univariate specifications utilized in USP <905> and <711>
tests for content uniformity and dissolution, respectively. The simulated results
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underscore several potential deficiencies. First, in-specification product demonstrated a
large range of quality. This was especially true for the content uniformity results, where
all of the 288 uniform lots assessed conformed to the final product specifications.
Secondly, dissolution testing, which was conducted using criteria outlined in USP <711>
and the individual monograph for extended-release theophylline capsules, revealed that
certain out-of-specification lots posed a lower risk of inefficacy and toxicity. Lastly, the
relationship between final product specifications and clinical performance was
obfuscated even further when the specifications for USP <905> and <711> were
considered simultaneously in the context of acceptable/unacceptable levels of inefficacy
and toxicity risk. The simulated results illustrated that the criteria for dissolution testing
were too strict for inefficacy and were inaccurate for toxicity. This was related to the
tests’ inabilities to account for interaction between content uniformity and dissolution
variability.
This work also addressed, principally for design space, the consequences of redefining pharmaceutical quality in terms of risk by linking production characteristics to
clinical attributes. A risk simulator was used to define the underlying relationship
between quality attributes and clinical performance for the model theophylline extendedrelease tablets. Both critical (i.e., content uniformity) and non-critical (i.e., Weibull
dissolution time constant) attributes were used as inputs to the design space, which was
conditioned on quantitative estimates of inefficacy and toxicity risk. Such a design space
can then be applied to specific processes using process models, which relate PCCPs to
the quality attributes, as transfer functions to ultimately link process parameters to
clinical performance. The direct link enhances the information content of the design
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space by omitting quality surrogates (e.g., dissolution, moisture content) that are utilized
in current design space practices. Design spaces conditioned on estimates of clinical
performance may ultimately expedite real-time product release efforts by moderating
final product testing.
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Chapter 4: A Near-Infrared Spectrscopic Investigation of Relative
Density and Crushing Strength in a Four-Component Solid Dosage
System

The material presented in Chapter 4 was previously published in Short SM, Cogdill RP,
Wildfong PLD, Drennen III JK, Anderson CA 2009. A near-infrared spectroscopic
investigation of relative density and crushing strength in four-component compacts.
Journal of Pharmaceutical Sciences 98(3):1095 - 1109.

4.1 Introduction
Near-infrared spectroscopy (NIRS) has demonstrated its utility for the analysis of
intact pharmaceutical dosage systems.124 Given the quantitative capabilities when used in
conjunction with multivariate calibration, NIRS is frequently employed for the nondestructive prediction of constituent concentrations within pharmaceutical compact and
tablet matrices. It is well understood, however, that near-infrared (NIR) spectra convey
information pertaining to both the chemical and physical nature of the samples.127
Signals related to physical variation (e.g., hardness or crushing strength) are commonly
treated as interferences in composition calibration models. Generally, variations in
physical factors such as relative density (solid fraction) result in a characteristic baseline
shift,128-133 the effect of which can be suppressed by mathematical treatment. Two
common chemometric algorithms used for this purpose are standard normal variate
(SNV)134 scaling and multiplicative scatter correction (MSC).135 Suppression of these
physical features usually reduces the number of model factors required to achieve
optimum performance.
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Beyond chemical quantification, numerous studies have documented the
modeling of NIR data for the characterization of physical attributes. One aspect of solid
oral dosage forms that has been examined using this technology is tablet hardness or
crushing strength. Drennen and Lodder pioneered the use of NIRS for the measurement
of tablet hardness.129,136 Subsequently, numerous publications have demonstrated NIR
calibrations for crushing strength.128-133,137-149 The majority of these articles suggest that
an increase in tablet hardness results in a smoother tablet surface, increasing apparent
NIR absorption (presumably because more light is lost to specular reflectance). Otsuka
and Yamane took a unique approach in which they generated calibration models to
predict the eventual hardness of tablets produced at constant compaction pressure from
powder mixtures having varying blend times (hence, changing the distribution of
constituents).138 While the authors were able to generate calibration models having
significant correlation to tablet hardness, they were unable to relate spectral changes to a
particular constituent. The authors suggested that the NIR calibration was detecting not
only composition, but more subtle factors including porosity, pore structure, and the
tablet surface and geometry.138 Three other groups have investigated the use of NIRS for
the analysis of tablet porosity; all determined that NIRS was suitable for the measurement
of tablet porosity, reporting varying levels of success with the use of different
mathematical techniques.141,143,149
The objectives of this work were to demonstrate (1) characteristic absorption
effects of NIR radiation by compacts of varying relative density and crushing strength,
(2) the source of spectral variability resulting from varying relative density and crushing
strength, (3) how multivariate analysis can be used to elucidate the effects of chemical
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composition upon the physical parameters of pharmaceutical solid oral dosage forms, and
(4) how calibration experimental design influences spectroscopic variance. Finally, these
data are used to present a revised rationalization for NIR sensitivity to compact hardness.

4.2 Materials and Methods
4.2.1 Compact Production
The details regarding the production of the compacts used for this work have been
described elsewhere.150 Briefly, a fully-balanced, four-constituent mixture design
consisting of anhydrous theophylline (Lot No. 92577, Knoll AG, Ludwigshafen,
Germany), Lactose 316 Fast Flo NF Monohydrate (Lot No. 8502113061, Hansen Labs,
New Berlin, WI), microcrystalline cellulose (MCC, Avicel PH-200, Lot No. M427C,
FMC BioPolymer, Mechanicsburgh, PA), and soluble starch GR (Lot No. 39362, EMD
Chemicals Inc., Gibbstown, NJ) was generated. The approximate median particle size of
the theophylline, lactose, MCC, and starch (reported by documentation from their
respective suppliers), was 90, 100, 180, and 17 microns, respectively. No further
analyses or operations were performed on the raw materials to determine or alter their
particle size or distribution. Twenty-nine design points were chosen to cover a wide
composition range and to remove any possibility of factor aliasing (Table 4.1). The
mixture covariance matrix demonstrates that the design is balanced in all factors, giving
equal emphasis to all constituents.
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Table 4.1. Concentration design for the 4-component compacts.
Design
Point
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

Anhydrous
Theophylline
(w/w)
0.600
0.400
0.200
0.400
0.200
0.200
0.600
0.400
0.200
0.600
0.400
0.200
0.000
0.400
0.200
0.000
0.200
0.000
0.400
0.200
0.400
0.200
0.000
0.200
0.000
0.200
0.200
0.000
0.250

Lactose
Monohydrate
(w/w)
0.200
0.400
0.600
0.200
0.400
0.200
0.200
0.400
0.600
0.000
0.200
0.400
0.600
0.000
0.200
0.400
0.000
0.200
0.200
0.400
0.000
0.200
0.400
0.000
0.200
0.200
0.000
0.200
0.250

MCC
(PH200)
(w/w)
0.200
0.200
0.200
0.400
0.400
0.600
0.000
0.000
0.000
0.200
0.200
0.200
0.200
0.401
0.400
0.400
0.600
0.600
0.000
0.000
0.200
0.200
0.200
0.400
0.400
0.000
0.200
0.200
0.250

Soluble
Starch
(w/w)
0.000
0.000
0.000
0.000
0.000
0.000
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.400
0.400
0.400
0.399
0.400
0.400
0.400
0.600
0.600
0.600
0.250

Materials for each design point mixture were dispensed by weight (Data Range,
Model No. AX504DR, Mettler Toledo, Columbus, OH), and subsequently transferred to
25 mL glass scintillation vials. In total, 6000 mg of material was weighed out for each
point, and the nominal weights for all constituents were adjusted to the observed mass
data to calculate actual concentration. The vials were mixed for 5 minute cycles by
placing them on the rotating drive assembly of a Jar Mill (US Stoneware, East Palestine,
OH, USA). After each blending period, a NIR reflectance spectrum was acquired
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through the bottom of each vial (FOSS NIRSystems 5000, FOSS NIRSystems, Inc.,
Laurel, MD), and an ad hoc partial least-squares II (PLS-2) calibration was constructed to
assess homogeneity. Mixtures were assumed to be homogeneous when further mixing
failed to yield an increase in the calibration coefficient of determination.
The mixtures from each design point were then subdivided and compacted at one
of 5 pressures (67.0, 117.3, 167.6, 217.8, 268.1 MPa) using a Carver Automatic Tablet
Press (Model No. 3887.1SD0A00, Wabash, IN) equipped with 13 mm flat-faced punches
and die. A dwell time of 10 seconds was employed. Six compacts weighing
approximately 800 mg were produced per design point, with the sixth tablet’s compaction
pressure pseudo-randomly selected from one of the five possible levels, for a total of 174
compacts. The compaction order was randomized to minimize heteroscedastic errors.
Following compaction, the samples were retained in the sealed vials for 15 days prior to
spectroscopic analysis.
Compacts consisting of each pure component were produced in a similar manner.
Approximately 800 mg of each component was compacted at 9 different compaction
pressures (67.0, 90.5, 117.3, 140.8, 167.6, 191.0, 217.8, 241.3, and 268.1 MPa) using the
same press and tooling. Four additional pressures were employed to increase the number
of data points in each compaction profile. Three replicate compacts were produced at
every compaction pressure for each constituent, yielding 27 pure compacts per material.
The manufacturer’s lot of lactose monohydrate used for the compaction profiles differed
from that used to make the 4-component compacts (Lot No. 8505010961, Hansen Labs,
New Berlin, WI); all other materials were from the aforementioned lots.
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4.2.2 Data Acquisition, Instrumentation, and Software
Near-infrared reflectance measurements were acquired for both sides of each
compact (excludes pure component compacts) using a scanning monochromator
instrument, equipped with a Rapid Content Sampler, over the wavelength range of 1100 –
2498 nm at a 2 nm increment, averaging 32 scans (FOSS NIRSystems 5000-II, Vision
version 2.00, FOSS NIRSystems, Inc., Laurel, MD). Two ad hoc partial least-squares II
(PLS-2) calibrations, using the constituent concentrations as reference data, were
constructed from reflectance spectra corresponding to a specific surface of the tablets.
Since the coefficients of determination did not differ until the third decimal place, it was
decided to only consider measurements for one compact face.
Transmittance measurements were acquired on a scanning monochromator
instrument equipped with an InSightTM Tablet Analyzer over the wavelength range of 600
– 1898 nm at a 2 nm increment, averaging 32 scans (FOSS NIRSystems 6500, Vision
version 2.00, FOSS NIRSystems, Inc., Laurel, MD). The wavelength range of the
transmittance spectra was truncated to 800 – 1400 nm due to limitations imposed by the
sample pathlength.
All spectral data were analyzed in the Matlab environment (version 7.1, The
MathWorks, Natick, MA) using the PLS_Toolbox (version 3.0, Eigenvector Research,
Inc., Manson, WA) and software developed at Duquesne University.

4.2.3 Physical Testing
Following compaction, the samples were stored in sealed glass scintillation vials
and were removed only for analysis. After an approximate 40 day span to allow for
radial expansion, the compacts were weighed (Data Range, Model No. AX504DR,
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Mettler Toledo, Columbus, OH) and their thicknesses and diameters were measured
using a digital micrometer (TESA Micromaster, Model No. IP54, Brown & Sharpe,
North Kingstown, RI). Assuming a cylindrical geometry, these data were used to
estimate each compact’s density (ρcomp) according to the formula

ρ comp =

m

(4.1)

2

⎛d ⎞
π ⋅⎜ ⎟ ⋅t
⎝2⎠

where m, d, and t are compact mass, diameter, and thickness, respectively. The pure
component tablets were allowed to relax for approximately 55 days before their masses
and dimensions were acquired. The true density of each constituent was estimated via
helium pycnometry (Micromeritics Accupyc, Model No. 1330, Particle & Surface
Sciences Pty. Limited, Gosford, New South Wales, Australia). The mean of five powder
sub-samples was used for each constituent (Table 4.2). The true densities (ρtrue) of each
compact were estimated using the equation
Table 4.2. Component true densities as determined by helium pycnometry.
Component
3

True Density (g/cm )
True Density (g/cm3)
True Density (g/cm3)
True Density (g/cm3)
True Density (g/cm3)
3

Average True Density (g/cm )
3

Standard Deviation (g/cm )

Theophylline

Lactose

MCC

Starch

1.41
1.4071
1.4034
1.4024

1.5063
1.5072
1.5072
1.5076

1.5084
1.5084
1.508
1.5053

1.477
1.4768
1.4766
1.4766

1.4012

1.5074

1.5058

1.4767

1.405

1.507

1.507

1.477

0.0036

0.0005

0.0015

0.0002

n

ρ true = ∑ X i ⋅ ρ true,i

(4.2)

i =1

where Xi and ρtrue,i are the w/w contribution and the true density for the ith component
within a n-component sample. For the work herein, n was either 4 or 1 corresponding to
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the mixture and pure component compacts, respectively. The relative density (D) of each
mixture and pure component compact was estimated as

D=

ρ comp
ρ true

(4.3)

The crushing strength of the compacts, reported in kiloponds (kp), was estimated
for the mixture compacts by a diametric crushing test (Vision Tablet Testing System,
Model No. ElizaTest 3+, Elizabeth-Hata International, North Huntingdon, PA). The
maximum recordable value for this particular instrument was 55.9 kp. Twelve calibration
compacts and one test compact were evaluated to have values of (at least) 55.9 kp; one
other test sample yielded a value of 0.0 kp. The information pertaining to these 14
compacts was withheld from the subsequent crushing strength modeling but was included
in the relative density analyses.

4.2.4 Regression Analyses
Near-infrared reflectance and transmittance spectra were independently modeled
in an identical manner. Partial least-squares (PLS) regression122 was used via the
SIMPLS algorithm123 to relate spectroscopic response to relative density and crushing
strength. No spectral preprocessing was employed; data were only transformed to
absorbance (log (1/R) or log (1/T)) and subsequently mean-centered. All reference data
(relative density and crushing strength) were scaled to zero mean and unit variance prior
to modeling. Given that the calibrations were intended to model the physical variance
within the spectra, preprocessing routine(s) were not applied. Certain applications may
necessitate spectral preprocessing to suppress interfering signals (e.g., spectrometer drift);
however, implementation of such methods may reduce the net analyte signal150 of a
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feature. For this work, preprocessing routines, including SNV scaling, detrending,
derivatives, and combinations of the preceding, were tested at the outset;124 all of these
pretreatments reduced the ability to predict relative density and crushing strength from
NIR reflectance and transmittance spectra.
The optimum model was selected based on minimization of “batch-wise” crossvalidation error,151 where the batches in this instance corresponded to the 29 different
concentration levels. The root-mean-standard error (RMSE) for cross-validation
(RMSECV), calibration (RMSEC), and testing (RMSET) were calculated using the
formula
n

RMSE =

∑ (y
i =1

− yˆ i )

2

i

n

(4.4)

where y i is the measured parameter, ŷi is the predicted parameter, and n is the number of
samples for the data set under consideration. The testing data set consisted of the sixth
compact from each design point, whose compaction pressure was pseudo-randomly
assigned one of the five possible levels. While this does not constitute a truly
independent dataset for model validation (i.e., for use in process control), the course of
action is suitable for exploratory analyses such as this.

4.3 Results and Discussion
4.3.1 Optical Effects of Varying Compaction Pressure
The optical effects of varying compaction pressure, which elicits change in the
physical parameters of the samples, are difficult to visualize amongst the broad chemical
variation built into the design. Thus, Figure 4.1a and Figure 4.1b display the
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characteristic baseline shifts for reflectance and transmittance spectra associated with
changes in tablet density when the percent contributions of the constituents are
unchanging. The baseline slope increases with increasing compaction pressure for
reflectance spectra while the opposite trend is observed for transmittance measurements.

Figure 4.1. Raw NIR absorbance spectra illustrating the spectral effect of compaction pressure when
concentration is unchanging for reflectance (a) and transmittance (b) measurements. The design point
illustrated is 40% theophylline, 40% lactose, 20% MCC, and 0% starch. The intensity recorded at the first
wavelength of each scan was subtracted from all remaining wavelengths to facilitate viewing.

The characteristic increase in measured absorbance as a result of an increase in
compaction pressure for NIR reflectance spectra (Figure 4.1a) is consistent with the
results published over the last fifteen years.128-133,137-149 An increase in compaction
pressure results in a decrease in reflected intensity. Without the benefit of corresponding
transmittance measurements, it is difficult to determine whether the effect is due to
specular reflectance, absorption, or transmission of the source radiation. As suggested by
Cogdill and Drennen,124 Figure 4.1b reveals that the latter may well be true; as
compaction pressure increases, transmission also increases.
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Otsuka et al. recently published the results of a detailed scientific study of this
effect.152 The authors cite a light penetration model based on time-of-flight analysis of
wood chips, where the transmittance of NIR radiation can be ascribed to the pore
structure of the sample. It was shown that as the tablet porosity decreases, the solid/solid
boundary surface area increases, resulting in less scattered light and more transmitted
light. On the other hand, as the porosity increases, the air/solid boundary surface area
increases, and scattering predominates. As for reflectance of NIR radiation, the authors
hypothesize that for a tablet having low porosity, the light penetrates deep into the sample
and is consequently absorbed between the matrices. Conversely, reflectance intensity is
higher in a highly porous tablet due to scattering at the air/solid boundaries, which
precludes the radiation from penetrating deep into the sample.152
These results dispel a commonly held explanation for NIR reflectance sensitivity
in the presence of varying compact density (often referred to as tablet hardness).
Therefore, the notion that a more dense compact scatters less and absorbs more may not
be entirely accurate. While it is not feasible to generalize these conclusions to all
compact systems, it is expected that these results are generally applicable to most
compacted pharmaceutical powders. Based on the results of this work, the authors
speculate that a reduction in compact porosity or void fraction increases the forward
promotion of scattered photons, which is consistent with the phenomena observed in
Figure 4.1.

4.3.2 Relative Density Modeling
It was determined that three latent variables (PLS factors) were required to
adequately model the effect of relative density variation on reflectance and transmittance
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spectra based on the minimization of RMSECV. The use of three latent variables is
reasonable considering the number of degrees of freedom in the experimental design. A
summary of the calibration statistics is provided in Table 4.3. Calibration and test set
prediction plots for both reflectance and transmittance are shown in Figure 4.2. The
comparison of predicted and reference relative density values suggest a non-linear
relationship; a potential explanation for this is the non-linear relationship between
relative density and compaction pressure (Figure 4.3a).
Table 4.3. Calibration statistics for the prediction of relative density and crushing strength for NIR
reflectance and transmittance geometries.
Reflectance Geometry
Data Type
Relative Density
Crushing Strength
Method
SIMPLS
Preprocessing
Raw Spectra
Raw Spectra
Latent Variables
3
3
RMSECV [unitless, kp]
0.013
4.640
RMSEC [unitless, kp]
0.013
4.182
RMSET [unitless, kp]
0.017
4.739
R2CV

0.922

0.832

R2CAL

0.928

0.864

R2TEST

0.906

0.856

BiasCV [unitless, kp]

1.141E-04

5.301E-02

BiasTEST [unitless, kp]

2.921E-03

-1.437E-01

Transmittance Geometry
Data Type
Relative Density
Crushing Strength
Method
SIMPLS
Preprocessing
Raw Spectra
Raw Spectra
Latent Variables
3
5
RMSECV [unitless, kp]
0.018
3.678
RMSEC [unitless, kp]
0.017
3.257
RMSET [unitless, kp]
0.013
3.187
R2CV

0.850

0.895

R2CAL

0.868

0.917

R2TEST

0.936

0.938

BiasCV [unitless, kp]

1.402E-04

9.543E-02

BiasTEST [unitless, kp]

-5.263E-04

-5.638E-01
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Figure 4.2. Predicted versus measured relative density plots for the calibration (a,c) and test (b,d) data sets
for reflectance (a,b) and transmittance (c,d) geometries.

Figure 4.3. Plots of relative density (a) and crushing strength (b) versus compaction pressure. Only
calibration samples are plotted.
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The PLS loadings, scores, and regression vectors from the optimized calibration models
were studied to evaluate the potential link between the physical data modeled and the
chemical composition of the compacts. The calibration samples were grouped into
different datasets based on constituent concentration and compaction level prior to
modeling. Figure 4.4a and Figure 4.4b display the score values on the second versus the
first latent variables for transmittance and reflectance geometries, respectively. The
majority of the variance (89.07 and 85.69%) associated with the first latent variable is
attributable to compaction pressure. This is expected as compaction pressure was one of
the independent factors varied in the design; changing compaction pressure results in
different relative densities.

Figure 4.4. Plot of PLS scores for relative density on latent variable two versus latent variable one for
reflectance (a) and transmittance (b) where the anhydrous theophylline concentration calibration samples
were grouped into the following classes: red-triangle = 0.0 w/w, green-asterisk = 0.2 w/w, blue-square =
0.25 w/w, cyan-plus = 0.4 w/w, and black-diamond = 0.6 w/w.

Similar to differing compaction pressures, changes to constituent concentrations
result in varying compressibilities. When the calibration samples were grouped based on
theophylline concentration (Figure 4.4), a pronounced separation in score space was
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evident along the second latent variable (8.89 and 8.27% variance). This pattern suggests
the influence of theophylline on the modeling of relative density as a function of
compaction pressure. Its influence was also demonstrated by the second loading that
weighted wavelength regions associated with features in the pure component spectrum of
anhydrous theophylline (second loading vector not shown). No separation was observed
in reflectance or transmittance for the other components among all possible combinations
of the first three latent variables.
The PLS regression vectors used for the prediction of relative density appear in
Figure 4.5a and Figure 4.5b for reflectance and transmittance geometries, respectively.
The regression vectors also have several features correlated to the pure component
spectra of anhydrous theophylline, which is not unexpected. A slightly greater
correlation was observed between the regression vectors and the pure component
spectrum for the reflectance data. The regression vectors further convey the importance
of anhydrous theophylline for the prediction of relative density via NIR reflectance and
transmittance spectra.
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Figure 4.5. PLS regression vectors for relative density (solid) and crushing strength (dotted) and the pure
component spectrum of anhydrous theophylline (dashdot) for reflectance (a) and transmittance (b)
geometries. All vectors were scaled to the range of 0 to 1 to facilitate viewing.

Pure component compacts were produced to assess which component (1)
produced compacts having the highest relative densities at a given compaction pressure
and (2) was most susceptible to changes in relative density upon compaction. The pure
component compaction profiles evaluating relative density versus compaction pressure
for all four constituents after production are shown in Figure 4.6. The trend did not
change following the approximately 55 day relaxation period (plot not shown). Of the
four components, anhydrous theophylline consistently produced pure component
compacts with the highest values. Relative density can also be used to estimate the
porosity (ε) of a cylindrical compact from the equation
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Figure 4.6. Relative density versus compaction pressure profiles for anhydrous theophylline (squares),
lactose monohydrate (triangles), MCC (diamonds), and soluble starch (circles) immediately after
production.

ε = 1−

ρ comp
ρ true

(4.5)

where ρcomp and ρtrue are the same as previously defined. Applying Equation 4.5 to
consider the results shown in Figure 4.6 in terms of porosity (void fraction), anhydrous
theophylline consistently produced the least porous pure component compacts. As far as
the gross change in porosity is concerned, MCC displayed the largest change in porosity
over the compaction range tested. This is not unexpected considering the microstructure
and propensity of MCC to deform under mechanical stress.153,154 It was expected that
MCC would have a large influence (leverage) on the spectroscopic analyses; however,
this affect was not observed. This may be explained by the spectroscopic signals of each
constituent.
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The pure component spectrum of anhydrous theophylline is more orthogonal to
the interfering factors; there was much greater collinearity between lactose monohydrate,
MCC, and soluble starch (Figure 4.7). This orthogonality enhances the net analyte signal
for anhydrous theophylline, which inherently augments the sensitivity of the method to
this material. Therefore, the wide anhydrous theophylline concentration range tested
(Table 4.1) most likely overwhelmed the signal attributable to the other three
constituents.

Figure 4.7. Pure component spectra for transmittance (a) and reflectance (b) geometries. Individual vectors
appear as the mean spectrum of twenty-seven pure-component compacts varying over the compaction
pressure range of 67.0 - 268.1 MPa.

4.3.3 Crushing Strength Modeling
Based on the minimization of RMSECV, it was determined that three latent
variables were required to adequately model the crushing strength variation for
reflectance data while five were required for transmittance measurements; this result was
independent from relative density modeling. A summary of the calibration statistics is
provided in Table 4.3. These data demonstrate that there was sufficient sensitivity in
both the NIR reflectance and transmittance data to model crushing strength as observed
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in the relative density analyses. This can be observed in the predicted versus measured
crushing strength plots for the calibration and testing data sets (Figure 4.8). It should be
noted that the inclusion of the samples reading 55.9 kp would not have considerably
altered the results shown in Figure 4.8 and Table 4.3. These data were excluded as they
were at the limit of the testing instrumentation.

Figure 4.8. Predicted versus measured crushing strength plots for the calibration (a,c) and test (b,d) data
sets for reflectance (a,b) and transmittance (c,d) geometries.

Comparing the plots in Figure 4.8 with those in Figure 4.2, it is apparent that the
predicted versus measured plots for crushing strength demonstrate a more linear
relationship than was observed for relative density. However, there is an apparent
reduction in model accuracy, which may be attributed to the reduced precision of the
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reference measurements. The crushing strength calibration may be more linear than the
relative density model because the measurement is more closely analogous to the
structural factors affecting photon propagation, namely particle-particle interaction. If
the tensile strength of an object at zero porosity is defined as the intrinsic strength of the
material(s) multiplied by the area normal to the applied force, then greater compaction
pressures must increase the effective area of particle-to-particle contact, even as compact
volume is reduced. As more and more particles fuse together, the effective path-length of
photons through the material is enhanced, decreasing the reflectance and increasing the
transmittance intensities of the samples. It is important to note that an increase in particle
fusion will also enhance (to a certain extent, although the enhancement is ultimately
limited by the material’s crystallographic density) the relative density of a sample, having
an analogous effect on the reflectance and transmittance intensities.
Subsequent to model optimization, the PLS scores, loadings, and regression
vectors were analyzed for a relationship between physical and chemical information
within the spectra. In a similar manner, the calibration samples were grouped according
to compaction and concentration levels. Separation of the samples by compaction
pressure demonstrated that the variance associated with the first latent variable is most
likely due to consolidation. The separation among different compaction levels was not as
clear for the crushing strength analysis. This may be explained by the relatively lower
precision of diametric compression testing; note the tighter distribution of data points
around the unity line for relative density (Figure 4.2 and Figure 4.8). This uncertainty
effectively reduces the covariance between the NIR spectra and the reference data, which
decreases the likelihood of separation in scores space. Ultimately, this reduction in
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covariance deflates the signal-to-noise ratio, causing the data for adjacent compaction
levels to blur together, perhaps because of increased rotational ambiguity during solution
of the factor structure.
As was previously observed in the relative density analyses, a division in score
space is evident when the calibration samples are grouped according to anhydrous
theophylline concentration for both reflectance and transmittance data (Figure 4.9a and
Figure 4.9b, respectively). This separation indicates the influence of anhydrous
theophylline (on the calibration model) for the prediction of crushing strength. The
influence of anhydrous theophylline is further demonstrated by the second loading vector
that tracked the loss of theophylline (observed for both sensing geometries). Several
segments of the vectors corresponded to features in the pure component spectrum of
anhydrous theophylline (loading vector not shown). No discernible patterns were
observed for the remaining components among all possible combinations of the first three
and five latent variables for reflectance and transmittance geometries, respectively.

Figure 4.9. Plot of PLS scores for crushing strength on latent variable two versus latent variable one for
reflectance (a) and latent variable three versus latent variable two for transmittance (b) where the
calibration samples were grouped into classes (see Figure 4.4 caption) based on anhydrous theophylline
concentration.
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The crushing strength regression vectors have several features related to the pure
component spectrum of anhydrous theophylline (as observed in the relative density
analyses). The PLS regression vectors used for the prediction of crushing strength appear
in Figure 4.5. Once again, the correlations between the regression vectors and anhydrous
theophylline were slightly less intense for the transmittance data.
While models employing baseline fitting algorithms have proven effective in the
presence of both chemical and physical variation,130 PLS regression was used due to the
extended concentration range (0 – 60% w/w for all constituents). When composition was
held constant (by selecting sub-sets of the calibration data), baseline fitting methods
performed comparably with PLS regression (results not shown). Additionally, this
regression method was implemented based on its tangible outputs (e.g., scores, loadings,
and full-spectrum regression vectors), which can be used to better understand the effects
of chemical variation on physical parameters of pharmaceutical compacts.
To assess the effect of concentration variation, 29 sub-calibrations where
constructed using linear regression to relate the standard deviation of each spectrum to
relative density or crushing strength. In order to mitigate concentration’s leverage, a
sub-calibration was built at each experimental design point (Table 4.1); only calibration
samples corresponding to the above models were used. For the prediction of relative
density, the mean, median, and standard deviation of the sub-calibrations’ coefficient of
determinations were (0.954, 0.957, 0.027, n = 29) and (0.529, 0.578, 0.333, n = 29) for
reflectance and transmittance geometries, respectively. The ability to model relative
density as a function of the standard deviation of the spectrum is compromised in the
presence of the extended concentration range as evidenced by the reduction in R2 when
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all 145 calibration samples are assessed simultaneously (0.840 and 0.189 for reflectance
and transmittance geometries, respectively).
The ability to predict crushing strength as a function of the standard deviation of
each spectrum is compromised in the presence of concentration variation when all 133
calibration samples are modeled (R2 = 0.511 and 0.005 for reflectance and transmittance
geometries, respectively). For the prediction of crushing strength, the mean, median, and
standard deviation of the sub-calibrations’ coefficient of determinations were (0.945,
0.970, 0.079, n = 29) and (0.436, 0.337, 0.358, n = 29) for reflectance and transmittance
geometries, respectively.
When concentration is held constant, both relative density and crushing strength
are modeled well by the standard deviation of the log (1/R) spectra. The authors suggest
that the thickness of the compacts (mean = 4.387 mm, median = 4.307 mm, standard
deviation = 0.237 mm, n = 174) in conjunction with tablet positioning error155 may have
compromised the integrity of the transmittance results due to nonlinearity.

4.3.4 Rationalization of NIR Sensitivity to Compact Density
It is proposed that NIR sensitivity to variation in compact density is attributed to
changes in the distribution of forward and back photon propagation. It is well understood
that scattering events occur only where there is a transition in refractive index.156 In the
absence of a transition, an impinging photon will tend to be transmitted without a change
of direction. Similarly, when the transition is small (e.g., between particles of different
materials having similar refractive indices), the change in photon direction will be small.
Particle-particle interfaces present a smaller refractive index change relative to airparticle interfaces.
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When contrasting the photon path in highly porous and highly dense compacts,
the latter present fewer air-particle interfaces, and more particle-particle interfaces.
Consequently, photons incident on less porous compacts encounter fewer scattering
opportunities per unit of pathlength, and tend to exhibit enhanced forward propagation
due to increased particle-particle transmission. It is understood that individual
constituents have different optical properties, and therefore, each would be expected to
exhibit a unique optical response to varying porosity. This argument is similar to that
posed by Isaksson, Miller, and Naes, where they investigated the spectral effects of
laminate films covering homogenized meat.157 The authors found that the addition of the
laminate, whose refractive index is more similar to that of the meat than the air, reduced
the specular scattering observed at the laminate-meat interface (as opposed to the airmeat interface). Ultimately, the addition of the laminate film decreased the diffuse
reflectance intensity and increased the transmitted light intensity.
As noted above, an increase in compaction pressure (alternatively, relative density
and crushing strength) resulted in higher amounts of transmitted radiation. For the
compacts studied, increasing density did not lead to higher absorbance intensities as has
been previously asserted.128,130-132,141 While the data necessary to definitively state the
reason(s) why this occurs have yet to be published, the theory of large-particle (e.g., Mie)
scattering may offer a plausible first approximation.156,158
For large-particle scattering, intensity can be viewed in terms of its forward and
back distribution (or transmission and remission), where for particles larger than
wavelength of the impinging radiation, interference is such that the forward direction is
favored.156,158 If we can assume that, as porosity decreases, the average size of scattering
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centers (e.g., particle size) within the compact increases, Mie theory would predict a
greater propensity for scatter in the forward direction. Moreover, as the void fraction
decreases, the relative area of low refractive index (particle-particle) transitions in
comparison to high refractive index (air-particle) transitions increases, resulting in
scattering (refraction) angles favoring forward propagation.156,158 Forward scatter does
not necessarily favor additional scatter more so than absorption; however, the reduction
of scattering in the reverse direction would ostensibly reduce the reflectance intensity
while increasing the transmittance intensity. Moreover, this would lead to increased
pathlength for diffuse reflectance measurements, and reduced pathlength for (diffuse)
transmittance measurements. The specific application of Mie theory to consolidated
pharmaceutical powders, however, violates many of the underlying assumptions (e.g.,
isolated particles, spherical particles, single scattering events). 156,158
Taking into consideration the anisotropy of both pharmaceutical solid materials
and the composites formed by their compaction, it is reasonable to consider alternative
methods which are valid for particles having non-spherical shape and contact with other
particles. Grundy, Douté, and Schmitt proposed a model based on ray tracing and Monte
Carlo simulation of the linear polarization and scattering by anisotropic particles of sizes
much larger than the wavelength of incident light.159 While this reference dealt
exclusively with individual particles, their S-Scat model yielded results similar to those
predicted by Mie theory. Additionally, the authors observed that for irregular particles,
scattering in the forward direction (larger phase angles) was favored.159 Utilizing models
with the ability to compensate for the anisotropy of pharmaceutical solids (e.g., S-Scat)
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may help to clarify the spectroscopic intricacies observed during the modeling of relative
density and crushing strength.
Additional research is required to address concomitant issues such as variation in
raw material particle shape, size, etc. to understand how photons interact with compacts
of varying density and composition. Future research will be focused on developing
comprehensive NIR photon migration simulation algorithms to address these issues.

4.4 Conclusions
Calibration models were constructed using PLS regression to relate NIR
reflectance and transmittance spectra to compact relative density and crushing strength
values. Both reflectance and transmittance data had adequate sensitivity to model both
physical characteristics. Second to compaction pressure, anhydrous theophylline was
most influential on the spectral analyses of relative density and crushing strength, which
was mainly a function of the experimental design and the enhanced chemical sensitivity
to this particular component. Additionally, the calibration models for relative density and
crushing strength demonstrated that the latter was more linear but less accurate in
prediction. This study also demonstrated that, in contrast to the existing interpretations,
increasing tablet density does not necessarily reduce scattering or increase absorbance of
NIR radiation. The optical interactions are a function of changing compact porosity,
which promotes greater scattering in the forward direction. Propagation of light in the
forward direction is detected as an increase in transmitted intensity. Future studies will
focus on using empirical data combined with in silico simulations to discern what
happens to source photons as they interact with compacted pharmaceutical powders of
varying relative densities.
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Chapter 5: Determination of Figures of Merit for Near-Infrared and
Raman Spectrometry by Net Analyte Signal Analysis for a Four
Component Solid Dosage System

The material presented in Chapter 5 was previously published in Short SM, Cogdill RP,
Anderson CA 2007. Determination of figures of merit for near-infrared and raman
spectrometry by net analyte signal analysis for a 4-component solid dosage system.
AAPS PharmSciTech 8(4):Article 96. DOI: 10.1208/pt0804096.

5.1 Introduction
A number of technologies may be suitable for a given analytical measurement
application. Ultimately, a decision must be made as to which device will be deployed.
Common methods for comparison of instruments based upon different fundamental
principles are not well established. While there are multiple considerations upon which
instrument selection is based (cost, performance, infrastructure, etc.), this work will focus
only on method performance characterization for two sample technologies.
The advent of the Process Analytical Technology (PAT) initiative6 has increased
the performance demands upon, and the need for understanding of, analytical methods.
In a PAT environment, sensors are controlling processes (as opposed to advising).
Pharmaceutical literature often gives the impression that a multivariate sensor is
generally applicable for in-, on-, and at-line process monitoring applications. These
applications typically require chemometric modeling/calibration160 to transform
instrument signal into useable information. Multivariate calibration provides a platform
for data driven analyzer selection.
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Process analytic measurement applications in pharmaceutical science include
qualitative and quantitative identification of compounds, examination of phase
transformations and polymorphs, and investigations of manufacturing and process
development. Near-infrared (NIR) and Raman spectroscopy are both sensitive to, and
capable of accurately predicting, these phenomena.124,161 As NIR is based on optical
absorption and Raman on the measurement of inelastic scattering, comparison of the
parallel performance of these two classes of instrumentation is indirect. More often than
not, the instrument eventually deployed is selected based on limited criteria which do not
consider all aspects of performance.
Calibrations are frequently evaluated using the coefficient of determination (R2)
and/or estimation of prediction error. 162-166 Neither of these measures directly consider
issues such as precision164,165 and signal-to-noise (S/N) ratio.167,168 While these are
important statistics, they should not be considered independently; rather, the effectiveness
of a method should be judged based on a complete assemblage of indicators which
describe all aspects of performance and are generalized across technological platforms.
Net analyte signal (NAS) theory provides a mechanism for determining figures of merit
indicative of an instrument’s utility.
Net analyte signal theory is the concept of separating relevant signals for a
particular component of interest from the remaining interfering elements present within
the spectra.169 Lorber170 is widely acknowledged as the originator of multivariate NAS
theory; Brown,171 however, makes the clarification that Morgan172 published on a similar
topic prior to Lorber, although the work “contains some errors.”171 Net analyte signal
provides a tool for calculating multivariate figures of merit; prior to Morgan/Lorber,
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techniques similar to NAS were applied only to data from univariate methods.173 A
detailed description of univariate calibration and the corresponding determination of
figures of merit are outside the scope of this work. For a more detailed discussion, please
refer to Olivieri et al. and their references.173
Multivariate NAS was first implemented using pure component projection170 and
classical regression;174 i.e., constituent concentration was directly related to instrumental
response vectors. However, implementation of NAS via pure component or classical
regression methods is cumbersome in that the spectra or concentrations for all
contributing species are required.169 The implementation of multivariate NAS was solved
in terms of inverse regression by Lorber, Faber, and Kowalski, requiring only the
concentrations for the component(s) of interest to be known.169 For inverse regression,
concentration is expressed as a function of instrumental response.174 Nonetheless, both
classical and inverse regression mathematics are suitable for the determination of NAS;
however, the remaining descriptions and the work herein strictly assume the application
of inverse regression.
Mathematically, NAS is defined as the portion of signal unique to the constituent
being considered and is orthogonal to all other factors present in the data.169,170 NAS,
therefore, comprises the signal directly useful for quantification.169 A mixture spectrum
(r) extracted from a spectral matrix containing multiple constituents can be resolved into
r = r* + r ⊥

(5.1)

where r* and r┴ are mutually orthogonal components representing the NAS vector for the
particular component of interest and the vector of interferences, respectively.169
However, it is well understood that controllable and uncontrollable errors influence the
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performance of any analytical technique. This error (ε), which will be slightly different
for each sample acquired, can also be partitioned into its respective mutually orthogonal
components: the part that is orthogonal to the interferences (ε*), and the portion that lies
within the interference space (ε┴).175 It is important to understand that the estimated r*
will not lie exactly in the true direction of the NAS vector as a result of ε*.175 The former
(ε*) is the portion of total stochastic error (ε) which contributes to imprecision.
Multiple algorithms for calculating NAS have been reported in the literature,176,177
with the method of computation and resulting output differing. In this work, the method
proposed by Bro and Andersen is utilized.178 All equations use X to represent spectral
matrices; bold characters other than X, e.g., x, y, and NAS, represent vectors; small,
italicized characters, e.g., x and y, represent scalars. Additionally, the notation ||x||
signifies the Euclidean norm of a vector, the square root of the sum of the squared
elements. The superscript T indicates the transpose of a vector.
Bro and Andersen calculate the net analyte signal vector for a particular
component of interest by

(

∧

NAS i = (x i ⋅ b ) ⋅ b T ⋅ b

)

−1

⋅ bT

(5.2)

where xi is a sample spectrum from matrix X and b is a column vector of the regression
coefficients for X;178 principal components regression (PCR) or partial least-squares
(PLS) are common regression techniques used to estimate b.160 It should be noted that X
∧

is corrected for the mean; thus, outputs from computations employing NAS are meancentered. Results can be rescaled using the vector of means from the centering operation
of X to the original range. Net analyte signal can also be expressed in scalar form, with
no loss in information (but reduced interpretability), by the equation169
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∧

∧

NAS i = NAS i

(5.3)

As Lorber et al. have noted, the term “NAS” is often interchangeably used to represent
the NAS vector and the scalar NAS quantity.169 Additional discussion concerning the
mathematics behind the determination of net analyte signal can be found elsewhere.169172,175-181

5.2 Materials and Methods
5.2.1 Tablet Production
A fully-balanced, four-constituent mixture design comprised of anhydrous
theophylline (Lot No. 92577, Knoll AG, Ludwigshafen, Germany), Lactose 316 Fast Flo
NF Monohydrate (Lot No. 8502113061, Hansen Labs, New Berlin, WI), microcrystalline
cellulose (MCC, Avicel PH 200, Lot No. M427C, FMC BioPolymer, Mechanicsburgh,
PA), and soluble starch GR (Lot No. 39362, EMD Chemicals Inc., Gibbstown, NJ) was
generated. The approximate median particle size of the theophylline, lactose, MCC, and
starch (reported by documentation from their respective suppliers), was ~90, ~100, ~180,
and ~17 microns, respectively. No further analysis or alterations were performed on the
materials to determine or alter the particle size distribution. Twenty-nine design points
were chosen to cover a wide range in all constituents and to remove any possibility of
factor aliasing (Figure 5.1). Analysis of the mixture covariance matrix (not shown)
demonstrated the design is balanced in all directions, giving equal emphasis to all
constituents.
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Figure 5.1. Diagram illustrating the concentration design matrix. The four-component design matrix can be
viewed in three dimensions, and is in the shape of a tetrahedron because of the constraint imposed by
concentration closure. The center of the pyramid represents the point of equal concentration in all
components and the vertices represent the points of pure constituents. The solid lines are not labeled for
their corresponding constituents as they are all equivalent due to the balanced design.

Materials for each design point mixture were dispensed by weight (Data Range,
Model No. AX504DR, Mettler Toledo, Columbus, OH) in accordance with the design,
and were immediately transferred to 25 mL glass scintillation vials. In total, 6000 mg of
material was weighed out for each point, and the nominal weights for all constituents
were adjusted to the observed mass data to calculate actual concentration. After all
components were added to each vial, they were tumbled for 5 minute cycles on a rotating
Jar Mill (US Stoneware, East Palestine, OH, USA). After every blending period, each
vial was manually inverted to collect a NIR reflectance spectrum directly through the
bottom of the glass (FOSS NIRSystems 5000, FOSS NIRSystems, Inc., Laurel, MD). An

ad hoc partial least-squares II (PLS-2) calibration, using the constituent concentrations as
reference data, was constructed after each blending cycle to assess homogeneity.
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Mixtures were assumed to be homogeneous when further mixing failed to yield an
increase in the calibration’s coefficient of determination.
The mixtures from each design point were then subdivided and tableted at 5 levels
of compaction force (67.0, 117.3, 167.6, 217.8, 268.1 MPa) on a Carver Automatic
Tablet Press (Model 3887.1SD0A00, Wabash, IN) using flat-faced punches and a 13 mm
die. A dwell time of 10 seconds was employed. Six compacts were produced per design
point, with the sixth tablet’s compaction force randomly selected from one of the five
possible levels. The compaction order was randomized to ensure homoscedasticity of
experimental error. In total, 174 compacts were produced with a nominal target weight
of 800 mg per tablet. A small arrow was drawn on the perimeter of each tablet (to avoid
spectroscopic interference) to distinguish between the two flat surfaces. Tablet
preparation and compaction occurred over a three day period, after which the compacts
were left to relax for 15 days prior to spectroscopic analysis to compensate for any radial
and/or axial tablet expansion.

5.2.2 Data Acquisition, Instrumentation, and Software
Near-infrared reflectance measurements (expressed as log(1/R), or absorbance
intensity) for both sides of each tablet were acquired over the wavelength range of 1100 –
2498 nm at a 2 nm increment (FOSS NIR Systems 5000, FOSS NIRSystems, Inc.,
Laurel, MD). Thirty-two sub-scans were accumulated for each resultant sample
spectrum. Prior to scanning, the tablets were precisely centered using the positioning iris
standard on this particular instrument. Absorbance data were collected by way of Vision
data acquisition software (version 2.00, FOSS NIRSystems Inc.) and exported in .NSAS
file format. Two ad hoc partial least-squares II (PLS-2) calibrations, using the
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constituent concentrations as reference data, were constructed from spectra corresponding
to a specific surface of the tablets. Since the coefficients of determination did not differ
until the third decimal place, it was decided to only consider measurements of one tablet
face (arrow pointing upwards) for both technologies.
Raman data were measured using a prototype PhAT System spectrometer with a
laser excitation wavelength of 785nm and equipped with a fiber-coupled probe head
(Kaiser Optical Systems, Inc., Ann Arbor, MI). The PhAT System samples a spot size of
approximately 6 mm. Two accumulations were acquired per scan employing an
integration time of 10 seconds over the range of -64.2 to 1895.7 cm-1 at a 0.3 cm-1
increment. A dark scan was subtracted and the cosmic ray filter and intensity calibration
options were selected. The tablets used in this study were larger than could be
accommodated in the tablet holder located in the sample chamber of the PhAT System
requiring the tablets to be manually positioned such that the laser spot was visually
centered on the flat face. Raman intensity data were collected via the HoloGRAMS
software package (version 4.0, Kaiser Optical Systems, Inc.) and exported in .GRAMS
file format.
The Unscrambler (version 9.0, Camo Software Inc., Woodbridge, NJ) was used to
convert both .NSAS and .GRAMS files to .mat format to allow further data manipulation.
All spectral data were analyzed in the Matlab environment (version 7.1, The MathWorks,
Natick, MA) using the PLS_Toolbox (version 3.0, Eigenvector Research, Inc., Manson,
WA) and software developed by the Duquesne University Center for Pharmaceutical
Technology (DCPT).
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5.2.3 Partial Least-Squares Analysis
NIR and Raman data were analyzed separately but in an identical fashion. The
NIR spectral range and resolution were not altered; however, the Raman spectral range
was truncated to 205.5 - 1895.7 cm-1 to remove residual Rayleigh line radiation and to
reflect the operating range of the analyzer. Prior to calibration, the Raman data were
evaluated using a moving-window calibration technique179 with various window widths
to determine if further wavenumber truncation would be beneficial. Wavelength
selection was not shown to enhance calibration performance. Partial least-squares
regression122 was used via the SIMPLS algorithm123 to relate spectroscopic response to
concentration for each constituent on an individual basis. Since analyte concentration is
incorporated in the denominator of some figure of merit calculations, samples having a
corresponding zero concentration for the component being considered were excluded.
Therefore, samples included in the actual calibration data sets were unique for each
component.
Preprocessing routines, including standard normal variate (SNV) scaling,
detrending, derivatives, and combinations of the preceding were tested.124 The most
favorable data pretreatment method was selected based on a minimization of “batchwise” cross-validation error, where the batches in this instance were the five different
compaction levels. During each cross-validation iteration tablets produced at a particular
compaction force were removed, a calibration was constructed, and the concentrations of
the excluded samples were predicted via the temporary model. This procedure was
continued until all of the samples had been predicted, thereby allowing for the
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determination of the root-mean-standard error (RMSE). The RMSE for cross-validation
(RMSECV) and calibration (RMSEC) were calculated using the formula
n

RMSE =

∑ (y
i =1

− yˆ i )

2

i

n

(5.4)

where y i is the measured concentration, ŷi is the predicted concentration, and n is the
number of samples for the data set under consideration. According to ICH guidelines,
accuracy expresses the agreeability between reference and predicted values.182
Therefore, RMSEC and RMSECV are used to report the accuracy of the selected
calibration.

5.2.4 Multivariate Figures of Merit
The optimal number of latent variables selected during the estimation of each PLS
regression vector was determined by minimizing RMSECV and RMSEC. Once
established, the regression vector was used to determine the NAS according to equations
(5.2) and (5.3). Given the number of chemical constituents and physical factors varying
in this design, it was anticipated that no more than 4 latent variables would be required;
however, models with greater rank are feasible but would be increasingly difficult to
justify. The NAS vector affords the opportunity to calculate numerous figures of merit,
such as sensitivity, analytical sensitivity, selectivity, and S/N ratio. Figures of merit can
be determined for every sample using the following formulae.
Sensitivity characterizes the extent of signal variation as a function of analyte
concentration; the higher the sensitivity, the greater the instrumental response to an
increase in concentration.169,170 Sensitivity is calculated as169,173,177
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∧

NAS i
SEN i =
yi
∧

∧

(5.5)

∧

where SEN i , NAS i , and yi are the vector of sensitivities for each instrument variable,
the net analyte signal vector, and the measured concentration for the ith sample,
respectively. Sensitivity is reported in units of instrument intensity per concentration.
Measured concentrations are autoscaled before being utilized in equation (5.5). It is also
possible to express sensitivity as a univariate figure of merit by taking the Euclidean
norm of the sensitivity vector
∧

∧

SEN i = || SEN i ||

(5.6)

∧

where SEN i is the univariate measure of sensitivity for the ith sample.177,180 Sensitivity is
reported in this document as the mean of the univariate sensitivity values for all samples
under consideration.
Sensitivity is only applicable to calibrations constructed on devices operating
under the same fundamental principles because it incorporates units of instrument signal
(NIR absorbance intensity and Raman scattering intensity). The parameter analytical
sensitivity (γ) was developed to provide an impartial assessment between dissimilar
analytical techniques.180 Analytical sensitivity is calculated as
∧

SEN
γ=
δr

(5.7)

∧

where SEN is the mean of the sensitivity values under consideration found using
equation (5.6) and δr is a measure of instrumental noise. This normalization procedure
allows direct comparison of the measure of sensitivity associated with NIR and Raman
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data. Analytical sensitivity has the dimensions concentration-1. δr was determined as the
∧

mean standard deviation of NAS i (for the component under consideration) of four tablets
broadly varying in constituent concentrations. Additionally, this figure of merit allows an
estimation of the minimum discernible concentration difference given the dynamic range
modeled180 (γ-1); this is referred to as effective resolution.
Predicted values were determined by183
∧

y = X⋅b

(5.8)

where X is the spectral matrix and b is the PLS regression vector, which varies depending
on the number of latent variables applied. It should be noted that the concentration data
have been previously autoscaled; thus, predicted values need to be rescaled using the
mean and standard deviation of the measured concentrations before the accuracy is
determined via equation (5.4).
It is important to observe that all predicted values herein are independent of any
NAS calculations performed. Certain NAS techniques allow the determination of
predicted concentrations using the equation169,177
∧

yi =

∧

∧

|| NAS i ||
∧

(5.9)

|| SEN i ||

∧

where NAS i , SEN i , and ŷi are as defined previously. Considering equation (5.5) for the
calculation of the sensitivity vector, the NAS method employed within this paper forbids
the use of equation (5.9) because it forces yˆ i = yi .
Selectivity is a dimensionless univariate measure of the portion of instrumental
signal that is not lost due to spectral overlap, in other words the quantity of signal
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unaffected by interfering factors, restricted to a value between 0 and 1.169 This statistic is
calculated for each sample by169,181
∧

|| NAS i ||
SEL i =
|| x i ||
∧

(5.10)

∧

where NAS i and x i are the NAS vector and the original spectrum for the ith sample. The
magnitude of the selectivity parameter is directly dependent on the degree of spectral
interference associated with the particular analyte under consideration. Selectivity is
reported in this document as the mean of the selectivity values for all samples under
consideration.
Signal-to-noise ratio is one of the most important metrics for general comparison
of methods. It is calculated as169
∧

NAS i
S / Ni =
δr
∧

(5.11)

∧

where NAS i is the scalar representation of the NAS vector, and δr was estimated as the
mean standard deviation of the predicted concentrations (for the component under
consideration) of four tablets broadly varying in constituent concentrations (i.e., the same
four tablets previously used). Linear regression was performed between measured
concentration and the univariate NAS values in order to estimate scale (a1) and offset (ao)
coefficients to transform the NAS value to units of concentration. This enables S/N to be
a dimensionless statistic for this four constituent mixture design.
⎛ ∧ ⎞
⋅
a
⎜ NAS i ⎟ + ao
1
∧
⎝
⎠
S /Ni =
δr

229

(5.11a)

Signal-to-noise ratio is reported in this document as the mean of the S/N values for all
samples under consideration.
Given the wide range of concentrations present within the design, limit of
detection (LOD) is a practical figure of merit. Limit of detection can be computed as184

LOD =

k Dσ
m

(5.12)

where kD is the statistical confidence factor (here, kD = 3), m is the slope of a univariate
classical least-squares fit of the predicted and reference data, and σ is defined as δr in
equation (5.11). Since the predicted versus measured plot was not significantly different
from unity, a value of 1.0 was assumed for m in all cases.

5.2.5 Precision Statistics
Precision figures of repeatability and intermediate precision were determined in
accordance with ICH guidelines182, and were reported as the standard deviation of the
predicted concentration values (equation 5.8) for repeat measurements. Repeatability and
intermediate precision values were established using the randomly-chosen design point
comprised of 20% theophylline, 20% lactose, 0% MCC, and 60% starch, compacted at a
force of 167.6 MPa. Repeatability, a measure of short-term sampling error, was
determined without repositioning of the tablet between successive scans, as well as by
removing and subsequently re-centering the compact before acquiring the next
measurement. Six scans for each type of repeatability test were collected one after the
other on the same day. Intermediate precision, which should incorporate typical
variations such as between analysts and days, was determined by scanning the tablet once

230

a day for six consecutive days. The same analyst collected these scans and the
repeatability scans to determine day to day variability of the instruments.

5.3 Results and Discussion
5.3.1 Near-Infrared Analysis
The RMSEC and RMSECV values were plotted against the number of latent
variables selected for PLS modeling (Figure 5.2). Savitsky-Golay first derivative
preprocessing185 (11 point smoothing and 2nd order polynomial fit) was chosen based on
the minimization of RMSECV. It was independently determined that to adequately
model the NIR absorbance data, theophylline required three latent variables, while four
were required for lactose, MCC, and starch. Model rank was chosen as the point where a
rapid decline in the incremental variance captured was observed, cognizant of the
expected feasible limit of dimensionality based on the factors varying within the design.
Without derivative preprocessing, an additional latent variable would have been required
to compensate for the variation in compact density. It is speculated that the derivative
preprocessing most effectively suppressed the physical effect of compaction, which has
been shown to have a significant effect on the spectral baseline.124,161
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Figure 5.2. Plot of RMSEC (squares) and RMSECV (triangles) versus the number of PLS factors used to
model NIR data for theophylline (a), lactose (b), MCC (c), and starch (d), respectively.

Figure 5.3 displays the regression vectors in addition to the pure component
spectra for theophylline, lactose, MCC, and starch; note that the pure component spectra
and the PLS regression vectors were scaled to facilitate viewing. To gather the pure
component scans, powder for each constituent was placed in a glass scintillation vial and
spectra were acquired directly through the bottom of the glass; each pure component
spectrum represents a mean of three scans. As expected, each regression vector is highly
correlated with its associated pure component scan. The goodness-of-fit seen in the
predicted versus measured concentration values for the four constituents demonstrates the
linearity of the PLS models implemented (Figure 5.4a).
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Figure 5.3. NIR pure component spectra (upper solid lines), PLS regression vectors (lower solid lines), net
analyte signal (black), and interference (grey) vectors for each calibration sample, for theophylline (a),
lactose (b), MCC (c), and starch (d), respectively. Note that the pure component spectra and the PLS
regression vectors were scaled to facilitate viewing.

Figure 5.4. Predicted versus measured concentration plot for NIR (a) and Raman (b) data. Circles represent
the 50th percentile while the upper and lower stars represent the 25th and 75th percentiles, respectively.
The unity line is shown in black.
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Following estimation of the PLS regression vectors for each constituent, the
portion of the NIR signal related only to the component being analyzed was determined
for all calibration samples (equation 5.2). Figure 5.3 exhibits the NAS vector along with
the corresponding interference spectrum for each calibration sample for theophylline,
lactose, MCC, and starch. This unique plotting scheme directly illustrates the contrast
between analyte and interference signals. Furthermore, this graphically illustrates the
ability of multivariate calibration to achieve selectivity. For example, in Figure 5.3a, a
great deal of spectral variance can be observed around 1500 nm; however, this variation
is not attributed to the presence of theophylline, rather, it is the result of the interfering
components. This effect is evident by the relatively small range in intensity for the NAS
spectra in comparison to the larger intensity range for the interference spectra.
Conversely, much of the spectral variation around 1650 nm is due to the variance in
theophylline concentration. Similar phenomena can be seen for the other three
components (Figure 5.3).

5.3.2 Raman Analysis
The RMSEC and RMSECV were plotted against the number of PLS latent
variables modeled in (Figure 5.5). Savitsky-Golay first derivative preprocessing185 (33
point smoothing and 2nd order polynomial fit), was also selected based on minimization
of RMSECV. Presently, there are no known published reports identifying any consistent
correlation between variation in Raman spectra and tablet hardness; implying that Raman
spectra are insensitive to compact hardness variation. The data collected in this study are
in agreement with this conclusion; no discernible pattern was observed relating Raman
intensity and tablet compaction force (Figure 5.6). Hence, the role of derivative
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preprocessing was apparently not to mitigate any spectral effect of hardness variation;
rather, it suppressed the baseline effect present in the spectra. Theophylline and lactose
each required four latent variables, while three were required for MCC and starch.

Figure 5.5. Plot of RMSEC (squares) and RMSECV (triangles) versus the number of PLS factors used to
model Raman data for theophylline (a), lactose (b), MCC (c), and starch (d), respectively.
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Figure 5.6. NIR (a) and Raman (b) spectra of the same design point (40% theophylline, 40% lactose, 20%
MCC, and 0% starch) compacted at 67.0, 117.3, 167.6, 217.8, and 268.1 MPa. For each spectrum, the
value for the first variable was subtracted to facilitate viewing.

Figure 5.7 displays the scaled regression vectors in addition to the scaled pure
component spectra for theophylline, lactose, MCC, and starch. Raman pure component
scans were gathered in the same manner as the NIR. Again, it was anticipated that the
PLS regression vectors would include information pertaining to the component, which
was confirmed by the similarities between the pure component scans and the regression
vectors for all four constituents. Less dispersion in predicted values was observed around
each concentration level, which is in agreement with the higher calibration R2 statistics
for the Raman calibration (Figure 5.4).
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Figure 5.7. Raman pure component spectra (upper solid lines), PLS regression vectors (lower solid lines),
net analyte signal (black), and interference (grey) vectors for each calibration sample, for theophylline (a),
lactose (b), MCC (c), and starch (d), respectively. Note that the pure component spectra and the PLS
regression vectors were scaled to facilitate viewing.

Following the construction of the PLS regression vectors for each constituent, the
∧

NAS i was determined for each calibration sample (equation 5.2). Figure 5.7 depicts the
NAS vector and the interference spectrum for each calibration sample for theophylline,
lactose, MCC, and starch. Although 205.5 - 1895.7 cm-1 was used during calibration, a
reduced range was plotted to highlight the contrast between NAS and interference
spectra. As was observed for NIR, the patterns demonstrate the selectivity of
multivariate calibration for each component.
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5.3.3 Figure of Merit Comparison
Table 5.1 displays the calibration statistics describing the performance of the NIR
and Raman spectrometers under investigation for this particular four-component solid
dosage system. With regard to accuracy, the Raman calibration appears to have an
advantage relative to NIR; as reflected by the lower RMSE as well as the superior
coefficient of determination. Among the four components, theophylline was modeled the
most accurately by both NIR and Raman. This is most likely attributable to two factors:
higher sensitivity and selectivity relative to the other components, which will be
addressed in greater detail in the following paragraphs.

238

Table 5.1. Calibration statistics and figures of merit for Reflectance NIR and Raman as determined for each constituent.
Data Type

NIR (Reflectance)

Raman

Method

PLS

Preprocessing

Precision

1st Derivative (33,2,1)

Latent Variables

3

4

4

4

4

4

3

3

Component

Theophylline

Lactose

MCC

Starch

Theophylline

Lactose

MCC

Starch

2

0.962

0.951

0.919

0.952

0.981

0.969

0.958

0.972

R - CV

2

0.962

0.942

0.902

0.941

0.979

0.962

0.955

0.966

RMSEC (%)

2.7

3.1

4.0

3.1

1.9

2.5

2.9

2.4

RMSECV (%)

2.8

3.4

4.4

3.4

2.0

2.8

3.0

2.6

R - Cal

Accuracy

1st Derivative (11,2,1)
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Repeatability - w/o repositioning (%)

0.01

0.16

0.16

0.02

0.28

0.27

0.09

0.04

Repeatability - w/ repositioning (%)

0.07

0.10

0.36

0.46

0.45

0.46

0.45

0.27

Intermediate (%)

0.11

0.16

0.52

0.66

0.35

0.66

0.36

0.26

Sensitivity (Instrument Intensity / %)

0.02

0.01

0.01

0.01

12768.61

5124.58

3732.26

3265.58

Analytical Sensitivity (1 / %)

126.36

82.47

37.09

31.18

15.13

17.31

11.85

10.53

Effective Resolution (%)

0.01

0.01

0.03

0.03

0.07

0.06

0.08

0.09

Selectivity (unitless)

0.59

0.33

0.24

0.27

0.37

0.24

0.18

0.16

Signal-to-Noise (unitless)

282.40

189.88

87.23

72.14

34.99

40.69

26.80

23.98

Limit of Detection (%)

0.33

0.50

1.08

1.31

2.70

2.32

3.53

3.94

The ICH guidance on method validation for repeatability182 provides a protocol
for partitioning sources of variance (i.e., instrumental noise, sample positioning error,
instrument drift). In particular, it was noted that repositioning inconsistency was a large
contributor to total error for both the NIR and Raman calibrations. For the Raman
analyzer approximate 6 mm of the surface (roughly 46 percent of the tablet surface) is
sampled; as opposed to the off-line NIR instrument that sampled nearly the entire
compact face. Further, NIR has a greater depth of sampling relative to Raman
spectroscopy. Therefore, sample heterogeneity and/or sample presentation effects have a
greater effect on Raman precision. The impact of sampling heterogeneity is reduced as
the number of samples analyzed per time period is increased as a result of averaging. For
example, if these methods were implemented in an at-line environment, the difference in
precision between Raman and NIR is expected to decrease. Additionally, more equitable
comparisons between these two analyzers could be made by implementing a modified
sample holder capable of precisely positioning 13 mm tablets, by analyzing tablets of a
diameter similar to the Raman sampling size, or by averaging multiple locations on either
side of the tablet.
In some cases, error statistics were inconsistent with expected trends, as shown in
Table 5.1. For example, intermediate precision values calculated using the Raman data
were actually lower than repeatability figures for both MCC and starch. This is
unexpected as intermediate precision includes the additional factor of day-to-day
instrument drift. This may be indicative of an incomplete estimate of the variance
associated with sample repositioning.
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While the accuracy and precision data provide a feasible means of comparing
these two spectrometers, the power of the evaluation can be enhanced by determining
additional calibration figures of merit. Sensitivity for both analytical devices was the
largest for theophylline; an increase in its concentration resulted in the greatest response
in instrumental intensity. The relative magnitude of peaks in un-scaled pure component
spectra (not shown) illustrates this effect. It is important to note that the sensitivity
values of individual constituents are not comparable between the two instruments.
Analytical sensitivity is used to compare sensitivity across different measurement
technologies. This normalized statistic quantifies sensitivity with respect to analytical
precision. Although both devices exhibited the greatest sensitivity for theophylline, the
NIR device was more sensitive to all four constituents (in terms of analytical sensitivity).
Error of repositioning has a direct effect on σ in equation (5.7), which in turn inflated the
denominator, thereby reducing the analytical sensitivity of Raman. The constituent
ordering for highest to lowest sensitivity is not identical between the two instruments.
This emphasizes the importance of pairing the instrument to the analytical task. The
effective resolution results reinforce the results reported for sensitivity. Despite the
apparent similarity, this statistic should be considered with respect to quality action
limits.
Selectivity is important only when adequate sensitivity is available. A lack of
selectivity has the effect of suppressing sensitivity. If adequate sensitivity is not
available, improvements of selectivity are futile. Theophylline, which exhibited high
relative sensitivity, also exhibited superior selectivity, which is directly attributable to its
inherent pure component orthogonality. In contrast, the collinearity among lactose,
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MCC, and starch (all being carbohydrates) reduced selectivity. For Raman in particular,
the sensitivity (equation 5.6) and selectivity are lower for these components. This is
manifested in the performance-related figures of merit (LOD, analytical sensitivity,
effective resolution, and S/N). An example of the enhanced interference between these
three components can be seen in the NIR at approximately 1500 nm, where the NAS
signal is quite large for all three (Figure 5.3).
From the results discussed thus far, the resulting S/N ratio analysis should be
straightforward. The NIR calibration included more useable signal in relation to
obstructive noise. In some cases, researchers assume that the coefficient of determination
is directly predictive of S/N ratio.186 It is for this reason that technology selection criteria
are often based upon R2 and RMSE, since these statistics are frequently generated during
calibration, requiring no additional calculations. The results of this work contradict these
assumptions. While Raman outperformed NIR in terms of linearity and accuracy, the
S/N ratio for NIR measurements was greater. This occurs because error statistics (R2 or
RMSE) are heavily influenced by the experimental design, while S/N ratio is inherent to
the method. Further studies are planned in which calibrations will be optimized
according to S/N ratio (as opposed to the traditional method of RMSE); the impetus is to
address the aforementioned precision issues, while simultaneously enhancing sensitivity,
selectivity, and LOD.
It is interesting to note that despite the lower relative precision of the Raman
measurements, which deflates several of the figures of merit, no negative effect on the
ability of the SIMPLS algorithm to resolve the covariance structure was observed. This
is because inverse least-squares regression is less affected by precision than sample

242

leverage in the estimation of the true solution. This supports the notion that calibration
quality is not sufficient to fully describe method performance.

5.4 Conclusions
This study demonstrates that multivariate figures of merit (determined from net
analyte signal theory) can be used to compare calibrations constructed from spectroscopic
data collected using two analytical instruments detecting different physical phenomena.
The observed calibration performance statistics demonstrate that NIR and Raman are
both suitable techniques for the quantitative determination of chemical components
within this tablet matrix. Beyond error statistics, multivariate figures of merit provide a
clearer assessment of the specific factors limiting performance of the methods while
providing a means for general characterization. Furthermore, figures of merit, such as
effective resolution and limit of detection, provide an additional mechanism for
determining the validity and significance of predicted values upon deployment. For all of
these reasons, figures of merit should take a more prominent place among chemometric
techniques used in pharmaceutical analytical method development.
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Chapter 6: Figures of Merit Comparison of Reflectance and
Transmittance Near-Infrared Methods for the Prediction of
Constituent Concentrations in Pharmaceutical Compacts

The material presented in Chapter 6 was previously published in Short SM, Cogdill RP,
Anderson CA 2008. Figures of Merit Comparison of Reflectance and Transmittance
Near-Infrared Methods for the Prediction of Constituent Concentrations in
Pharmaceutical Compacts. Journal of Pharmaceutical Innovation 3(1):41 - 50. DOI
10.1007/s12247-008-9020-8.

6.1 Introduction
The Process Analytical Technology (PAT) initiative6 has increased the
performance demands upon analytical methods. In a PAT environment, sensors are
implemented for control as opposed to inspection. Process analytical sensors require
chemometric modeling/calibration160 to transform instrument signal into useable
information. Multivariate calibration provides a platform for data driven analyzer
selection.
Near-infrared spectroscopy (NIRS) has emerged as a useful analytical technique
for the nondestructive characterization of solid oral dosage forms. Technology selection
is an important early process in method development; following technology selection, the
choice of the sampling system is critical for method suitability. Near-infrared (NIR)
tablet analyzers are constructed to operate in reflectance and/or transmittance modes.
Measurements of accuracy are often used as the sole discriminating factor in
selecting spectrometer configuration.157,187-207 All but two pharmaceutically-oriented
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studies205,207 determined transmittance NIRS to be superior for the analysis of intact
tablets. Most suggest that the enhanced accuracy was due to the larger volume of sample
interrogated with the transmittance mode.201-204 Cogdill et al.207 concluded that, despite
the enhanced accuracy, the impact of sampling position error was less for the reflectance
mode. Mean-squared error and the coefficient of determination assess agreement with a
reference method; multivariate figures of merit characterize the capability of the
measurement system.
Multivariate figure of merit, based on net analyte signal (NAS) theory,170,172 were
derived from univariate methods (refer to Olivieri et al.173 for additional information).
Net analyte signal theory involves the extraction of a particular portion of signal from the
remaining data; it separates information relevant to a particular factor (e.g., chemical
constituent) from the residual interfering elements. The NAS is useful for quantification
because, by definition, it is orthogonal to the remaining factors within the calibration
data. Multiple algorithms are available to estimate the NAS. Comprehensive reviews
detailing net analyte signal theory and its mathematics can be found elsewhere.150,169173,175-181

For this work, the net analyte signal was calculated using the formula developed
by Bro and Anderson178
∧

(

NAS i = (x i ⋅ b ) ⋅ b T ⋅ b

)

−1

⋅ bT

(6.1)

where, xi is a sample spectrum from matrix X and b is a column vector of the regression
coefficients for X. All equations herein use X to represent spectral matrices; bolded
characters other than X, e.g., y, and NAS, represent vectors, and italicized characters,
e.g., x and y, represent scalars. Additionally, the notation ||x|| signifies the Euclidean
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norm of a vector and the superscript T indicates the transpose of a vector. Principal
components regression (PCR) or partial least-squares (PLS) regression are common
techniques used to estimate b.160 The matrix X is generally corrected for the mean;
therefore, NAS outputs are mean-centered. Solutions can be rescaled to their original
range using the vector of means from the centering operation of X. Net analyte signal
can also be represented as a scalar using the equation169
∧

∧

NAS i = NAS i

(6.2)

This operation does not reduce the information contained by the net analyte signal.169
Once the NAS has been determined, multivariate figures of merit can be estimated.
The objectives of this work were twofold: (1) to assess the utility of net analyte
signal theory for the determination of figures of merit and (2) to apply NAS theory for
comparing performance of NIR reflectance and transmittance spectroscopy.

6.2 Materials and Methods
6.2.1 Experimental Design
A fully-balanced, quaternary mixture design comprised of anhydrous theophylline
(Lot No. 92577, Knoll AG, Ludwigshafen, Germany), Lactose 316 Fast Flo NF
Monohydrate (Lot No. 8502113061, Hansen Labs, New Berlin, WI), microcrystalline
cellulose (MCC, Avicel PH-200, Lot No. M427C, FMC BioPolymer, Mechanicsburgh,
PA), and soluble starch GR (Lot No. 39362, EMD Chemicals Inc., Gibbstown, NJ) was
generated. The approximate median particle size of the theophylline, lactose, MCC, and
starch (reported by documentation from their respective suppliers), was 90, 100, 180, and
17 microns, respectively. No further analyses or operations were performed on the
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materials to establish or modify the particle size distribution. Twenty-nine design points
were chosen to cover a wide range in all constituents and to remove any possibility of
factor aliasing (Table 6.1). Analysis of the mixture covariance matrix (not shown)
demonstrated the design is balanced in all directions, giving equal emphasis to all
constituents.
Table 6.1. Composition design.
Design
Point
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

Anhydrous
Theophylline
(w/w)
0.600
0.400
0.200
0.400
0.200
0.200
0.600
0.400
0.200
0.600
0.400
0.200
0.000
0.400
0.200
0.000
0.200
0.000
0.400
0.200
0.400
0.200
0.000
0.200
0.000
0.200
0.200
0.000
0.250

Lactose
Monohydrate
(w/w)
0.200
0.400
0.600
0.200
0.400
0.200
0.200
0.400
0.600
0.000
0.200
0.400
0.600
0.000
0.200
0.400
0.000
0.200
0.200
0.400
0.000
0.200
0.400
0.000
0.200
0.200
0.000
0.200
0.250

MCC
(PH200)
(w/w)
0.200
0.200
0.200
0.400
0.400
0.600
0.000
0.000
0.000
0.200
0.200
0.200
0.200
0.401
0.400
0.400
0.600
0.600
0.000
0.000
0.200
0.200
0.200
0.400
0.400
0.000
0.200
0.200
0.250

247

Soluble
Starch
(w/w)
0.000
0.000
0.000
0.000
0.000
0.000
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.400
0.400
0.400
0.399
0.400
0.400
0.400
0.600
0.600
0.600
0.250

6.2.2 Compact Production
Materials for each design point mixture were dispensed by weight into 25 mL
glass scintillation vials (Data Range, Model No. AX504DR, Mettler Toledo, Columbus,
OH) in accordance with the experimental design. The materials were mixed for 5 minute
cycles by placing them on the rotating drive assembly of a Jar Mill (US Stoneware, East
Palestine, OH, USA). Following each blending iteration, a NIR reflectance spectrum was
acquired directly through the bottom of the glass (FOSS NIRSystems 5000, FOSS
NIRSystems, Inc., Laurel, MD). Using the constituent concentrations as reference data,
an ad hoc partial least-squares II (PLS-2) calibration was constructed after each blending
cycle to evaluate homogeneity. Mixtures were assumed to be homogeneous when further
mixing failed to yield an increase in the calibration’s coefficient of determination.
The mixtures from each design point were then subdivided and compacted at 5
pressures (67.0, 117.3, 167.6, 217.8, 268.1 MPa) on a Carver Automatic Tablet Press
(Model 3887.1SD0A00, Wabash, IN) using a 13 mm die and flat-faced punches. The
dwell time was set to 10 seconds. Six compacts were produced per design point, with the
sixth compact’s compaction pressure randomly chosen from one of the five possible
levels. The compaction order was randomized to minimize heteroscedasticity of
experimental error. In total, 174 compacts were produced with a nominal target weight
of 800 mg per compact. Preparation and compaction occurred over a three day period,
after which the compacts were kept in sealed scintillation vials for 15 days prior to
spectroscopic analyses to compensate for any radial and/or axial expansion.
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6.2.3 Data Acquisition, Instrumentation, and Software
Near-infrared reflectance measurements for both sides of each compact were
acquired using a scanning monochromator instrument, equipped with a Rapid Content
Sampler, over the wavelength range of 1100 – 2498 nm at a 2 nm increment, averaging
32 scans (FOSS NIRSystems 5000-II, Vision version 2.00, FOSS NIRSystems, Inc.,
Laurel, MD). Prior to spectral acquisition, the compacts were positioned via the
centering iris standard on this instrument. Two ad hoc partial least-squares II (PLS-2)
calibrations, using the constituent concentrations as reference data, were constructed from
reflectance spectra corresponding to a particular surface of the compacts. Due to the
subtle differences in calibration accuracy, measurements pertaining to only one side of
the compacts were used.
Transmittance measurements were acquired on a scanning monochromator
instrument equipped with an InSightTM Tablet Analyzer over the wavelength range of 600
– 1898 nm at a 2 nm increment, averaging 32 scans (FOSS NIRSystems 6500, Vision
version 2.00, FOSS NIRSystems, Inc., Laurel, MD). Samples were positioned via a
tablet holder suited for compacts ~14.5 mm in diameter. Subsequent to acquisition, the
wavelength range of the transmittance spectra was truncated to 800 – 1400 nm.
Reflectance and transmittance data were expressed as log (1/R) and log (1/T),
respectively. All spectral data were analyzed in the Matlab environment (version 7.1,
The MathWorks, Natick, MA) using the PLS_Toolbox (version 3.0, Eigenvector
Research, Inc., Manson, WA) and software routines developed at Duquesne University
Center for Pharmaceutical Technology (DCPT).
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6.2.4 Partial Least-Squares Analysis
NIR reflectance and transmittance data were analyzed separately but in an
identical fashion. Partial least-squares regression122 was used via the SIMPLS
algorithm123 to relate spectroscopic response to concentration for each constituent on an
individual basis. Compacts lacking the particular constituent being analyzed were
omitted for the analysis as analyte concentration is incorporated in the denominator of
some figures of merit calculations. Thus, the calibration data sets were unique for each
analysis.
Preprocessing routines, including standard normal variate (SNV) scaling,
detrending, derivatives, and combinations of the preceding were tested.124 Assessment of
the most effective data pretreatment method was made based on a minimization of
“batch-wise” cross-validation error, where a batch is defined by a compaction level.
Within each cross-validation iteration, compacts produced at a specific pressure were
removed, a calibration was constructed, and the concentrations of the omitted samples
were predicted by the temporary model. This process was iterated until all of the samples
had been predicted, thereby allowing for the determination of the root-mean-standard
error (RMSE). The RMSE for cross-validation (RMSECV) and calibration (RMSEC)
were calculated using the formula
n

RMSE =

∑ (y
i =1

− yˆ i )

2

i

n

(6.3)

where y i , ŷ i , and n are the measured concentration, the predicted concentration, and the
number of samples for the current data set, respectively. According to ICH guidelines,
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accuracy expresses the agreeability between reference and predicted values,208 and thus,
RMSEC and RMSECV indicate the accuracy of the particular calibration.

6.2.5 Multivariate Figures of Merit
Upon determining the optimum calibration model, the PLS regression vector can
be used to determine the net analyte signal according to equations (6.1) and (6.2). Net
analyte signal is the basis for calculation of numerous figures of merit, including
sensitivity, analytical sensitivity, selectivity, signal-to-noise ratio, and limit of detection
and are estimated for each sample (compact) according to the following formulae.
Sensitivity characterizes signal intensity as a function of analyte concentration.
Larger sensitivities signify an enhanced instrumental response to a given change in
concentration.169,170 Sensitivity is calculated as169,173,177
∧

∧

NAS i
SEN i =
yi
∧

(6.4)
∧

where SEN i is the vector of sensitivities for each instrument variable, NAS i is the net
analyte signal vector, and yi is the measured concentration for the ith sample. Sensitivity
is reported in units of instrument intensity per concentration. For the work herein,
measured concentrations were autoscaled before applying equation (6.4). It is also
possible to express sensitivity as a univariate statistic by taking the Euclidean norm of the
sensitivity vector
∧

∧

SEN i = || SEN i ||
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(6.5)

∧

where SEN i is the univariate measure of sensitivity for the ith sample.177,180 For this
work, sensitivity is reported as the mean of the univariate sensitivity values for the
particular data set.
Given that equation (6.4) utilizes instrument intensity, sensitivity of multiple
devices is directly comparable only when they operate under the same fundamental
principles (and units of measure). Considering this limitation, the statistic analytical
sensitivity (γ) was developed to provide an impartial assessment between dissimilar
analytical techniques.180 Analytical sensitivity is calculated as
∧

SEN
γ=
δr

(6.6)

∧

where SEN and δr are the mean of the sensitivity values under consideration found using
equation (6.5) and a measure of instrumental noise, respectively. Analytical sensitivity is
reported in units of inverse concentration. δr was estimated as the mean standard
∧

deviation of NAS i (for the component under consideration) of four compacts widely
varying in constituent concentrations. The compacts were scanned once a day for six
consecutive days. Additionally, this figure of merit provides a means to estimate the
minimum discernible concentration difference for the dynamic range modeled (γ-1);180
this is referred to as effective resolution.
Predicted values were determined according to the equation183
∧

y = X⋅b

(6.7)

where X represents the spectral matrix and b is the PLS regression vector, which is
dependent on the number of latent variables applied and the component being considered.
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The predicted values were scaled to zero mean and unit variance; consequently, they
must be rescaled prior to determining accuracy via equation (6.3). It is important to note
that all predicted values are independent of any NAS computations.
Selectivity is a dimensionless univariate measure of the fraction of instrumental
signal remaining after accounting for spectral overlap; it is the proportion of signal
unaffected by the interfering factors.169 This metric is calculated for each sample by169,181
∧

|| NAS i ||
SEL i =
|| x i ||
∧

(6.8)

∧

where NAS i and x i are the NAS vector and the original spectrum for the ith sample,
respectively. The magnitude of the selectivity parameter is determined by the degree of
spectral interference associated with the particular analyte under consideration. For the
work herein, selectivity is reported as the mean of the selectivity values for the current
data set.
Signal-to-noise ratio is one of the most important metrics for the general
comparison of methods and, using net analyte signal theory, is calculated as169
∧

NAS i
S / Ni =
δr
∧

(6.9)

∧

where NAS i is the scalar representation of the NAS vector, and δr was estimated as the
mean standard deviation of the predicted concentrations (for the component under
consideration) of four tablets broadly varying in constituent concentrations (i.e., the same
four tablets previously used). Linear regression was performed between measured
concentration and the univariate NAS values to estimate scale (a1) and offset (ao)
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coefficients to convert NAS scalars to units of concentration. Thus, S/N is a
dimensionless metric specific to the current application.
⎛ ∧ ⎞
⋅
a
⎜ NAS i ⎟ + ao
1
∧
⎝
⎠
S /Ni =
δr

(6.9a)

Signal-to-noise ratio is reported in this document as the mean of the S/N values for all
samples under consideration.
Considering the concentration range encompassed by the experimental design,
limit of detection (LOD) is a valid figure of merit. Limit of detection can be estimated
by184
LOD =

k Dσ
m

(6.10)

where kD is the statistical confidence factor (here, kD = 3), m is the slope of a univariate
classical least-squares fit of the predicted and reference data, and for this work, σ and δr
were calculated using the same procedure. A value of 1.0 was assumed for m in all
computations given that the slopes of the predicted versus measured plots were not
significantly different from unity.

6.2.6 Precision Statistics
Repeatability and intermediate precision were determined according to ICH
guidelines.208 These statistics function as estimates of precision and were reported as the
standard deviation of predicted concentrations for the corresponding repeat
measurements. Precision statistics were calculated using the randomly-chosen design
point comprised of 20% theophylline, 20% lactose, 0% MCC, and 60% starch,
compacted at a pressure of 167.6 MPa. Repeatability, a measure of short-term sampling

254

error, was determined without repositioning of the compact between successive scans, as
well as by removing and subsequently re-centering the compact prior to spectral
acquisition. Six scans for each repeatability test were collected consecutively on the
same day. Intermediate precision, which should incorporate typical variations such as
between analysts and days, was assessed by scanning the compact once a day for six
consecutive days. All precision data were collected by the same analyst.

6.3 Results and Discussion
6.3.1 Wavelength Selection Criteria
The raw NIR response for all 174 compacts is shown in Figure 6.1 for both the
reflectance and transmittance geometries. Mathematical assessment is necessary to
establish whether or not the entire wavelength range is useful for the prediction of
constituent concentrations. While multiple methods for the selection of optimum
wavelength ranges are available (e.g., moving-window algorithms, manual trial and error
truncation), this work employed correlation vectors to establish if truncation was
warranted. Specifically, the correlation between spectral response and component
concentration was assessed for each constituent across all wavelengths; only samples
corresponding to the calibration data sets were considered. This procedure yields a fullspectrum correlation vector for each constituent (Figure 6.2).
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Figure 6.1. Plots of raw reflectance (a) and transmittance (b) spectra for all 174 compacts.

Figure 6.2. Correlation vectors for the reflectance (a) and transmittance (b) instruments illustrating the
correlation between instrument intensity and concentration at each wavelength.

Wavelength regions for calibrations should be carefully selected. Figure 6.2
illustrates that the low and high wavelength regions contain meaningful correlations for
anhydrous theophylline. Therefore, the entire wavelength range was utilized for the
reflectance data. As for the transmittance measurements, Figure 6.2 illustrates that the
low and high wavelength extremes are not informative. Furthermore, the transmittance
spectra in Figure 6.1 appear to be saturated at higher wavelengths, consistent with the
unstable regions of the correlation vector (~ 1400nm). Saturation can be attributed to
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sample thickness (mean = 4.387 mm) in combination with the general increase in
absorption coefficient that accompanies an increase in wavelength;209 this results in low
transmittance values. For these reasons, the transmittance wavelength range was
truncated to 800 – 1400 nm.

6.3.2 Model Development
All predicted values are independent of any net analyte signal mathematics
employed. Savitsky-Golay first-derivative preprocessing185 (eleven point smoothing and
second-order polynomial) was used for the reflectance spectra, while a combination of
first-derivative preprocessing (three point smoothing and second-order polynomial) and
linear detrending was chosen for the transmittance spectra based on the minimization of
cross validation error. Model rank was determined (Figure 6.3) using plots of RMSECV
and RMSEC versus the number of PLS latent factors. The optimum number of factors
was selected based on the inflection point of incremental RMSE (or variance) captured,
also considering the agreement between RMSECV and RMSEC values. Model
dimensionality was further justified according to the degrees of freedom varying within
the experimental design.
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Figure 6.3. Plot of RMSEC and RMSECV versus the number of PLS factors selected to model anhydrous
theophylline concentration using reflectance (a) and transmittance (b) spectra.

For both reflectance and transmittance data, three latent variables were required to
effectively model anhydrous theophylline concentration, while four latent variables were
necessary for lactose monohydrate, MCC, and soluble starch. Calibration is
demonstrated by the composite constituent concentration plot (Figure 6.4), which
assesses all components simultaneously. The specificity of the calibration models is
assessed by comparing the agreement between the regression vectors and the pure
component spectra (Figure 6.5). Comparable correlations were observed for the other
three constituents (plots not shown).

258

Predicted Concentration (%)

70

60

Circle = 50th Percentile
Asterisks = 25th and 75th Percentiles
Red (solid) = Reflectance
Blue (dashed) = Transmittance

50

40

30

20
15

20

25

30
35
40
45
50
Measured Concentration (%)

55

60

65

Figure 6.4. Plot of predicted versus measured concentration for reflectance and transmittance data. Circles
symbolize the 50th percentile, while the upper and lower asterisks represent the 25th and 75th percentiles,
respectively. Transmittance data were offset 10 percent along the ordinate axis to facilitate viewing. The
accuracy of all constituents is represented simultaneously.

Figure 6.5. Plots containing the pure component spectrum (upper dashed vector), the PLS regression vector
(lower bold vector), and the net analyte signal (black) and interference (grey) vectors for each calibration
sample, for anhydrous theophylline. Reflectance (a) and transmittance (b) data were scaled to zero mean
and unit variance, and were offset, to facilitate viewing.

Subsequent to model selection, the PLS regression vectors were used to determine
the net analyte signal for each constituent. The net analyte signal and interference
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vectors for each calibration sample are plotted in Figure 6.5 for both the reflectance and
transmittance geometries. Contributions of spectral variance, whether from the
constituent itself or the other interfering elements, can be observed with this plotting
scheme. Additionally, regions enhancing or suppressing the sensitivities, selectivities,
and S/N ratios can be examined.

6.3.3 Comparison of Reflectance and Transmittance Methods
The calibration statistics detailing the performance of the reflectance and
transmittance geometries for the quantification of constituent concentrations are provided
in Table 6.2. Both geometries offer similar results in terms of accuracy. Among the four
constituents, the anhydrous theophylline models were most accurate. The most probable
explanation for the enhanced accuracy of anhydrous theophylline is its pure component
orthogonality, which will be discussed in the following paragraphs. Additionally, the
ordering of calibration model accuracy for the different components was identical
between the two instruments; however, anhydrous theophylline and lactose monohydrate
were more accurately predicted by the transmittance measurements whereas MCC and
soluble starch were more accurately assessed by the reflectance measurements. The
transmittance method may appear superior, as often times, more importance is placed on
the prediction on API concentration, which in this system, is anhydrous theophylline.
The negative consequences of this conclusion will be addressed shortly.
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Table 6.2. Calibration statistics and figures of merit summarizing method performance for the reflectance and transmittance NIR instruments.
Data Type

Reflectance

Transmittance

Method

SIMPLS
st

Preprocessing

1st Derivative (3,2,1)a and Detrend

Latent Variables

3

4

4

4

3

4

4

4

Component

Theophylline

Lactose

MCC

Starch

Theophylline

Lactose

MCC

Starch

2

0.962

0.951

0.919

0.952

0.992

0.952

0.890

0.928

2

R - CV

0.955

0.942

0.902

0.941

0.992

0.933

0.855

0.909

RMSEC (%)

2.7

3.1

4.0

3.1

1.2

3.1

4.7

3.8

RMSECV (%)

3.0

3.4

4.4

3.4

1.3

3.7

5.4

4.3

Repeatability - w/o repositioning (%)

0.01

0.16

0.16

0.02

0.03

0.37

0.34

0.36

Repeatability - w/ repositioning (%)

0.07

0.10

0.36

0.46

0.11

0.22

0.56

0.80

Intermediate (%)

0.11

0.16

0.52

0.66

0.12

0.16

0.58

0.46

Sensitivity (Instrument Intensity / %)

0.02

0.01

0.01

0.01

0.10

0.03

0.02

0.03

Analytical Sensitivity (1 / %)

126.36

82.47

37.09

31.18

32.28

39.54

13.34

16.12

Effective Resolution (%)

0.01

0.01

0.03

0.03

0.03

0.03

0.07

0.06

Selectivity (unitless)

0.59

0.33

0.24

0.27

0.61

0.23

0.15

0.20

Signal-to-Noise (unitless)

282.40

189.88

87.23

72.14

74.20

91.32

32.73

36.59

Limit of Detection (%)
0.33
0.50
1.08
1.31
Paranthetical data corresponds to window width, polynomial order, and derivative order, respectively.

1.27

1.04

2.89

2.58

R - Cal

Accuracy

Precision
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1 Derivative (11,2,1)

a

Attempts to partition sources of variance, including instrumental noise, sample
repositioning error, and instrumental drift, were made according to the ICH guidance on
the validation of analytical procedures.208 The variation in sample repositioning limits
the performance of both modes. Issues of sample inhomogeneity amplify the effects of
sample repositioning error; however, its influence can be suppressed through sample
averaging. The data in Table 6.2 suggest that the error associated with sample
repositioning was not fully captured due to the unanticipated trend in the precision
statistics. It is expected that the error of repeatability without repositioning would be
lower than repeatability with repositioning, which should be lower than intermediate
precision, as each statistic consecutively includes additional factors that are projected to
increase precision error. The inclusion of additional data (e.g., scans, repositions,
scientists) may help to clarify this issue. Issues such as this must be adequately addressed
before comparing methods for possible deployment.
The conventional accuracy and precision data provide a reasonable means of
characterizing these two methods; however, this effort can be enhanced with the
consideration of multivariate figures of merit. Unlike previous FOM applications where
sensitivities were not directly comparable due to dissimilar measurement technologies,150
the sensitivity values reported in Table 6.2 can be compared, because both the reflectance
and transmittance spectrometers measure sample response in absorbance intensity. While
the transmittance measurements were more sensitive for all constituents, the order of
decreasing sensitivity for both geometries was anhydrous theophylline, lactose
monohydrate, soluble starch, and MCC.
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Instrumental noise altered the constituent rank ordering for analytical sensitivity.
The highest analytical sensitivity for the transmittance method (lactose monohydrate) was
roughly comparable to the lowest analytical sensitivity for the reflectance data (soluble
starch). This illustrates the power of the analytical sensitivity metric, even when the
instruments operate using the same fundamental principles, as the significance of
instrumental noise (i.e., sample repositioning) on the transmittance data may have been
otherwise overlooked.
The trend for component selectivity mirrors that of sensitivity. It is expected that
adequate sensitivity yields acceptable selectivity and equally, inadequate sensitivity
generates poor selectivity. In situations where sensitivity is insufficient, attempts to
enhance selectivity will be ineffective. The anhydrous theophylline pure component
spectrum is the most orthogonal to the interfering (spectral) elements (Figure 6.6). This
orthogonality is evident in not only the improved sensitivity, but also the selectivity
statistics. The inherent collinearity between lactose monohydrate, microcrystalline
cellulose, and soluble starch most likely resulted in the reduced selectivity.
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Figure 6.6. Plots of raw reflectance (a) and transmittance (b) pure component spectra. Each spectrum
represents the mean response of twenty-seven pure component samples compacted over the range of 67.0 268.1 MPa.

The rank order for S/N ratio follows that of analytical sensitivity. Although the
transmittance measurements were consistently more selective, the reduction in sample
repositioning error (analogous to noise) associated with the reflectance method results in
greater S/N ratios for all constituents.
While the statistics summarizing the accuracy of the two methods were generally
similar, the disparate performance between the reflectance and transmittance geometries
is apparent when considering analytical sensitivity, S/N ratio, and LOD. Upon
examination of these statistics, the superiority of the reflectance method for the given
application is evident. Although the transmittance method was more accurate and
selective for anhydrous theophylline, it was outperformed by the reflectance method in
all other figures of merit. Considering only the comparable predictive performance of
lactose monohydrate, microcrystalline cellulose, and soluble starch, one may have
incorrectly selected the latter method due to its increased accuracy for anhydrous
theophylline. The reduction in performance is most likely a consequence of the larger
sampling position error observed for the transmittance geometry. It is anticipated that
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positioning error could be mitigated by obtaining a tablet holder intended for 13 mm
samples. At the time of spectral acquisition, an optimized holder was unavailable.
However, it remains a possibility that the transmittance instrument may be inherently
noisier (larger δr).
Multivariate figures of merit provide an additional degree of method
characterization that cannot be gained from calibration accuracy statistics; however, other
factors should be taken into account prior to method deployment. Logistical issues such
as cost of implementation, compatibility with existing process/production equipment, and
ease of transferability, may dictate the selection. Although a particular method may
outperform another in terms of calibration accuracy, ancillary performance and
operational issues should be considered when making evaluations.

6.4 Conclusions
The results of this work show that the evaluation of multivariate figures of merit
provides a rigorous means of comparing the performance of reflectance and transmittance
NIR spectroscopy for the nondestructive prediction of constituent concentrations within
compact matrices. The figures of merit analyses revealed performance factors that
otherwise may have gone unobserved. Both reflectance and transmittance geometries
performed adequately when comparing the calibration accuracy statistics. The precision
studies, and more notably the figures of merit, highlight the limitations of the
transmittance instrument for this specific system. Performance limitations were most
likely attributable to sample positioning error, which was present for both spectrometers,
but was more detrimental to the transmittance method. This work also emphasizes the
platform that net analyte signal theory provides for the determination of figures of merit,
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which are useful for the characterization of calibration performance. While figures of
merit are valuable for method characterization, additional logistical factors should be
taken into consideration.
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Chapter 7: Integration of Process Analytical Technology with
Quality by Design to Control the Clinical Performance of a Model
Drug Delivery System

7.1 Introduction
The union between PAT and QbD was conceived some years back when the
respective initiatives were under development. Although each has an independent role in
transitioning from the current to the desired state, the greatest benefits will come from
synergistic efforts that integrate PAT and QbD. Together, they are responsible for key
tasks in establishing, overseeing, and ensuring pharmaceutical quality.
Recent efforts to remold pharmaceutical quality in terms of risk by relating
clinical attributes to production characteristics have transformed approaches to QbD
(refer to Chapter 3). While this work presented a comprehensive review of the changes
that are to be expected for design space, little discussion was devoted to PAT or its
integration within the revised QbD framework. On-, in-, or at-line multivariate sensors
are used extensively in a PAT environment, particularly to obtain a greater understanding
of the process (and its associated components, including raw and in-process materials),
and to ultimately control characteristics of the final product. Applications such as these
typically require chemometric modeling (calibration) to transform instrument signal into
relevant data (e.g., API/excipient concentration, moisture content, incoming process
parameter). Specific information regarding the process (determined via process models)
can be used adjust the process (via feedforward or feedback control) to obtain a desired
response.
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Within the new QbD paradigm, the desired response is final product which
demonstrates clinical performance as dictated by the design space. As such, PAT will
play an integral role in understanding how (explicitly) the process impacts clinical
performance, and, subsequently, how to control the process such that final product meets
the safety and efficacy constraints of the design space. The objective of this study was to
propose a hypothetical scenario that coupled PAT with QbD such that production could
be maintained in a low-risk state.

7.2 Materials and Methods
Data pertaining to 12 distinct wet granulation batches of the model theophylline
tablets were utilized to construct the hypothetical scenario. In addition to the 12 and 10
units per batch that were sampled for dissolution and content uniformity testing,
respectively, the crushing strength of 10 tablets was estimated for each batch by a
diametric crushing test (ElizaTest 3+ Vision Tablet Testing System, Elizabeth-Hata
International, North Huntingdon, PA). A reflectance spectrum for both sides of each
tablet was acquired before the tablets underwent the relevant destructive analyses.
Reflectance was measured over the wavelength range of 1100 – 2498 nm at a 2 nm
increment, averaging 32 scans (FOSS NIRSystems 5000-II, Vision version 2.00, FOSS
NIRSystems, Inc., Laurel, MD).
Calibration models were constructed using NIR reflectance data, expressed in
absorbance units, of the 120 tablets (240 spectra) and the crushing strength measurements
(MPa). Partial least-squares regression122 was used via the SIMPLS algorithm123 to relate
spectroscopic response to crushing strength. Preprocessing routines, including standard
normal variate (SNV) scaling, detrending, derivatives, and combinations of the preceding
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were tested.124 The optimal calibration model was selected based on a minimization of
cross-validation error. Contiguous block cross-validation with a block size of 5 was used
to generate the temporary cross-validation models. Irrespective of the preprocessing
routine(s) employed, spectroscopic data were mean-centered while reference data were
scaled to zero mean and unit variance. Model rank was chosen as the point where a rapid
decline in the incremental variance captured was observed, cognizant of the expected
feasible limit of dimensionality based on the factors varying within the design.
Calibration efforts revealed that no data pretreatment was necessary. Two latent
variables were necessary to adequately model these NIR absorbance data for the
prediction of tablet crushing strength. The 288 spectra of the 144 tablets subjected to
dissolution testing were projected onto the calibration model to predict their crushing
strengths (i.e., testing data set); predictions were compared to the nominal values for each
tablet as specified in the original design.117 Predicted and reference values were used to
determine the root-mean-standard error (RMSE). The RMSE for cross-validation
(RMSECV), calibration (RMSEC), and testing (RMSET) were calculated using the
formula
n

RMSE =

∑ (y
i =1

i

2
− yˆ i )

n

(7.1)

where y i is the measured crushing strength, ŷi is the predicted crushing strength, and n is
the number of samples for the data set under consideration. The calibration model is
summarized in Table 7.1.
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Table 7.1. Calibration summary statistics for the prediction of crushing strength.
Data Type
Method
Preprocessing
Latent Variables
Component

NIR (Reflectance)
PLS
Raw Spectra
2
Crushing Strength

R2CAL

0.836

R2CV

0.770

R2TEST
RMSEC (MPa)
RMSECV (MPa)
RMSET (MPa)

0.926
0.30
0.37
0.20

BiasCV (MPa)

0.043

BiasTEST (MPa)

-0.038

These data augment the available information content (i.e., Weibull shape and
scale parameters, theophylline content) for the same tablets used in previous studies. As
a result of minor spectroscopic differences detected between the two tablet surfaces, the
predicted crushing strengths varied slightly for the same tablet. Thus, 288 distinct
responses were available for the 144 tablets. These data were then used to determine if
an underlying relationship existed between crushing strength and T63.2. Modeling efforts
utilized standard least-squares regression. Transformations to both the predictor
(crushing strength) and the predicted (T63.2) variables were explored.

7.3 Results and Discussion
7.3.1 Relationship between Crushing Strength and the Weibull Scale Parameter
Standard least-squares regression revealed a weak correlation between crushing
strength and T63.2 when all 288 responses were considered simultaneously (r = -0.3217).
As previous work has demonstrated,210 however, varying constituent concentrations, as
dictated by the experimental design, can mask (spectroscopically and non-
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spectroscopically) underlying relationships involving crushing strength (see Chapter 4).
When the relationship was re-evaluated with the relative contributions of each component
held constant, a much stronger correlation was observed (r = 0.9188); this was
determined using 72 of the 288 responses. This was equivalent to assessing one
formulation, which was tableted with the distinct purpose of obtaining several target
crushing strength values. The function describing the relationship between these two
variables was determined to be
T63.2 = 0.52 ⋅ (Crushing Strength ) − 0.043

(7.2)

7.3.2 Integration of PAT with QbD
Simulation revealed that both inefficacy and toxicity risk concerning the model
solid oral dosage system were a function of, among other factors, content uniformity and
dissolution variability (refer to Chapters 2 and 3). This knowledge was used to generate
process-independent design spaces for the model system, which explicitly defined the
clinically acceptable combinations of theophylline (% nominal) and T63.2 (hours). Based
on the findings of the previous studies, the following discussion focuses on integrating
PAT at several strategic stages prior to final product release.
Given the relationship between content uniformity and risk, blending of the
formulation presents the first viable opportunity to monitor heterogeneity. Numerous
non-invasive analytical techniques have proven useful for evaluating blend uniformity
(e.g., NIR, Raman). Although uniformity, at least so much as in USP <905>, is solely
expressed in terms of the API, process modeling can easily be extended to include
various excipients.
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Taking advantage of the correlation between crushing strength and T63.2,
feedforward control can be used to adjust the crushing strength of the final tablets to
compensate for the clinical risk associated with various levels of content uniformity.
Therefore, the PAT sensor(s) informs the control model (via the process model) of the
content uniformity, which then sends a set-point(s) to adjust the compaction pressure
(and other pertinent process variables) to modify the release profile and ultimately
regulate clinical performance. Since other downstream unit operations have the potential
to affect the content uniformity estimated during blending (e.g., wet granulation, milling,
tableting) additional calibrations can be deployed to monitor uniformity and/or crushing
strength of the product post-tableting. These data can be used to update or even adjust (in
real-time) the process and/or control models, as necessary. Various factors, including
spectrometer drift, machinery and/or tooling deterioration, or a change in raw materials,
could render the use of feedback control invaluable. Ideally, however, the majority of
these factors would be accounted for prior to model deployment. The PAT system,
therefore, monitors and controls the attributes which are critical-to-quality to ensure that
the final product lies within the design space. The integration of PAT and QbD is
depicted in Figure 7.1.
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Figure 7.1. Schematic illustrating the integration of PAT with QbD to control clinical performance.

7.4 Conclusions
PAT is an important component of QbD applications. The methodologies
developed in the previous phases of this dissertation were used as the basis to propose a
hypothetical scenario that coupled PAT with QbD such that production could be
maintained in a low-risk state. PAT can be integrated to monitor and control production
to ultimately ensure that the critical-to-quality attributes of the final product lay within
the design space bounded by clinical risk. Feedfoward control is proposed to adjust
tableting such that dissolution would compensate for risk imparted by various levels of
content uniformity imposed by upstream processing. Additionally, feedback control
could be utilized to retrospectively update or modify the process and/or control models,
as needed. Multivariate modeling is an indispensible component of PAT. Future studies
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should focus on the effects of model uncertainty and how it propagates through QbD
methodologies to ultimately impact estimates of clinical performance.
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Chapter 8: Summary
Despite recent advances, the pharmaceutical industry has failed to adequately
integrate innovative approaches into its drug discovery and development programs. A
2003 Wall Street Journal article declared that the “pharmaceutical industry has a little
secret: Even as it invents futuristic new drugs, its manufacturing techniques lag far
behind those of potato-chip and laundry-soap makers.” “To the FDA, with its mission of
protecting patient safety, it seemed more important to manufacture drugs precisely to
specification, using tried-and-true systems, than to latch on to the latest in manufacturing
trends.” Furthermore, “in other industries, manufacturers constantly fiddle with their
production lines to find improvements. But FDA regulations leave drug-manufacturing
processes virtually frozen in time.”211 The FDA has since stepped forward to accept
partial responsibility for the current state of affairs and introduced or endorsed numerous
regulatory initiatives, reports and guidances intended to modernize the Agency’s as well
as manufacturers’ approach to drug discovery and development. This new approach is
centered on risk-based decisions.
While the new documents were a colossal step in the right direction, multiple
definitions and ambiguous interpretations of “pharmaceutical quality,” an element
fundamental to every facet of the regulatory, pharmaceutical, and consumer industries,
were at odds with the modernization efforts. Mindful of the misnomer, requests were
made by a few pioneering individuals to re-define pharmaceutical quality in terms of risk
by relating clinical attributes to production characteristics. This work was predicated on
this very concept.
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The predominant focus of this dissertation was to assemble a platform capable of
evaluating the effects of product and patient variability on clinical performance in silico.
To the best of the author’s knowledge, this is the first tool of its kind. Theophylline was
selected as the model drug for these studies on the basis of its narrow-therapeutic index
and the preponderance of available literature data detailing this compound. Population
data specifying asthma rates, anthropometric measurements, and other physiological,
pathophysiological and behavioral factors known to influence treatment with
theophylline were accrued and used to generate a hypothetical asthmatic patient
population. Concurrently, in vitro-in vivo correlation, pharmacokinetic, and
pharmacodynamic data/models for theophylline were amassed and used to define the
architecture of the risk simulation platform.
Specifics regarding the structure of the risk simulation platform were described in
great detail. Its framework utilized Monte Carlo simulation and probabilistic risk
assessment to evaluate the impact that manufacturing variability had on the clinical
performance of model extended-release theophylline tablets. Clinical performance was
evaluated through quantitative risk scores for inefficacy and toxicity, which was made
possible by utilizing a probabilistic pharmacodynamic model that expressed the
probabilities of each adverse event as a function of theophylline plasma concentration.
Production data for a solid oral theophylline dosage system that was formulated,
processed, and compacted prior to the conception of this work was used to generate
estimates of inter- and intra-batch content uniformity and dissolution variability. These,
along with estimates of patient compliance (both percentage of doses consumed and
adherence to the dosing regimen), were used to evaluate their impact on clinical
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performance in the simulated asthmatic population. A total of 6 factors were studied via
two full factorial experimental designs to determine which factor(s) posed a significant
risk of inefficacy or toxicity. Sensitivity analyses revealed that patient compliance and
intra-batch content uniformity had a significant impact on inefficacy and toxicity risk
scores. Intra-batch content uniformity, therefore, was identified as a critical quality
attribute. The results of these initial risk simulations demonstrated the conditional risk of
manufacturing variability on the clinical performance of the model drug delivery system.
With the framework of the risk simulator solidified and the relationship between
product attributes and risk established, the next phase of this research explored the
regulatory undertones of re-defining quality. This research initially addressed the
potential limitations of the final product specifications utilized in the USP <711> and
<905> methods for dissolution and content uniformity, respectively. A series of risk
simulations were conducted to highlight the fact that the univariate specifications, upon
which the USP methods are centered, disregard potential multivariate and nonlinear
interactions that affect clinical performance. The simulations revealed that inspecification product demonstrated an extensive range of inefficacy and toxicity risk
scores, magnitudes of which were in excess of those determined to be significant in the
sensitivity analyses. Furthermore, the specifications were not consistently sensitive to the
lots which offered the utmost safety and efficacy. These results suggested that the final
product release tests were unable to adequately appraise final product quality as it related
to clinical performance of the model drug delivery system.
The same series of risk simulations were also used to examine the implications
that re-casting quality might have on design space initiatives. Contrary to the current

277

approach to constructing a design space, re-defining quality in terms of risk by relating
clinical attributes to production characteristics offers the ability to generate a hyperspace
that is explicitly bounded by estimates of clinical performance. Given the new approach
to design space, performance-based quality specifications were proposed to be the link
between critical quality attributes and clinical performance. The performance-based
quality specifications, which are delineated via the risk simulation platform, define a
process-independent design space. Design spaces that were conditioned on quantitative
estimations of inefficacy and toxicity risk were generated for the model system.
Although critical-to-quality attributes are compulsory inputs to a design space, attributes
which interact with those determined to be critical should also be included. A design
space that defines the relationship between quality attributes and clinical performance can
then be applied to specific processes using process models as transfer functions to
ultimately link process parameters to clinical performance.
The last segment of this research briefly addressed the role that Process Analytical
Technology will play in implementing performance-based quality specifications.
Multivariate data analysis has been and will continue to be a key factor in coupling
Process Analytical Technology and Quality by Design. Portions of this dissertation
explored routines for evaluating the performance of predictive models, particularly
calibrations developed using on-, in-, or at-line multivariate sensors. As these types of
models undoubtedly will be used to identify, predict, and control elements fundamental to
linking manufacturing to clinical performance, their adequacy in terms of predictive
performance must be accounted for. Future research should be conducted to investigate
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the impact that model uncertainty has on the generation of performance-based quality
specifications.
This work described within this dissertation is significant in that it facilitates the
transition of the pharmaceutical industry to the desired state. The proposed concepts not
only embrace the Process Analytical Technology and Quality by Design initiatives, they
support the objectives of the Critical Path Initiative by adopting an innovative approach
to pharmaceutical product development. With a direct emphasis on clinical performance,
manufacturers and regulators can more easily focus on controlling manufacturing in a
manner commensurate with patient risk.
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